

October 7-10
www.ever.be

EVER 2015 NICE




Programme book



European Association for Vision and Eye Research

21 CME Credits



L'innovation en Ophtalmologie va bien au-delà des médicaments

Téléchargez l'Application Retina Base pour tablettes tactiles sur l'App Store® ou le Google Play® et découvrez plus de 120 cas cliniques de pathologies rétinienues rédigés par des experts, disponibles en Français et en Anglais.



- Naviguez à travers l'organisation planétaire des pathologies et cas cliniques.
- Recherchez facilement les clichés grâce au moteur de recherche intuitif et filtrez les résultats par mot-clé, technique d'imagerie et auteur.
- Recevez les notifications dès que de nouveaux cas sont disponibles.

Rendez-vous sur www.viaopta.fr pour découvrir ou redécouvrir tous les services ViaOpta™ dédiés à l'ophtalmologie



Dear EVER members, colleagues and friends,

As President of EVER 2015, I would like to take this opportunity to welcome you again to Nice, France. This pearl on the French Riviera has now been the home of EVER for three years, and, in agreement with your vote, will be that for another four.

EVER continues to be a dynamic, strong organisation with the annual Meeting acting as a conduit for researchers, clinician-scientists and clinicians, as well as industry partners in the field of vision and eye disease to exchange ideas, learn, enthuse and stimulate, with solid science in a relaxed atmosphere and an Old World charming environment.

The latter ensures that the interactions between participants can continue beyond those at the Meeting, in a setting of a historic city with a thriving restaurant scene for all budgets, and good weather. In addition, you may sometimes just want to go for a bit of culture, a shopping spree or absorb some Indian summer sunrays. The Annual EVER Meeting offers all of that.

Over the years in Nice, we have seen a steady rise in the number of participants, which encourages the EVER Board to continue on the same path. A fantastic mix of opinion leaders, basic researchers, clinicians and clinician-scientists from Europe and far beyond, all flock to Nice, to interact, explain and absorb the latest novelties in our field. Strong support from our Industry partners has helped EVER flourish over its history, in particular during the last few years in Nice. Gratitude for their support is abundant.

The Annual EVER Meeting is certainly large enough to have the scientific clout required for an international meeting, but at the same time small enough not to overwhelm and allow one to meet those one really wants to. The Meeting program offers a wide variety of scientific exchange formats in ophthalmology and vision research, and includes plenary lectures by internationally renowned leaders in their fields, special interest symposia and courses by the experts, and free paper and poster sessions to present new results.

I'm very grateful that you are joining us in Nice for the EVER 2015 Meeting, and thank you in advance for sharing your insights, knowledge and new ideas.

Bart P LEROY
President EVER 2015


YOUR VISION, OUR SITE

We'll see you through your drug development every step of the way, supporting your ocular research with scientific excellence and a unique suite of services:

- Laboratory support
- Custom disease models
- Specialized administration
- Advanced imaging
- Model-based ocular surgery

Visit us at our booth to meet one of our scientists, or find out more at www.criver.com/ever.


charles river



Word from the president	1
About EVER	4
Composition of the board 2015	8
Congress information	10
Grants and prizes	14
Floorplan	16
Exhibitors	17
Partners of EVER	18
About the programme book	20
Scientific sections 2015	21
Industry Sponsored Symposia	22
Courses	23
Wednesday, October 7	25
Noon session	26
First afternoon session	30
Opening Ceremony	33
Second afternoon session	34
European Ophthalmology Heritage lecture	38
Keynote lecture - Brenda GALLIE	39
Welcome reception	41
Thursday, October 8	43
First morning session	44
EVER-Acta lecture	49
Second morning session	50
Lunchtime session - CIS	55
Ophthalmic Research lecture	57
First afternoon session	58
Coffee with the Prof	62
Poster session 1	63
Second afternoon session	71
Third afternoon session	75
Evening session - CIS	79
Friday, October 9	81
First morning session	82
Keynote lecture - Reza DANA	87
Second morning session	88
Lunchtime sessions - CIS	92-93
First afternoon session	94
Poster session 2	98
Section Business Meetings	107
Second afternoon session	108
General Assembly	113
Congress dinner	114
Saturday, October 10	115
First morning session	116
Poster session 3	120
Keynote lecture - Bitu ESMAELI	127
Second morning session	128
Lunchtime session - CIS	133
Afternoon session	134
Prize award ceremony and conclusion of the congress	138
Presenting first authors	147
Presenting all authors	155
Time schedule	164
Sponsors	back cover

The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

Membership

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.

The benefits of EVER membership are:

- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.844)
- voting rights for the election of the Board Members
- travel grants and poster prizes
- quarterly E-Newsletter


Elections 2015

In 2015 new representatives of the scientific sections


- **NSPH** **Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History of Ophthalmology**
- **PO** **Pathology / Oncology**

will be elected through electronic voting. Voting 2015 will close on October 8, midnight. The result of the elections will be announced at the General Assembly on Friday 9 October 2015, 17:55 -18:30.

Affiliation to scientific sections



Congress participants:



EVER

European Association for Vision and Eye Research

www.ever.be



We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

EVER

EVER Foundation

www.ever-f.eu



In 2010, the EVER Foundation was created to raise money to organize EVER  Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

Fellowships 2015:

1. Dr. Sepehr FEIZI, Iran - host institute : Queens Medical Centre, Nottingham, UK
2. Dr. Sabina SAPETA, Poland - host institute : Medical University of Vienna, Austria

Fellowships 2014:

1. Dr. Ganne PRATYUSHA, India - host institute : Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute : Queens Medical Centre, Nottingham, UK

Fellowships 2013:

1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIELSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite University Medicine in Berlin, Germany

Acta Ophthalmologica

EVER's journal

eu.wiley.com

Acta
Ophthalmologica

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.844)

Executive committee



Bart P LEROY
President



Constantin POURNARAS
Past President



Catherine CREUZOT
Secretary General



Aki KAWASAKI
President Elect



Steffen HEEGAARD
Treasurer



Werner SPILEERS
Vice President



Marcela VOTRUBA
Programme Secretary



Nadia KNOP
Vice President



Leopold SCHMETTERER
EVER / liaison



Laurence DESJARDIINS
Vice-President Elect

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be

mecodi
www.mecodi.eu

Section chairs



Kai KAARNIRANTA
Anatomy / Cell Biology



Thomas FUCHSLUGER
Cornea / Ocular Surface



Miguel CASTELO-BRANCO
Electrophysiology, physiological
Optics, Vision Sciences



Alain BRON
Glaucoma



Andrew DICK
Immunology / Microbiology



Rafael BARRAQUER
Lens / Cataract



Jochen GRAW
Molecular Biology / Genetics /
Epidemiology



Aki KAWASAKI
Neuro-ophthalmology / Strabismology /
Paediatric / History



Laurence DESJARDINS
Pathology / Oncology



Gerhard GARHÖFER
Physiology / Biochemistry /
Pharmacology



Peter WIEDEMANN
Retina / Vitreous

EVER representatives in Acta Board

Constantin POURNARAS

Leopold SCHMETTERER

Senior advisory committee

Jean-Jacques DE LAEY
Jost JONAS

Graham HOLDER
Einar STEFANSSON

Representatives

Bozena ROMANOWSKA-DIXON
Representative East Europe

Jean-Pierre CAUJOLLE
Local representative France

Venue

EVER 2015 will be held at the Acropolis Convention Center in Nice, France

⇒ www.nice-acropolis.com

The scientific programme of the EVER congress starts on Wednesday, October 7 at 12:00 and concludes on Saturday, October 10 at 16:00.

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Onsite registration starts on Wednesday, Oct 7, 9:00.

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status with a document signed by the Head of your Department

Registration fees on-site

	EUR	EUR
EVER member / Course invited speakers	455	390 *
Member-in-training	250	200 *
Non-member	800	645 *
Non-member-in-training	400	310 *
Eye-Care / Technician / Nurse	200	180 *
Congress Dinner (member / non-member)	90	90
Congress Dinner (in training)	60	60

* Citizens of these listed countries only:
Albania, Algeria, Armenia, Belarus,
Bosnia and Herzegovina, Congo, Egypt,
Georgia, Iran, Libya, Macedonia, Moldova,
Montenegro, Morocco, Ouzbekistan,
Pakistan, Serbia, Tunisia, Ukraine

Cancellation policy

Refunds - up to 75% of the advance registration fee will be granted for cancellation received in writing prior to Sept 15, 2015. Refunds will not be granted for later cancellations or no-shows.

Website

The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2015 meeting and view the status (session, hour, place) of your presentation
- pay on-line and print your invoice
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

Housing

ADVANCEDFAIR

AdvancedFair has negotiated special rates for accommodation in several categories of hotels.

⇒ www.advancedfair.com

Travel

The Nice Côte d'Azur Airport is located at 7 km from the city centre. The tramway line connects most of the hotels with the Acropolis Convention Center.

Weather

In Nice there is an average 6 hours of sunshine/day during October so it remains warm and pleasant. It is a perfect time of year to go and explore the city and discover for yourself the many fantastic historic and cultural landmarks Nice has.

There are also a variety of museums and art galleries that can be a worthwhile way to while away a day in the city.

Welcome reception

The Welcome reception is open for all participants and exhibitors.

- Wednesday 19:30 - 21:00 in the Exhibition area, Acropolis Convention Center

Congress dinner

Registration required.

Members / non-members: 90 EUR - Members in training: 60 EUR

Space is limited.

- Friday 20:00 in Hotel NEGRESCO - 37, promenade des Anglais, Nice

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

Internet access

Wi-Fi internet access is available in the Convention Center.

Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls.



Publication of the abstracts

The abstracts of the EVER 2015 congress are published on-line in a special issue of *Acta Ophthalmologica*, the EVER journal. Access for members-only through EVER homepage.

Section Business Meetings

EVER Section Business Meetings of the scientific sections
 Friday, 15:45 - 16:15

- ACB Gallieni 5
- COS Rhodes 2
- EOVS Rhodes 1
- G Rhodes 1
- IM Rhodes 4
- LC Hermes
- MBGE Gallieni 1 & 2
- NSHP Rhodes 2
- PO Rhodes 3
- PBP Rhodes 3
- RV Hermes

The sections

- IM - Immunology / Microbiology
- PBP - Physiology / Biochemistry / Pharmacology

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2016.

Agenda see page 107

EVER General Assembly

Friday, 17:55 - 18:30 in room Hermes
Agenda see pages 113

Prize award ceremony and conclusion of the congress

Saturday, 15:30 - 16:00 in room Hermes
Agenda see page 138

NEW!

Women 4 EVER

Wednesday 7 October 2015 from 17:00 to 18:30

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. *See page 34.*



Coffee with the Prof

Thursday, October 8 2015 from 15:15 - 16:00 in poster area

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called "Coffee with the Prof". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers.

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faculty, can share comments and ideas with an expert.

This new initiative is scheduled on Thursday, Oct 8, 15:15 - 16:00 in the poster area. *See page 62.*

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 21 European CME credits (ECMEC) to the EVER 2015 congress on Oct 7 - 10 in Nice, France. CME credit certificates can be printed from the EVER website after the congress.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

EVER 2015 congress App



All congress information in a nutshell:

- About EVER
- Floorplan and sponsors
- My congress bag
- My schedule
- News Feeds
- Photo sharing
- Session rating
- etc.



EVER section travel grants

We are pleased to announce that the following 14 members have received an EVER section travel grant of 750 EUR each:

- **ACB - Jong Hwa JUN - South Korea**
4171 - MicroRNA-124 Regulates Transforming Growth Factor β 1-induced Epithelial-Mesenchymal Transition in the Retinal Pigment Epithelium by Down-regulating Expression of the RhoG
- **COS - Lana FARAJ - United Kingdom**
1344 - In-vitro anti angiogenic effects of cryo-preserved amniotic membrane
- **COS - Zhiguo HE - France**
2431 - Mass production of high quality corneal endothelial cells from old donors
- **EOVS - Naznin MIRZA - United Kingdom**
F050 - Testing of an automated tablet-based method for the determination of low contrast near visual acuity in ophthalmic patients
- **G - Camilla SANDBERG MELIN - Sweden**
2544 - Pigment epithelium central limit - Inner limit of the retina, Minimal Distance, PIMD, a morphometrical variable for glaucoma follow-up
- **G - Seskoati PRAYITNANINGSIH - Indonesia**
3571 - The Effect of Hypertension on Intraocular Pressure and Apoptosis of Retinal Ganglion Cell Through ET-1 Signaling Pathway Activation in Trabecular Meshwork of Hypertension Rat Model
- **IM - Micheal O'ROURKE - Ireland**
2572 - The role of dendritic cells in non-infectious anterior uveitis
- **LC - Erin THORNELL - Australia**
3251 - α B-Crystallin Phosphorylation as a Precursor to Cataractogenesis
- **MBGE - Cerys EVANS - United Kingdom**
3163 - Investigation of genotype-phenotype correlation of TGFBI mutations reveals c.1868G>A; p.(Gly623Asp) is associated with a variable clinical phenotype, including epithelial basement membrane dystrophy
- **NSPH - Kristina IRSCH - France**
3454 - The influence of lingering fusional adaptation on the Bielschowsky head tilt test in superior oblique paresis
- **PBP - Madhu NATH - India**
F045 - Angiotensin Receptor Blockade in Retinopathy of Prematurity: An Experimental Study
- **PO - Martina ANGI - United Kingdom**
4145 - Proteomic analysis of the uveal melanoma (UM) secretome reveals novel insights and potential biomarkers
- **RV - Elizabeth STEWART - United Kingdom**
S054 - Dexamethasone Reverses the Effects of High Glucose on Human Retinal Endothelial Cells In Vitro
- **RV - Robert SCOTT - United Kingdom**
4272 - Cell Penetrating Peptide Constructs: A novel Drug Delivery to the Eye

EVER Poster Prizes

Poster prizes of 500 EUR will be awarded for the best posters across all sections.

The winners will be chosen by the poster moderators and will be announced in the Prize award ceremony on Saturday, 15:30 - 16:00 in room Hermes. No prize will be given after the congress.



EVER Award Ceremony 2014


quartett diagnostica Research Award

3 grants supported by quartett for best paper in COS


- Translational Research Award
- Basic Science Research Award
- Clinical Research Award

The papers will be chosen during the congress and the grants will be handed over during quartett diagnostica Research Award Session on Friday, 9 October 2015 from 13:30 - 15:00 in room Rhodes 2.

Acropolis Convention Center, 2nd floor



Exhibitors



**ARVO****Association for Research in Vision and Ophthalmology**www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. *See page 128.*

**EBO****European Board of Ophthalmology**ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level.

It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress.

See pages 27, 31.

**EUPO****European University Professors of Ophthalmology**www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2016 course on Neuro-ophthalmology and Strabismus will be organized in conjunction with the EVER congress in Nice, France.

**FAN****European Fluorescein Angiography Club**www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. *See page 94.*

**FRO****Belgian Fund for Research in Ophthalmology**www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. *See pages 130, 136.*

**GOA****Groupe Ophtalmo Allergo**

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. *See page 85.*

**OOG****The Ophthalmic Oncology Group**www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. *See pages 117, 129 and 135.*

Sessions

	Business Meeting		Joint Meeting
	Course		Keynote lecture
	Industry Sponsored Symposium		Special Interest Symposium
	Free Paper session		Social
	General Assembly		Poster session
			Plenary session

Symbols

	=	EVER section travel grant recipient
<i>rf</i>	=	Rapid fire presentation
★	=	Conflict of interest disclosed

Scientific sections

ACB	=	Anatomy / Cell Biology
COS	=	Cornea / Ocular Surface
EOVS	=	Electrophysiology, Physiological Optics, Vision Sciences
G	=	Glaucoma
IM	=	Immunology / Microbiology
LC	=	Lens and Cataract
MBGE	=	Molecular Biology / Genetics / Epidemiology
NSPH	=	Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology
PBP	=	Physiology / Biochemistry / Pharmacology
PO	=	Pathology / Oncology
RV	=	Retina / Vitreous Section programme secretaries

Programme Secretary, Marcela VOTRUBA



Section programme secretaries

ACB	Anatomy/Cell Biology	Goran PETROVSKI
COS	Cornea/Ocular Surface	Jean-Jacques GICQUEL
EOVS	Electrophysiology, Physiological Optics, Vision Sciences	Rebekka HEITMAR
G	Glaucoma	Francesca CORDEIRO
IM	Immunology/Microbiology	Piergiorgio NERI
LC	Lens and Cataract	Stefan LÖFGREN
MBGE	Molecular Biology/Genetics/Epidemiology	Petra LISKOVA
NSPH	Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/ History of Ophthalmology	Antonella BOSCHI
PBP	Physiology/Biochemistry/Pharmacology	Alexandre MOULIN
PO	Pathology/Oncology	Neville OSBORNE
RV	Retina/Vitreous	Stephanie BAILLIF


The Industry Sponsored Symposia throughout the EVER 2015 congress:
Thursday, October 8

THÉA Pharma 12:00 - 13:00 Rhodes 2 Ocular surface: What's new? 55

THÉA Pharma 19:00 - 20:30 Hermes How to create a new generation of glaucoma patient ? 79


Friday, October 9

BAYER 12:30 - 13:30 Rhodes 2 Macular edema: from basic science to clinical evidences... 92



Santhera Pharmaceuticals

12:30 - 13:30 Rhodes 3 A rare breakthrough in mitochondrial medicine:
changing the patient journey in LHON 93


Saturday, October 10

ALLERGAN 13:00 - 14:00 Rhodes 2 Update in the management of DME, RVO and Uveitis 133





The courses throughout the EVER 2015 congress:

Wednesday, October 7

RV	12:00 - 13:30	The Diabetic Retinopathy: A neurodegenerative disease	26
IM	12:00 - 13:30	EBO course: Intraocular inflammation and infection (Part I)	27
COS	12:00 - 13:30	How to perform Deep Anterior Lamellar Keratoplasty	27
NSPH	12:00 - 13:30	Papilloedema and its Mimics: What's new in Pseudotumor Cerebri Syndrome?	29
RV	13:30 - 15:00	Macular Hole Surgery: New facts and tips for a successful result	30
PO	13:30 - 15:00	Mistakes in the diagnosis of fundus tumors	30
IM	13:30 - 15:00	EBO course: Intraocular inflammation and infection (Part II)	31
IM	13:30 - 15:00	In vivo confocal microscopy in corneal disorders....	31
	17:00 - 18:30	How to publish - hints and "tricks"....	36

Thursday, October 8

PBP	8:00 - 9:30	Ultrasound Course	45
NSPH	16:00 - 17:30	Nystagmus and non-nystagmic abnormal spontaneous eye movements	73

Friday, October 9

RV	8:30 - 10:00	Degenerative myopia	82
PO	8:30 - 10:00	Eyelid tumors.....	83

Saturday, October 10

NSPH	8:30 - 10:00	ABC in retina structure and function	118
------	--------------	--	-----

EVER 2015
Wednesday, Oct 7





12:00 - 13:30 | HERMES

RV: The diabetic retinopathy: A neurodegenerative disease

Intermediate

Diabetic retinopathy is the first cause of visual impairment and blindness in the adult working-age population. This complication of diabetes mellitus has been considered primarily a retinal microvascular disorder nevertheless, some recent studies have demonstrated that retinal neurodegeneration is present even before the development of clinically detectable microvascular damage. Early recognition of retinal changes in diabetic patients is essential in the prevention of vision loss. Recently, optical coherence tomography (OCT) has been introduced into clinical practice as one method to visualize the retina. It allowed to performed quantitative and qualitative measurements of different retinal layers. Considering the impact of an early detection of retinopathy diabetic, the idea behind the Course is to try to sum up the data of what the recognition of the neurodegeneration is an important target worth looking from a clinical point of view.

FERREIRA J , VUJOSEVIC S

1111	12:00	Diabetic retinopathy - pathophysiology <i>MARQUES-NEVES C - Lisbon</i>
1112	12:22	Neurodegeneration and vascular impairment in the eye of diabetic patients <i>SIMO R , Hernández C - Barcelona</i>
1113	12:44	The changes of the retinal layers in diabetic patients without retinopathy <i>FERREIRA J , Costa L , Proença R , Vicente A , Cunha J P , Abegão L P - Lisbon</i>
1114	13:06	The changes of the retinal layers in diabetic patients with retinopathy <i>VUJOSEVIC S , Bini S , Berton M , Midena G , Martini F , Midena E - Padova</i>



12:00 - 13:30 | RHODES 1

G: Virtual review: Setting new standards in glaucoma care

Glaucoma specialists are increasingly using technology to support follow up care for low risk patients and screen new referrals to maximise the use of existing resources. We will explore various systems of virtual review and hear first hand the experiences of pioneers and users of the technology.

CRAWLEY L , AHMED F

1121	12:00	Virtual review- in glaucoma and beyond <i>CRAWLEY L - London</i>
1122 ★	12:22	Managing a 100 patient glaucoma clinic <i>AHMED F - London</i>
1123	12:44	Early adopters- ahead of the curve and lessons learned <i>LONGSTAFF S - Sheffield</i>
1124 ★	13:06	New software for an old problem <i>DIAMOND J - Bristol</i>



12:00 - 13:30 | RHODES 2

IM: EBO course: Intraocular inflammation and infection (Part 1)



Intermediate

The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.

BODAGHI B , HERBORT CP

1131	12:00	Pathophysiology of uveitis <i>DICK A - Bristol</i>
1132	12:15	Classification of uveitis <i>ANDROUDI S - Thessaloniki</i>
1133	12:30	Signs and symptoms of uveitis <i>NERI P , Arapi I , Pirani V , Gresti G - Agugliano</i>
1134	12:45	Laboratory work-up and specialized investigations <i>PLEYER U - Berlin</i>
1135	13:00	Imaging in uveitis : techniques and indications <i>HERBORT C P - Lausanne</i>
1136	13:15	Therapeutic management of uveitis <i>DICK A - Bristol</i>



12:00 - 13:30 | RHODES 3

COS: How to perform deep anterior lamellar keratoplasty

Intermediate

Deep anterior lamellar keratoplasty (DALK) is the preferred transplant option for corneal stromal pathology. This course will aim as beginners and intermediate level surgeons taking them in a step by step manner through the indications, case selection for beginners, different techniques with emphasis on the most popular big bubble technique, what deviations from the 'routine' can occur and how to recognise and address them and the post-operative management and care required for best visual outcome including how to recognise rejection in DALK grafts. At the end, at least 20-30 minutes will be devoted to interaction with the course delegates to answer specific questions they have related to their technique(s) and problems they have encountered. Besides power point and videos we will also make use of flip chart or blackboard to make drawings to explain fine details as and when required. All delegates will be given a pdf of the powerpoint presentations and some illustrative and instructional videos as part of the package offered on behalf of EVER.

DUA H S

1141	12:00	DALK Techniques from manual to femtolaser <i>NUBILE M , Salgari N , De Nicola C , Mastropasqua L - Chieti</i>
1142	12:18	Big Bubble DALK: The ladder to success, step by step <i>KATAMISHT - Cairo</i>
1143 ★	12:36	DALK: Intraoperative pitfalls and how to manage them <i>DUA H S - Nottingham</i>
1144	12:54	DALK: Post operative management <i>SAID D - Maadi, Cairo</i>
1145 ★	13:12	Discussion, Questions and Answers <i>DUA H S - Nottingham</i>



12:00 - 13:30 | RHODES 4

NSPH: Papilloedema and its Mimics: What's new in pseudotumor cerebri syndrome?

Intermediate

This course will cover 3 areas:

- The differential diagnosis of papilloedema
- The work up of the patient with suspected pseudotumor cerebri syndrome
- The follow-up and decision making on treatment choices of the patient with established pseudotumor cerebri syndrome

SZATMARY G , KAWASAKI A , PARS A C

1151 *	12:00	Differential diagnosis of papilloedema <i>KAWASAKI A - Lausanne</i>
1152	12:30	Work up of the patient with suspected pseudotumor cerebri syndrome <i>SZATMARY G - Hattiesburg</i>
1153	13:00	Follow-up and decision making on treatment choices of the patient with established pseudotumor cerebri syndrome <i>PARSA C - Paris</i>



13:30 - 15:00 | HERMES

RV: Macular hole surgery : New facts and tips for a successful result

Advanced

We are aiming to present new pathophysiological and clinical facts regarding macular hole and give tips in order to perform safer and affective surgery. Expert speakers will present their views in different subjects of macular hole problem. They will present the use of novel advance technology in practice. There will also be panel discussion for the controversial issues of the condition in order to set guidelines for treatment and approach.

PAPPAS G

1211	13:30	Pathophysiology of macular hole formation <i>STAPPLERT - Liverpool</i>
1212	13:48	Macular hole peeling <i>FERRARA V - Borgomanero</i>
1213	14:06	Posturing or not <i>SIMCOCK P - Exeter</i>
1214	14:24	Myopic macular holes <i>MURA M - Amsterdam</i>
1215	14:42	Partial thickness Macular holes and pharmaceutical treatment of FTMH <i>POURNARAS JA - Lausanne</i>



13:30 - 15:00 | RHODES 1

PO: Mistakes in the diagnosis of fundus tumors

Intermediate

This course will describe the diagnosis and management of fundus tumors insisting on the main difficulties: tumors developing in children, problems with the practical attitude in front of a suspicious choroidal naevus, difficulties in the diagnosis of achromic tumors, special problem encountered in the diagnosis of intraocular lymphomas and for all these difficult cases the indications and results of the different imaging tools.

DESJARDINS L , ZOGRAFOS L

1221	13:30	Mistakes in the diagnosis of children intraocular tumors <i>CASSOUX N - Paris</i>
1222	13:48	Suspicious choroidal naevi: when to observe when to treat <i>KIVELÄ T - Helsinki</i>
1223	14:06	Difficulties in the diagnosis of achromic and hemorrhagic lesions <i>DESJARDINS L - Paris</i>
1224	14:24	Problems in the diagnosis of intraocular lymphoma <i>CASSOUX N - Paris</i>
1225	14:42	Indications and interpretations of various imaging techniques <i>ZOGRAFOS L - Lausanne</i>



13:30 - 15:00 | RHODES 2

IM: EBO course: Intraocular inflammation and infection (Part 2)



Intermediate

The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

BODAGHI B , HERBORT C P

1231	13:30	B27-associated uveitis, Fuchs uveitis <i>WILLERMAIN F - Bruxelles</i>
1232	13:48	Infectious uveitis <i>PLEYER U - Berlin</i>
1233	14:06	Behçet's disease, VKH, sarcoidosis <i>KHAIRALLAH M , Kahloun R , Ksiao I - Monastir</i>
1234	14:24	Inflammatory choroiditis <i>HERBORT C P - Lausanne</i>
1235	14:42	Retinal vasculitis <i>BODAGHI B - Paris</i>



13:30 - 15:00 | RHODES 3

COS: In vivo confocal microscopy in corneal disorders

Beginner

Corneal confocal microscopy in vivo makes it possible to analyze corneal architecture on ultrastructural level, including single corneal cells as well as accompanying structures. Introduction with tips how to perform successfully confocal examination – type of used devices and additional lenses, conditions of examination room and preparation of patient that increase quality of obtained scans and improve proper interpretation of images.

WYLEGALA E , SMEDOWSKI A

1241	13:30	Introduction of conofocal examination <i>WYLEGALA E - Katowice</i>
1242	13:45	Conofocal features of healthy cornea <i>DOBROWOLSKI D - Katowice</i>
1243	14:00	Infectious and non infectious keratitis <i>SMEDOWSKI A - Katowice</i>
1244	14:15	Corneal dystrophies <i>NOWINSKA A - Bytom</i>
1245	14:30	Corneal degeneration <i>WOWRA B - Katowice</i>
1246	15:00	Case examples summarizing knowledge of course <i>WYLEGALA E - Katowice</i>



13:30 - 15:00 | RHODES 4

MBGE: Grand rounds in ophthalmic genetics

Cases in ophthalmic genetics. Clinical cases will be shown. Everyone is encouraged to present unknown of interesting diagnostic cases in inherited eye disease. Submission of cases can be done in the room where the Grand Rounds in Ophthalmic Genetics are being held.

LEROY B , HAMEL C

1251	13:30	Cases <i>HAMEL C - Montpellier</i>
1252	13:48	Cases <i>BLACK G C , Hall G , Ramsden S - Manchester</i>
1253	14:06	Cases <i>AUDO I - Paris</i>
1254	14:24	Cases <i>HOLDER G - London</i>
1255	14:42	Cases <i>LEROY B - Ghent</i>



15:30 - 17:00 | HERMES

Opening ceremony

15:30

Welcome by the President EVER 2015

LEROY B - Ghent



15:50

EVER $\mathcal{F}$ Fellowship highlights

SCHMETTERER L - Vienna

Introduction by Bart Leroy



16:00

EVER Past president lecture:
Retinal Vein Occlusions:
From pathophysiological mechanism to clinical
therapeutical issues

POURNARAS C - Genève

Introduction by Bart Leroy



16:40

European Ophthalmology Heritage - A celebration
Homage at Professor Ignacio Barraquer
Melanoma of the ciliary body.
Iridocyclectomy (1968)

BARRAQUER J - Barcelona

Introduction by Bart Leroy





17:00 - 18:30 | HERMES

Women 4 EVER

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed.

DESJARDINS L , KAWASAKI A

17:00 - 18:30 | RHODES 1

G: OCT in glaucoma: Clinical and experimental applications

Optical Coherence Tomography has a leading role in glaucoma management. Hardware and software innovations have given the possibility of studying structures previously inaccessible. Novel objective assessments of structural abnormalities could lead to a change in current diagnostic paradigms. One of the objectives of this SIS is to discuss how to establish new OCT parameters for clinical practice. After diagnosis, robust follow-up methods are essential. Current OCT instruments are equipped with useful progression analysis software which have moderate capability of discrimination between age-related changes, instrument's intrinsic noise, and pathological changes. A second objective of this SIS is to discuss the latest novelties in assessing glaucoma progression with OCT. Due to their accessibility and usefulness, animal models of glaucoma are playing a major role in understanding some of the underlying causes of glaucoma. Optical coherence tomography has been used extensively in animal models of glaucoma and has given the exceptional advantage of longitudinal in-vivo assessments of the natural history of the disease. The third objective of this SIS is to discuss the current applications of OCT in animal models of glaucoma.

NORMANDO E M , GARWAY-HEATH D , CORDEIRO MF

1321	17:00	Establishing new OCT parameters: Is race-specific phenotyping necessary? <i>CHAUHAN B - Halifax, NS</i>
1322	17:30	OCT in assessing glaucoma progression <i>GARWAY-HEATH D - London</i>
1323	18:00	OCT in animal models <i>NORMANDO E M - London</i>



17:00 - 18:30 | RHODES 2

MBGE: Monogenic corneal disorders

Monogenic corneal disorders comprise a group of more than 20 clinically distinct entities. During the last two decades most disease-causing genes have been identified. The special interest symposium will provide an overview of the molecular genetic mechanisms underlying corneal disorders inherited in a Mendelian fashion, advances in the field of genetic testing, the current status of gene-based therapies and how knowledge gained so far has influenced the clinical management of disease.

LISKOVA P , DAVIDSON A

1331	17:00	Understanding the molecular genetic causes of inherited corneal disorders <i>DAVIDSON A - London</i>
1332	17:22	The impact of genetics on the clinical management of patients with monogenic corneal diseases <i>TUFT S J , Evans C , Davidson A , Hardcastle A - London</i>
1333	17:44	Monogenic corneal disorders in children <i>KHAN A - Riyadh</i>
1334	18:06	The Czech Republic experience in a corneal clinic <i>LISKOVA P - Prague</i>



17:00 - 18:30 | RHODES 3

COS: Free paper session - Cornea and ocular surface inflammation

GICQUEL JJ

1341	17:00	Comparative Study of Tacrolimus and Bevacizumab on Corneal Neovascularization in Rabbits <i>KIM S E , Park J H , Chung S K - Seoul</i>
1342	17:12	HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Japanese and Korean populations <i>UETA M , Tokunaga K , Sotozono C , Sawai H , Yoon K C , Kim M K , Seo K Y , Joo C K , Kinoshita S - Kyoto</i>
1343	17:24	Expression of Tissue inhibitor of metalloproteinase in ocular Stevens-Johnson Syndrome: An Immunohistochemical Study <i>VENUGOPAL R , Sen S , Kashyap S , Sharma A , Agarwal T , Sharma N - New Delhi</i>
1344	 17:36	In-vitro anti angiogenic effects of cryo-preserved amniotic membrane <i>FARAJ L , Stewart E , Albert R , Allen C , Petrovski G , Dua H , Amoaku W - Nottingham</i>
1345	 17:48	Intratarsal injection of kenacort in the treatment of severe cases of VKC <i>LAZREG S - Dar el Beida</i>
1346	 17:54	3D model of pterygium and corneal limbus: Investigating histopathology and stem cell distribution. <i>BLOM N , Andreasen A , Heegaard S , Hjortdal J , Nielsen K - Aarhus C</i>
1347	 18:00	Analysis of molecular mechanisms that predispose patients to develop post-PRK haze <i>RAJIV KUMAR N , Ghosh A , Shetty R , Pahuja N - Bangalore</i>
1348	 18:06	Corneal lenticules as an ex-vivo model to study keratocyte biology <i>SHROFF R , Shetty R , Kumar D , Kumar S , Pahuja N , GHOSH A - Bangalore</i>



17:00 - 18:30 | RHODES 4

How to publish - hints and "tricks".....
Beginner

How to get your research published? Pleyer U, Dua H, Kivelä T, Stefánsson E. The goal of this session will be to provide some "keys" to write a high quality paper that will help to transform your ideas and findings into a research article. The panelists will discuss major aspects of the editorial process including basic decisions. We will raise the discussion on issues like: How to choose a journal? How to organize your paper? What are the characteristics of a good manuscript? How to interpret the letter from the editor? How to write a good reply to the reviewers? What to do when your paper is rejected? When can it be appropriate to request a reevaluation of a rejected paper? How to keep your work published – do we have to expect the unexpected....? Most important: The personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

PLEYER U

1351	17:00	Reviewer - friend or foe? <i>PLEYER U - Berlin</i>
1352	17:22	What do we need... <i>DUA H S - Nottingham</i>
1353	17:44	How to keep your research published <i>KIVELÄ T - Helsinki</i>
1354	18:06	Ingredients of a good paper... <i>STEFANSSON E - Reykjavik</i>



17:00 - 18:30 | GALLIENI 1+2

LC: But doctor, will this IOL last my lifetime?

Intraocular lenses were first successfully introduced in cataract surgery in 1950. Initial lenses were plagued by design issues and clinical problems including uveitis, glaucoma and hyphaema. Current lenses are considered to be effective and safe, but is this really the case? This course will review methods of evaluation of IOL biomaterials and contemporary issues that have been identified with lenses.

GRZYBOWSKA A , BEIKO G

1361	17:00	History of IOLs - did it start in Poland? <i>GRZYBOWSKI A - Poznan</i>
1362	17:18	Visual quality assessment and imaging techniques used to study biomaterials <i>SPALTON D - London</i>
1363 ★	17:36	Does IOL choice impact on Driving Performance? <i>BEIKO G - St. Catharines</i>
1364	17:54	Opacification of intraocular lens <i>MATSUSHIMA H - Tochigi</i>
1365	18:12	Current problems with IOLs. <i>AUFFARTH G - Heidelberg</i>



17:00 - 18:30 | GALLIENI 5

PBP: Retinal and choroidal blood flow and oxygenation

Changes in retinal or choroidal blood flow/oxygenation have been found in several eye diseases. In some diseases, the change may be a primary event in the pathogenesis. In other diseases, the change in blood flow/oxygenation may be a secondary response to other processes, such as tissue atrophy. The technology for non-invasive measurements of blood flow and oxygenation is continuously improving and ongoing studies may help us better understand the diseases in question as well as allowing us to objectively measure their progression. This SIS will address the general physiology of blood flow and oxygenation of the retina and choroid and how these parameters change in ischemic and atrophic diseases as well as how the changes can be measured.

HARDARSON S , SIN M

1371	17:00	Physiology of retinal oxygenation <i>STEFANSSON E - Reykjavik</i>
1372	17:22	Blood flow and oxygenation in atrophic diseases <i>TODOROVA M - Basel</i>
1373	17:44	Relation of oxygen saturation to stage of diabetic retinopathy <i>SIN M , Chrapek O , Sinova I , Stanakova L , Rehak J - Olomouc</i>
1374	18:06	Choroidal blood flow and thickness measurements <i>SCHMIDL D - Vienna</i>



18:30 - 18:50 | HERMES

European Ophthalmology Heritage Lecture*Introduction by Marcela VOTRUBA***Visual impairment in opera characters***AYDIN P - Ankara*Summary:

Opera brings the work of singers and musicians together in a theatrical pageant of musical colour and dramatic art. The librettists who devise the stories in works of opera have variously used characters with eye diseases or blindness as major or minor characters in the plots of these stories. This talk will present an array of those operatic characters, along with the possible cause or diagnosis of their eye problems, and will explore the roles which they play in the operas in which they appear, along with their dramatic significance in the flow and resolution of the plot.



Award of the EVER Certificate of Honour

Biography Pinar Aydin O'Dwyer:

Award of the EVER Certificate of Honour Prof Aydin O'Dwyer, completed her ophthalmology training in Turkey and founded the Baskent University Ophthalmology Department, Ankara. She serves as: member of Academia Ophthalmologica Internationalis (AOI, chair LVI), member of the Board of Trustees, Head of the Ethics Committee, member of Eye Care Delivery Committee, member of the Examinations Committee and member of the Fellowships Committee of the International Council of Ophthalmology (ICO). She has served as the past treasurer and Neuro-ophthalmology section program officer of the European Association for Vision and Eye Research (EVER), and the immediate past treasurer of the European Neuro-ophthalmology Society (EUNOS). Author of some 200 scientific publications and editor of 28 books on ophthalmology in Turkish, she has been managing editor and editorial board member on several ophthalmic journals and has given many conferences and courses internationally. Her main interests include neuro-ophthalmology and coaching young academicians, particularly integrating local perspectives into an international approach recognizing cultural distinctiveness. She likewise aims to promote consensus and fellowship through art and music by her presentations on 'Ophthalmology in Art', and the pursuit of her hobbies of playing flute and cello, dancing ballet and writing opera critics. She has two published books on arts: The Book of Ballet (2012) and The Book of Opera (2015).



18:50 - 19:30 | HERMES

Keynote Lecture by Brenda GALLIE

Introduction by Laurence DESJARDIN

Rare retinoblastoma: a goldmine for discovery of fundamental principles of biology and healthcare

GALLIE B - Toronto, Ontario

Summary:

Study of retinoblastoma, a rare eye cancer in children, revealed the essential genetic basis of cancer and delivered personalized medicine for families. Where awareness and resources are available, 98% of children survive retinoblastoma. Next big impact will be the unique opportunity to conduct clinical trials of molecular retinoblastoma prevention trials. However, globally 70% of children with retinoblastoma still die. To address this disparity, One Retinoblastoma World, using a “constellation model” of collaboration, has emerged with multiple innovative partnerships. Ongoing studies map (www.1rbw.org) centres and link to a global learning health system, directly providing evidence from the bedside to optimize care of each newly diagnosed child. Retinoblastoma will become a “Zero Death” cancer.



Award of the EVER Certificate of Honour

Biography Brenda Gallie:

Dr. Brenda Gallie is Director of the Retinoblastoma Program at SickKids Hospital, Professor of Ophthalmology, Molecular Genetics, and Medical Biophysics, University of Toronto, and Senior Scientist at the Princess Margaret Cancer Centre, University Health Network. Dr. Gallie received the Order of Ontario for implementing genetic knowledge in care of children with retinoblastoma.



19:30 - 21:00

EVER Welcome Reception in Exhibition area



EVER 2015
Thursday, Oct 8





7:30 - 8:00 | HERMES
Coffee and Croissants



8:00 - 9:30 | HERMES

RV: Focus on fundus autofluorescence imaging: review and perspectives

This SIS will focus on importance of autofluorescence imaging analysis in fundus pathologies. Autofluorescence technique and photobleaching will be explained and clinical application will be shown in most of retinal and choroidal pathologies. Perspectives of this technique will be developed.

MAUGET-FAYSSE M , WOLFF B

2111	8:00	Fundus autofluorescence and Photobleaching : Definitions <i>MATHIST , De Bats F , Cahuzac A , Wolff B , Scemama Timsit C , Uzzan J , Kodjikian L , Mauget-Faÿsse M - Lyon</i>
2112	8:18	Fundus autofluorescence imaging in White Dot Syndromes <i>DE BATS F , Wolff B , Mathis T , Scemama Timsit C , Cahuzac A , Uzzan J , Mauget-Faÿsse M - Lyon</i>
2113	8:36	Fundus autofluorescence imaging in Toxic Retinopathies and in Gravitational descending atrophic retinal pigmented epithelial tracks <i>CAHUZAC A , Wolff B , Lehmann M , Scemama C , Mauget-Faÿsse M - Paris</i>
2114	8:54	Fundus autofluorescence imaging in Ocular Oncology <i>SCEMAMA TIMSIT C , Mauget-Faÿsse M , Wolff B - Paris</i>
2115	9:12	Fundus autofluorescence imaging in AMD and in Retinal Dystrophies and Perspectives <i>UZZAN J - Rouen</i>



8:00 - 9:30 | RHODES 1

G: All you ever wanted to know about the EGS!

The European Glaucoma Society stands for Innovation, Education and Communication in the field of glaucoma. Indeed the Society offers a wide range of educational opportunities, such as various publications including the EGS Guidelines and several books, educational videos, monthly clinical Tips and Journal Club items, but also Fellowship programs and Travel Grants. An overview of these educational opportunities will be provided. In 2014, an updated version of the EGS Guidelines was published, which is now freely downloadable from the EGS website. The highlights of the EGS Guidelines will be summarized during this SIS. Moreover, the EGS closely collaborates with the European Board of Ophthalmology (EBO). In a joint effort, an EGS-EBO subspecialty diploma was developed. The required curriculum and practical aspects of the examination will be summarized.

STALMANS I , HOMMER A

2121	8:00	The EGS Guidelines: from diagnosis to medical management <i>TRAVERSO C E - Savona</i>
2122 ★	8:18	The EGS Guidelines: a surgical approach to glaucoma <i>HOMMER A - Vienna</i>
2123	8:36	The link with the EBO: the glaucoma subspecialty diploma <i>SUNARIC MEGEVAND G - Geneva</i>
2124	8:54	Discovering the treasures of the EGS website: from educational opportunities to newsletter <i>STALMANS I - Leuven</i>
2125	9:12	Future and perspectives <i>TUULONEN A - Tampere</i>



8:00 - 9:30 | RHODES 2

PBP: Ultrasound course

Intermediate

Ophthalmic ultrasound is an important clinical tool for the characterization of intraocular and orbital pathology. A- and B-scan contact and immersion techniques which are widely used for the characterization of intraocular and orbital pathology. The physical principle underlying ultrasound is the generation of sound waves at MHz frequencies and its reflection by tissue interfaces. The present course first gives an introduction into ultrasound technology and summarizes new developments in the field. The next talk will deal with high-frequency ultrasound and its ability for the diagnosis of anterior segment disease. Another presentation will focus on the use of ultrasound in the diagnosis of orbital disease. A final talk will discuss Doppler ultrasound techniques and their ability to assess ocular blood flow.

SCHMETTERER L , KISSELEVAT

2131	8:00	New development in clinical ultrasound <i>SCHMETTERER L - Vienna</i>
2132	8:22	Ultrasound biomicroscopy in diagnosis of anterior segment pathology <i>RAMAZANOVA K , Kiseleva T , Lugovkina K - Moscow</i>
2133	8:44	Ultrasonography in the management of orbital diseases <i>GUTHOFF R F - Rostock</i>
2134	9:06	Ultrasound methods in the assessment of ocular blood flow <i>KISELEVAT , Ramazanova K , Gavrilenko A , Kuklin A , Adzhemyan N , Chudin A - Moscow</i>



8:00 - 9:30 | RHODES 3

PBP: Relationship between retinal neurons, glia and blood vessels

The coupling between blood flow and neuronal function is a fundamental mechanism for the central nervous system homeostasis. It has recently been shown that also in the human retina neurons, glia cells and blood vessels are tightly coupled. As such, increased neural activity in the retina leads to a subsequent increase in blood flow in the optic nerve head as well as in the retinal vasculature. It is now understood that also in the human retina, the coupling between neural activity and blood flow is an essential physiological mechanism to assure constant supply of the ocular tissue with oxygen and nutrients. This SIS aims to summarize our current knowledge on the physiological importance of the relationship between neurons, glia cells and blood vessels. In addition, the molecular mechanisms potentially involved in this regulation process will be covered. Finally the role of neuro-vascular coupling and its potential application in the diagnosis and follow up in neuro-degenerative diseases will be discussed.

GARHÖFER G

2141	8:00	Monocarboxylate transporters and their functions in the retina <i>OSBORNE N - Oxford</i>
2142	8:22	Doppler Optical Coherence Tomography - A New Method For The Assessment Of Neurovascular Coupling In The Retina <i>WERKMEISTER R , Aschinger G , Schmetterer L - Vienna</i>
2143	8:44	Neuro-vascular coupling – molecular mechanisms and potential clinical applications <i>GARHOFER G - Vienna</i>
2144	9:06	Candidate Retinal Biomarkers in CNS Neurodegenerative Disease <i>HUDSON C - Waterloo</i>



8:00 - 9:30 | RHODES 4

IM: Uveitis in the East and West

This Special Interest Symposium is presented in partnership between the Society of Ophthalmo- Immuno- Infectiology in Europe (SOIE), members of the Japanese Ocular Inflammation Society (JOIS) and EVER. The aim is to address specific aspects in the appraisal of uveitis between Japan and Europe.

NERI P , TAKEUCHI M

2151	8:00	Behçet's uveitis in Japan: evaluation of the long-term efficacy and safety of infliximab treatment <i>TAKEUCHI M - Tokyo</i>
2152	8:12	Behçet's uveitis in Turkey, why is it still number one? <i>TUGAL-TUTKUN I - Istanbul</i>
2153	8:24	Choroidal thickness in acute and convalescent VKH disease <i>TAKASE H - Tokyo</i>
2154	8:36	Stromal choroiditis in East (VKH) and West (birdshot) <i>HERBORT C P - Lausanne</i>
2155	8:48	Relationship of ocular disease activities before and after starting infliximab using Behçet's disease ocular attack score 24 <i>KABURAKI T , Okinaga K , Takamoto M , Ohtomo K , Yoshida A , Kawashima H , Komae K , Fujino Y - Tokyo</i>
2156	9:00	The CD4/CD8 ratio in vitreous fluids is of high diagnostic value in sarcoidosis <i>MARUYHAMA K - Sendai</i>
2157	9:12	Viral retinopathies: a spectrum of disease from East to West <i>BODAGHI B - Paris</i>



8:00 - 9:30 | GALLIENI 1+2

NSPH: New perspectives on the funny looking disc

This symposium addresses the optic disc that simply does not look normal. In some cases, it is a congenital anomaly. Several examples will be presented , notably optic disc hypoplasia with its neurologic and genetic considerations. We also discuss acquired structural alterations of the optic disc, notably myopia-associated changes. The participant will have a better understanding of congenital and acquired changes in optic disc appearance.

KAWASAKI A , OHNO-MATSUI K

2161	8:00	Myopia-associated changes of the optic disc <i>OHNO-MATSUI K - Tokyo</i>
2162	8:22	Optic nerve hypoplasia: Evaluation and genetic considerations <i>YU-WAI-MAN P - Newcastle upon Tyne</i>
2163	8:44	Optic disc tumors <i>BOSCHI A - Bruxelles</i>
2164	9:06	Using OCT to evaluate the funny looking disc <i>BORRUAT FX - Lausanne</i>



8:00 - 9:30 | GALLIENI 5

ACB: Corneal stem cells - from benchside to bedside

This SIS will focus on cell biology applications in corneal stem cells research, spanning from topics on the use of induced pluripotent cells' to adult stem cells, as well as gene modification applications from benchside to bedside.

PETROVSKI G , MOE M

2171	8:00	Human pluripotent stem cells as a source of corneal epithelium <i>SKOTTMAN H - Tampere</i>
2172	8:18	Genetic modification possibilities in treating corneal diseases <i>MOORET , Courtney D , Atkinson S , Maurizi E , Allen E , McLean I , Leslie Pedrioli D , Moore J , Nesbit A - Coleraine</i>
2173 ★	8:36	Novel techniques in corneal regeneration and bioscaffold engineering <i>LAGALI N , Rafat M , Xeroudaki M , Koulikovska M , Fagerholm P - Linköping</i>
2174	8:54	Clinical results and in vitro characterization of cornea limbal epithelial stem cells cultured in autologous serum <i>MOE M - Oslo</i>
2175	9:12	Long-term cultivation of corneal stem cells - possible applications from benchside to bedside <i>PETROVSKI G - Szeged</i>



9:45 - 10:25 | HERMES

EVER-Acta Lecture by Russell FOSTER

Acta
Ophthalmologica

Introduction by Einar STEFANSSON

Regulating the body clock – The unrecognised role of the eye

FOSTER R - Oxford

Summary:

Little more than a decade ago discussion that the eye might contain another photoreceptor, different from the rods and cones, generated either polite amusement or a hostile rebuttal. The dogma was that all light detection took place by these photoreceptors whilst the other cells of the retina act only to process visual signals. However, several lines of research led to the discovery that the vertebrate eye, including humans, contains another class of photoreceptor based upon a small number of photosensitive retinal ganglion cells (pRGCs). These specialised neurons detect environmental irradiance and regulate a wide range of physiology and behaviour including the regulation of 24h body clocks, sleep, alertness, mood and even pupil size. Furthermore, the pRGCs have been shown to utilize a novel light signalling pathway based upon the photopigment melanopsin. Collectively these findings have transformed our understanding of how the eye detects light and are redefining our assessment, treatment and care of individuals with eye disease. The discovery and current understanding of this "third" class of ocular photoreceptor will be reviewed in this presentation.



Award presentation

Biography Russell FOSTER:

Russell is Professor of Circadian Neuroscience at the University of Oxford, Chair of the Nuffield Laboratory of Ophthalmology, Director of the Sleep and Circadian Neuroscience Institute (SCNi), Fellow of Brasenose College and was elected to the Royal Society in 2008 and the Academy of Medical Sciences in 2013. His research considers the mechanisms that regulate and generate circadian rhythms and sleep; and what happens when these systems are disrupted in brain disease. He has over 180 publications and co-authored "Rhythms of Life"; "Seasons of Life" and most recently "Sleep a very short introduction" for OUP. He is Chair of the Cheltenham Science Festival; Member of Council for BBSRC; Member of the Governing Council, The Sainsbury-Wellcome Centre; In March 2012 he was awarded BBSRC Social Innovator of the Year.



10:30 - 12:00 | HERMES

RV: Free paper session - Diabetes

CREUZOT C , STAURENGHI G

2211	*	10:30	Intravitreal Aflibercept (IVT-AFL) for Diabetic Macular Edema (DME): 3 Year Data from VIVID-DME and VISTA-DME <i>STAURENGHI G , Metz C - Milan</i>
2212	*	10:42	Impact of Intravitreal Aflibercept (IVT-AFL) on Diabetic Retinopathy in the VIVID-DME and VISTA-DME Studies <i>LARSEN L M , Metz C - Glostrup</i>
2213		10:54	Evaluation of the Variation in Thickness of the Different Retinal Layers in Diabetic Patients with OCT <i>VICENTE A , Cardigos J , Lívio C , Proença R , Santos A , Cunha J P , Abegão Pinto L , Ferreira J - Lisbon</i>
2214		11:06	Choroidal Thickness in Diabetic Patients without Diabetic Retinopathy <i>FERREIRA J , Vicente A , Proença R , Dias-Santos A , Santos B , Cunha J P , Abegão-Pinto L - Lisbon</i>
2215	rf	11:18	Choroidal Thickness and Systemic Examination in Diabetic Patients with out Diabetic Retinopathy <i>CARDIGOS J , Vicente A , Costa L , Crisóstomo S , Marques N , Cunha J P , Pinto L A , Ferreira J - Lisbon</i>
2216	rf	11:24	Automatic method to distinguish manifestation areas of early diabetic retinopathy from image artefacts by using L*u*v* colour space <i>SUZUKI N , Yamane K - Numazu</i>
2217	* rf	11:30	Dexamethasone Reverses the Effects of High Glucose on Human Retinal Endothelial Cells In Vitro <i>STEWART E , Saker S , Amoaku W - Nottingham</i>



10:30 - 12:00 | RHODES 1

G: Lifetime risk of blindness from glaucoma

With the growing older population, the number of patients diagnosed and monitored with glaucoma is increasing. These patients are set to have lifelong ophthalmology care, but just what is their risk of blindness once diagnosed and are we managing our patients appropriately with respect to their risk? This SIS will tackle some of these questions and encourage a discussion on whether we need to reassess our management strategies for this group of patients.

KOTECHA A , MCNAUGHT A

2221		10:30	Risk management: how does patient management in ophthalmology compare with those of other medical disciplines? <i>KOTECHA A - London</i>
2222		10:48	Are we over prescribing in Glaucoma? <i>TUULONEN A - Tampere</i>
2223		11:06	Detecting and managing blindness risk in glaucoma <i>MCNAUGHT A - Cheltenham</i>
2224		11:24	Risk of visual impairment from glaucoma <i>CRABB D - London</i>
2225		11:42	Automated 'big-data' analysis to risk stratify your patients <i>JOHNSTON R - Gloucestershire</i>



10:30 - 12:00 | RHODES 2

COS: Free paper session - Tear film exploration and dry eye

DOAN S , GICQUEL JJ

2231		10:30	The Four Seasons of Dry Eye DiseaseSeasonal Variations in Presenting Symptoms and Signs of Dry Eye Disease in Norway <i>EIDET J R , Ræder S , Chen X , Badian R , Uttheim Ø , Uttheim T P - Oslo</i>
2232		10:42	Altered micro-RNA21 expression correlates with enhanced peripheral IL-23p19 levels patients with primary Sjögren's syndrome <i>NI GABHANN J , Pilson Q , Jefferies C , Murphy C - Dublin</i>
2233		10:54	Standardising the Schirmer Test by Enclosing the Strip in a Waterproof Sheath. <i>WILLSHIRE C , Buckley R , Bron A - Cambridge</i>
2234		11:06	A Fresh Look at Tear Film Structure and Dynamics <i>BRON A J , Yokoi N , Georgiev G - Oxford</i>
2235	rf	11:18	Novel role of PELI3 as a potential biomarker for Sjogren's syndrome related dry eyes <i>PILSON Q , Ni Gabhann J , Murphy C C - Dublin</i>
2236	rf	11:24	Three dimensional meibography for diagnosis of dry eye syndrome <i>BYUNY S , Yoo Y S , Eom T J , Na K S , Joo C K - Seoul</i>
2237	rf	11:30	Randomised, controlled study of the efficacy and safety of a new eye-drop formulation for moderate to severe dry eye syndrome <i>DOAN S , Baudouin C , Khairallah M - Paris</i>
2238	rf	11:36	Efficacy of Dry Eye Disease Treatment based on the 2007 Report of the International Dry Eye WorkShop (DEWS) <i>UTHEIM O , Ræder S , Uttheim T P , Eidet J R , Badian R , Stojanovic A , Chen X - Oslo</i>



10:30 - 12:00 | RHODES 3

PBP: Free paper session - Pharmacology / drug delivery / physiology

OSBORNE N , GARHÖFER G

2241	★	10:30	SRPK1 inhibitors as novel anti-angiogenic therapeutics for wet age-related macular degeneration (wAMD) <i>BATSON J , Toop H , Rowlinson J , Allen C , Gibbons B , Zhang J , Wearmouth S , Knapp S , Morris J , Bates D - Nottingham</i>
2242	rf	10:42	Ghrelin inhibits choroid-retinal cell migration, proliferation and in vitro angiogenesis, under a high glucose environment <i>ROCHA DE SOUSA A , Silva-Gomes R , Conceição G , Moleiro A , Santos C , Leite-Moreira A - Porto</i>
2243		10:48	Surface Modification of Intraocular Lenses Towards Controlled Drug Delivery <i>FILIFE H P , Bozukova D , Pimenta A , Vieira A P , Alves P , Coimbra P , Guiomar A J , Gil M H , Mata J L G , Serro A P - Lisbon</i>
2244		11:00	Use of retinal oximetry in estimating cerebral tissue oxygenation <i>VAN KEER K , Abegão Pinto L , Stalmans I , Vandewalle E - Leuven</i>
2245	rf	11:12	The diameter regulation of retinal arterioles during systemic hypoxia is impaired in diabetic patients without retinopathy <i>PETERSEN L , Bek T - Aarhus</i>



10:30 - 12:00 | RHODES 4

IM: Inflammation in diabetic retinopathy-part 1

Diabetic retinopathy (DR) is the commonest microvascular complication of diabetes and remains one of the leading causes of blindness worldwide. The two most important visual complications of DR are diabetic macular edema and proliferative diabetic retinopathy. Many of the molecular and functional changes that are characteristic of inflammation have been detected in retinas from diabetic animals or humans, and in retinal cells under diabetic conditions. A large body of evidence supports the role of proinflammatory cytokines, chemokines, matrix metalloproteinases and other inflammatory mediators in pathogenesis of diabetic retinopathy leading to persistent low grade inflammation, and influx of leukocytes contributing to damage to the retinal vasculature and neovascularization. The causal relationship between inflammation and angiogenesis is now widely accepted. An emerging issue in diabetic retinopathy research is the focus on the mechanistic link between activation of subclinical inflammation and angiogenesis. Leukostasis has been found to be significantly increased in retinas of diabetic animals and might contribute to the capillary nonperfusion in diabetic retinopathy. Leukostasis has been postulated to be a factor in death of endothelial cells and breakdown of the blood-retinal barrier. Leukocyte recruitment and adhesion to the retinal vasculature correlate with increased expression of retinal intercellular adhesion molecule-1 and elevated expression of the β -integrin subunit CD18 on neutrophils. In addition, the increased expression of many inflammatory proteins are regulated at the level of gene transcription through the activation of proinflammatory transcription factors such as NF- κ B.

ABU EL ASRAR A

2251	10:30	Matrix metalloproteinase in diabetic retinopathy <i>OPDENAKKER G - Leuven</i>
2252	10:52	Role of chemokines in diabetic retinopathy <i>STRUYF S , Mohammad G , Imtiaz Nawaz M , Van Raemdonck K , De Hertogh G , Van Damme J , Abu El-Asrar A M - Leuven</i>
2253	11:14	Inflammatory mediators of diabetic retinopathy: lessons from proteomic analysis <i>SIMO R , Simó-Servat O , Hernández C - Barcelona</i>
2254	11:36	Immune cell activation in diabetic retinopathy <i>XU H , Chen M - Belfast</i>
2218	11:58	Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT) <i>ABU EL ASRAR A , De Hertogh G , Van den Eynde K , Alam K , Van Raemdonck K , Opendakker G , Van Damme J , Geboes K , Struyf S - Riyadh</i>



10:30 - 12:00 | GALLIENI 1+2

MBGE: Mitochondrial optic neuropathies - classical disease and novel manifestation

A decline in mitochondrial function plays a role in the ageing process and increases the incidence of age-related disorders. A better understanding of mitochondrial function, including dynamics, is revealing that functional and structural changes in mitochondrial morphology are important factors in diseases of ageing in the eye and visual system. Key proteins have been discovered which control the balance of mitochondrial fusion and fission and have a range of other functions, such as controlling maintenance of mitochondrial DNA, cell death, autophagy, mitochondrial metabolism and redox signalling. This SIS will explore clinical aspects of mitochondrial optic neuropathy.

VOTRUBA M , YU-WAI-MAN P

2261	10:30	Extraocular phenotyping of mitochondrial optic neuropathy <i>MARTINUZZI A , Vavla M , Papayannis A , Petacchi E , Carraro E , Paparella G , Privato F , Prosdocimo G - Treviso</i>
2262	10:48	LHON and extraocular features <i>YU-WAI-MAN P - Newcastle upon Tyne</i>
2263	11:06	Vascular supply in mitochondrial optic neuropathy and glaucoma <i>BARBONI P - Bologna</i>
2264	11:24	Early-onset Behr syndrome due to compound heterozygous mutations in OPA1 <i>BONNEAU D , Lenaers G , Procaccio V , Amati-Bonneau P , Reynier P - Angers</i>
2265	11:42	Leber's Hereditary Optic Neuropathy (LHON) mtDNA mutations cause cell death by overproduction of reactive oxygen species <i>SADUN A , Carelli V , La Morgia C , Karanjia R - Los Angeles</i>



10:30 - 12:00 | GALLIENI 5

ACB: Inflammation, wound healing and tear proteomics

Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. The system has its own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. It consists of many overlapping processes like inflammation, fibroblast activation, ECM production and remodeling of the ECM and there are many mechanisms and mediators involved in it. Tear proteomics is a powerful tool to diagnose and detect mechanisms and drugable targets of the ophthalmic and systemic diseases. SIS is focusing in the proteomics and biomarkers of the tears and anterior surface of the eye in relation these diseases.

UUSITALO H , BEUERMAN R

2271	10:30	Tear proteomics in health and disease <i>BEUERMAN R - Singapore</i>
2272	10:52	Environmental factors in ocular surface disease <i>CALONGE M , Gonzalez-Garcia M J , Enriquez de Salamanca A , Fernandez I , Pinto-Fraga J , Teson M , Martin-Montanez V , Stern M E , Lopez-Miguel A - Valladolid</i>
2273	11:14	Inflammation, wound healing and tear proteomics in glaucoma <i>UUSITALO H - Tampere</i>
2274	11:36	Bioinformatics in tear proteome <i>NYKTER M - Tampere</i>



12:00 - 13:00 | RHODES 2

Ocular surface: What's new ?

SCHMETTERER L , BAUDOUIN C

2331	12:00	New paradigm in Dry Eye Disease (DED) <i>BAUDOUIN C - Boulogne Billancourt</i>
2332	12:12	Visual function impairment in Dry Eye Disease (DED) <i>PISELLA P J - Tours</i>
2333	12:24	MEIBUM survey: a closer look at the eyelids <i>DIAZ VALLE D - Madrid</i>
2334	12:36	New treatment to improve Tear film thickness in Dry Eye Disease (DED) <i>SCHMETTERER L - Vienna</i>



13:10 - 13:45 | HERMES

Ophthalmic Research Lecture

Introduction by Bart LEROY

Ophthalmic
Research

Degenerative myopia and its treatment

WIEDEMANN P - Leipzig

Summary:

High myopes are handicapped by visual impairment and degenerative complications eventually leading to blindness. Myopic refraction can be corrected by refractive lens exchange. Retinal detachment may be the consequence and a possible prevention by vitrectomy will be discussed. However, the fundamental problems of degenerative myopia, the features of myopic fundus disease and the posterior staphyloma cannot be treated. Scleral cross linking possibly stiffens the sclera. By this means we could stop eye growth and possibly reduce myopic complications. Experiments to stop eye growth by scleral crosslinking will be presented.



Award presentation

Biography Peter WIEDEMANN:

Peter Wiedemann is a specialist in medical and surgical retina and head of the Department of Ophthalmology at Leipzig University, Germany.

He studied medicine in Bochum, Rennes, Stanford, and Erlangen. Then he spent 4 years in pharmacology. At the Doheny Eye Institute in Los Angeles he worked with Stephen J. Ryan. Stephen J. Ryan and K. Heimann, who later became his teacher at the University of Cologne, were his mentors. Along with his clinical work in Leipzig, he continued his research work in the field of macular degeneration, diabetic retinopathy and proliferative vitreoretinopathy (PVR). He is co editor of Ryan's RETINA.

He was President of the Saxonian Ophthalmological Society (1994, 1999, 2005, 2008 and 2012), President of the German Ophthalmological Society (2009) and member of the Club Jules Gonin Executive Committee (2000–2006). He was the Scientific Program Chair for the World Ophthalmology Congress (WOC 2012 and 2014). He is a member of the German Academy of Sciences Leopoldina, Secretary-General of the Academia Ophthalmologica Internationalis, member of the European Academy of Ophthalmology and treasurer of the ICO (International Council of Ophthalmology).

Honors and awards

1989 Prix Galien / 1997 BEAVRS Alcon Professorship / 1998 Gonin Lecture / 2004 Montgomery Lecture / 2010 Doheny Scholar / 2011 ARVO Silver Fellow



13:45 - 15:15 | HERMES

RV: Free paper session - Surgery**BERROD J , POURNARAS C**

2411	13:45	The "complete vitrectomy performed early" treatment philosophy <i>ROCHA DE SOUSA A , Gouveia P , Correia-Pinto Jr J , Alves-Faria P , Falcao-Reis F - Porto</i>
2412	13:57	Early experiences with intravitreal ocriplasmin: a series of cases with vitreomacular traction <i>SCHULZ C , Saunders D , Lockwood A , Begum S - Portsmouth</i>
2413	14:09	Anatomic and functional follow-up of foveal microstructures after macula-off retinal detachment surgery <i>DESCHASSE C , Kauffmann Y , Frérot M , Chiquet C , Berrod J , Le Mer Y , Arndt C , Tadayoni R , Korobelnik J , Weber M , Gaucher D , Delbosc B , Bron A M , Creuzot Garcher C - Dijon</i>
2414	14:21	Anterior chamber aqueous flare in retinal detachment surgery. <i>BERROD J P , Kurun S , Mouna A , Jeancolas A L , Ferte A , Conart J B - Vandoeuvre les Nancy</i>
2415	<i>rf</i> 14:33	Improvement in retinal vessel oxygen saturation after vitrectomy <i>LIM S L , Tan L , Perera S - Singapore</i>
2416	<i>rf</i> 14:39	Imaging of intravitreal injected solution dispersion. <i>WILLEKENS K , Reyns G , Jonckx B , Feyen J H M , Yewei L , Coudyzer W , Yicheng N , Stalmans P - Leuven</i>
2417	<i>rf</i> 14:45	The use of intraoperative spectral domain optic coherence tomography in vitreoretinal surgery: The evaluation of efficacy. <i>LYTVYNCHUK L , Glittenberg C , Binder S - Lviv</i>
2418	<i>rf</i> 14:51	Epiretinal membrane peeling for eyes with asteroid hyalosis: a case-control study <i>MOUNA A , Conaert J B , Kurun S , Ameloot F , Berrod J P - Vandoeuvre les Nancy</i>



13:45 - 15:15 | RHODES 1

G: Does glaucoma affect only retinal ganglion cells in the retina?

The progressive loss of RGCs, and their axons, with concomitant insidious defects in the visual field, as well as changes in the optic disc, has been the classic hallmark of the glaucomatous optic neuropathies (GON). This concept however, has evolved and it is now well established that GON involve not only the RGC population, the nerve fiber layer of the retina, the optic disc and optic nerve head, but also the main retinorecipient subcortical and cortical nuclei of the primary visual pathway, such as the lateral geniculate nucleus and primary and secondary visual areas of the cortex. In addition, several groups have documented important molecular, functional and structural changes in the outer retinal layers of the retina in human glaucoma studies, as well as in non-human primate and rodent models of glaucoma or ocular hypertension. Thus, the concept of glaucoma as a solely disease of the retina and optic nerve has evolved to broader implications of the primary visual pathway. The Symposium will present studies focussing on changes in the non-retinal ganglion cell layers of the retina and will provide ample opportunity for interaction among scientists attending the conferences.

VIDAL-SANZ M , NORKT M

2421	13:45	Transneuronal degeneration in human glaucoma: A novel multiphoton-DAPI approach <i>MORGAN J E - Cardiff</i>
2422	14:15	Ocular hypertension in adult rodents does not affect non-RGC neurons in the ganglion cell layer but results in severe loss of cone-photoreceptors <i>VIDAL-SANZ M , Rodríguez-Llarena S , Ortín-Martínez A , Salinas-Navarro M , Nadal-Nicolás F M , Valiente-Soriano F J , Villegas-Pérez M P - Murcia</i>
2423	14:45	Anatomic, biochemical and functional evidence for cone injury in glaucoma <i>NORKT M , Kim C B Y , Nickells R W , Ver Hoeve J N - Madison</i>



13:45 - 15:15 | RHODES 2

COS: Free paper session - Corneal bioengineering

THURET G , LYNCH A

2431		13:45	Mass production of high quality corneal endothelial cells from old donors <i>HE Z , Forest F , Perrache C , Cognasse F , Cognasse H , Gain P , Thuret G - Saint Priest en Jare</i>
2432		13:57	Epithelial wound healing in a model of porcine corneas stored in an innovative bioreactor <i>GUINDOLET D , He Z , Bernard A , Regeade D , Piselli S , Perrache C , Forest F , Peoch M , Gain P , Gabison E , Thuret G - Paris</i>
2433		14:09	Ultrastructural maintenance of decellularized corneas using dextran <i>LYNCH A , Wilson S , Ahearne M - Dublin</i>
2434		14:21	Self-complementary vectors for optimization of AAV2-mediated gene-therapy of corneal endothelial cells <i>GRUENERT A , Buening H , Schnoedt M , Schmeer M , Schleef M , Kruse F E , Fuchsluger T A - Erlangen</i>
2435		14:33	Designing an innovative bioreactor destined to improve the endothelial viability of stored corneas <i>RAGEADE D , Bernard A , Nangoum-Fosso T , Herbepin P , He Z , Perrache C , Piselli S , Acquart S , Thuret G , Gain P - Saint Priest en Jarez</i>
2436		14:45	Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high risk penetrating keratoplasty: a 2-year follow-up study <i>SZAFLIK J P , Major J , Izdebska J , Lao M , Szafluk J - Warszawa</i>



13:45 - 15:15 | RHODES 3

NSPH: The role of the corpus callosum in binocularity and strabismus

The role of the corpus callosum in binocularity and strabismus In placental mammals there seems to be an important role for the corpus callosum in binocularity. The corpus callosum represents the midline. In order to perceive a smooth sensory fusion of the right and the left body parts, the middle is represented on both sides. The same holds true for vision. To be able to fuse the right and left visual field, the retina contains both crossed and uncrossed ganglion cells. A small strip in the middle of the visual field is seen by both the right and the left visual cortex. The corpus callosum is likely involved in human binocular motor fusion and disparity detection. In mammals like rats, binocularity almost completely depends on callosal transfer. Binocularity of the visual cortex is realized by both the signal of the contralateral eye through the geniculate pathway, and the signal from the ipsilateral eye through the contralateral geniculate and back through the corpus callosum. Transection of crossing ganglion cells in the cat chiasm does not change disparity detection of the cortex much. Animal and human data regarding the role of the corpus callosum in binocularity and strabismus are presented.

TEN TUSSCHER M

2441		13:45	Sensory and motor fusion <i>HOUTMAN A C - Brussel</i>
2442		14:07	Normal vision, strabismus and the corpus callosum in animals <i>MILLERET C - Saint Gratien</i>
2443		14:29	The origins of strabismus and loss of binocular vision. Implication of the corpus callosum <i>BUI QUOC E - Paris</i>
2444		14:51	The corpus callosum in human binocularity and strabismus <i>TENTUSSCHER M - Brussel</i>



13:45 - 15:15 | RHODES 4

IM: Inflammation in diabetic retinopathy-part 2

Diabetic retinopathy (DR) is the commonest microvascular complication of diabetes and remains one of the leading causes of blindness worldwide. The two most important visual complications of DR are diabetic macular edema and proliferative diabetic retinopathy. Many of the molecular and functional changes that are characteristic of inflammation have been detected in retinas from diabetic animals or humans, and in retinal cells under diabetic conditions. A large body of evidence supports the role of proinflammatory cytokines, chemokines, matrix metalloproteinases and other inflammatory mediators in pathogenesis of diabetic retinopathy leading to persistent low grade inflammation, and influx of leukocytes contributing to damage to the retinal vasculature and neovascularization. The causal relationship between inflammation and angiogenesis is now widely accepted. An emerging issue in diabetic retinopathy research is the focus on the mechanistic link between activation of subclinical inflammation and angiogenesis. Leukostasis has been found to be significantly increased in retinas of diabetic animals and might contribute to the capillary nonperfusion in diabetic retinopathy. Leukostasis has been postulated to be a factor in death of endothelial cells and breakdown of the blood-retinal barrier. Leukocyte recruitment and adhesion to the retinal vasculature correlate with increased expression of retinal intercellular adhesion molecule-1 and elevated expression of the β -integrin subunit CD18 on neutrophils. In addition, the increased expression of many inflammatory proteins are regulated at the level of gene transcription through the activation of proinflammatory transcription factors such as NF- κ B.

ABU EL ASRAR A

2451	13:45	Role of High-mobility group box-1 in diabetic retinal vasculopathy and neuropathy <i>ABU EL ASRAR A - Riyadh</i>
2452	14:07	Bioactive Lipids and Early inflammatory Response in diabetic Retinopathy <i>AL-SHABRAWAY M , Ibrahim A , Beasley S , Wang F , Tawfik A - Augusta</i>
2453	14:29	Mutual Enhancement Between High-Mobility Group Box-1 And NADPH Oxidase-Derived Reactive Oxygen Species Mediates Diabetes-Induced Upregulation Of Retinal Apoptotic Markers <i>MOHAMMAD M , Abu El-Asrar A - Riyadh</i>
2454	14:51	Evaluation of T-cell related cytokines in the vitreous of proliferative diabetic retinopathy <i>TAKEUCHI M - Tokyo</i>



13:45 - 15:15 | GALLIENI 1+2

MBGE: Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a clinical key feature. The commonest causes world-wide is mutation in mitochondrial DNA (causing Leber's Hereditary Optic Neuropathy) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). 60-80% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. Inherited optic neuropathy is an 'orphan' disease. However, the disease prevalence is not so low (1: 20,000 to 35,000), and it is estimated that there are 5000 to 8000 distinct rare diseases, affecting 6-8% of the population of the European Union (27-36 million people). Recent trials of the drug idebenone, a co-enzyme Q10 analogue, in patients with the mitochondrial optic neuropathy, Leber's hereditary optic neuropathy, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time this SIS will focus on disease mechanisms and potential avenues towards therapy.

VOTRUBA M , YU-WAI-MAN P

2461	13:45	Dominant Optic Atrophy plus phenotype caused by a deep intronic mutation and a modifier variant in the OPA1 gene <i>WISSINGER B , Bonifert T , Gonzalez-Menendez I , Theurer Y , Synofzik M , Schoels L - Tuebingen</i>
2462	14:03	Involvement of mitochondrial dynamics in the physiopathology of Dominant Optic Atrophy <i>LENAERS G - Montpellier</i>
2463	14:21	Genetic landscape of Leber's hereditary optic neuropathy: reflection on pathogenic mechanisms <i>CARELLI V , La Morgia C , Caporali L , Maresca A , Giordano L , Valentino M L , Barboni P , Cantatore P , D'Adamo P - Bologna</i>
2464	14:39	Update on treatment strategies for LHON <i>YU-WAI-MAN P - Newcastle upon Tyne</i>
2465 ★	14:57	Gene therapy in LHON <i>VIGNAL-CLERMONT C , Corral Debrinski M , Sahel J A - Paris</i>



13:45 - 15:15 | GALLIENI 5

ACB: New wine in new tubes - The re-advancement of scleral lenses in ocular surface disease

Even though the scleral "contact lens" - a precorneal lens with very large diameter that rests on the sclera and safely covers the cornea via a tear-filled vault zone - was the originally invented type of a contact lens it has rapidly lost the interests of eye doctors and patients after the advent of small diameter corneal lenses and eventually after the invention of soft contact lenses. Still, the large scleral lenses have certain advantages since they can safely bathe the cornea in a moist chamber that allows a surprising improvement and healing of chronic pathological processes at the ocular surface. Scleral lenses can often be the only possible way to restore acceptable or even perfect vision in corneas with higher order refractive disorders and/or keratokonus. Therefore scleral lenses can often preserve or restore vision without "needing a knife" - which may be an important advantage not only in countries with a less developed health system. In recent years new lens designs and high tech materials have distinctly improved the fitting as well as the wearing of scleral lenses. To some surprise, patients often consider, after an adaption phase, a scleral lens as that type of contact lens that is causing the least ocular irritation as compared to other contact lens types.

KNOP E , MEKKI M B

2471	13:45	Is there something like a "Healthy Contact Lens" ? <i>KNOP E , Knop N - Berlin</i>
2472	14:00	Longterm restoration of ocular surface function with scleral lenses <i>CARRASQUILLO K G - Boston</i>
2473	14:15	Scleral lenses in the management of exposure/neurotrophic keratopathy in patients with cranial nerve palsy <i>SCHORNACK M - Rochester</i>
2474 *	14:30	Scleral lens as a first therapeutic weapon in severe ocular burns <i>MEKKI M B , Yahiaoui S , Titah O , Belaoudmou R - Algiers</i>
2475 *	14:45	Indications for scleral lenses <i>LEYSEN I - Edegem</i>
2476	15:00	Improving vision and comfort of patients with corneal deformations with implementation of ultraHealth and ultraHealth FC S-H Hybrid Lenses <i>MANCZAK H - Poznan</i>



15:15 - 16:00 | POSTER AREA

Coffee with the Prof

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called "Coffee with the Prof". This will be a table of 6-8 "guests" at a table headed by one of the EVER speakers.

The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.

The Profs are:

- Pinar AYDIN
- Russell FOSTER
- Reza DANA
- Constantin POURNARAS
- Peter WIEDEMANN
- Marcela VOTRUBA
- Bart LEROY

Registration required and will open onsite at registration. First come first served.



15:15 - 16:00 | POSTER AREA

ACB: Anatomy / Cell Biology

PETROVSKI G , KAARNIRANTA K

T001	<i>rf</i>	Fisetin and Luteolin decrease inflammation and oxidative stress-induced cytotoxicity in ARPE-19 cells <i>HYTTI M , Piippo N , Korhonen E , Kaarniranta K , Kauppinen A - Kuopio</i>
T002	<i>rf</i>	cis-Urocanic acid prevents inflammation and cell death in UVB-treated ARPE-19 cells <i>KORHONEN E , Piippo N , Hytti M , Kaarniranta K , Kauppinen A - Kuopio</i>
T003		Nrf2- and PGC-1 -deficient mice: A novel animal model for impaired autophagy in AMD? <i>PATERNO J J , Smedowski A , Hytti M , Bjørkøy G , Amadio M , Levonen A L , Tavi P , Kauppinen A , Kaarniranta K - Kuopio</i>
T004		Hypoxia induces an inflammatory response in ARPE-19 cells <i>ARJAMAA O , Aaltonen V , Piippo N , Kaarniranta K , Kauppinen A - Turku</i>
T005		Autophagy stimulus affects different kinase pathways and promotes HuR protein activation and SQSTM1/p62 protein synthesis in ARPE-19 cells <i>AMADIO M , Marchesi N , Govoni S , Pascale A , Kaarniranta K - Pavia</i>
T006		SQSTM1/p62 depletion leads to the Rab7 accumulation and inflammatory response in ARPE-19 cells <i>PIIPPO N , Hyttinen J , Hytti M , Korhonen E , Kaarniranta K , Kauppinen A - Kuopio</i>
T007		Lack of collagen XVIII in mice evokes age-dependent deficiency in retinal pigment epithelium proteostasis <i>KIVINEN N , Felszeghy S , Aikio M , Pihjalaniemi T , Kaarniranta K - Kuopio</i>
T008	*	Interventions against VEGF overexpression, available strategies and future developments <i>AMADIO M , Bucolo C , Govoni S , Drago F , D'Agata V , D'Amico A G , Cupri S , Pignatello R , Pascale A - Pavia</i>
T009		Reversal of ischemic retinopathy in ocular ischemic syndrome following carotid artery stenting <i>ESTEBAN O , Nuñez E , Ascaso J , Perez I , Idoate A , Sanchez J , Cristobal J - Zaragoza</i>
T010		Lactate transport and receptor actions: Potential roles in inner retinal function and disease <i>VOHRA R , Vosborg F , Henriksen U , Gurubaran I S , Hasan-Olive M , Holm E , Skytt D , Gjedde A , Storm-Mathisen J , Kolko M , Bergersen L H - Copenhagen</i>
T011		The effect of macular edema on the measurement of retinal nerve fiber layer thickness and the thickness of peripapillary retina <i>KIM S , Lee S , Lee J - Busan</i>
T012		Mitochondrial DNA haplogroups associated with neovascular age-related degeneration in a Spain population <i>ESTEBAN O , Ascaso F , Calvo T , Montoya J , Ruiz-Pesino E , Martinez M , Almenara C , Del Buey M , Cristobal J - Zaragoza</i>
T013		Nuclear factor-erythroid 2-related factor-2 (Nrf2) and peroxisome proliferator-activated receptor coactivator-1 (PGC-1) regulates proteolysis in cornea <i>SMEDOWSKI A , Paterno J J , Amadio M , Levonen A L , Tavi P , Kaarniranta K , Wylegala E - Katowice</i>
T014	<i>rf</i>	Anterior lens epithelium in cataract patients with retinitis pigmentosa - scanning and transmission electron microscopy study <i>ANDJELIC S , Drašlar K , Hvala A , Hawlina M - Ljubljana</i>
T015	<i>rf</i>	The study of needle tip aspirates and entry sites after intravitreal injections with different needle types <i>LYTVYNCHUK L , Savytska I , Sergiienko A , Binder S , Petrovski G - Lviv</i>



15:15 - 16:00 | POSTER AREA

MBGE: Molecular Biology / Genetics / Epidemiology**DAVIDSON A E , LISKOVA P**

T016	Clinical aspects of Autosomic Recessive Retinitis Pigmentosa Caused by USH2A Mutations in Consanguineous Tunisian Families <i>CHEBIL A , LARGUECHE L , KORT F , HASSAIRI A , HABIBI I , MUNIER F , EL MATRI L - Tunis</i>
T017	Exome sequencing confirms ZNF408 mutations as a cause of familial retinitis pigmentosa <i>HABIBI I , Chebil A , Kort F , Munier F , F. Schorderet D , El Matri L - Sion</i>
T018 <i>rf</i>	Two Sisters with Congenital Blindness caused by Osteoporosis-pseudoglioma Syndrome due to new Mutations in the LPR5 Gene <i>WELINDER L , Robitaille J M , Boerkoel C F , Rupps R , Lyons C - Aalborg</i>
T019	A novel mutation in CNNM4 (G492C) associated with Jalili Syndrome <i>LOPEZTORRES LT , Schorderet D , Valmaggia C , Todorova M - Basel</i>
T020	Genotypes & Phenotypes in Belgian Patients with Albinism <i>DE BLESER E , Tack M , De Baere E , Leroy B P - Oostakker</i>
T021	Retinitis pigmentos: a new feature in hypohidrotic ectodermal dysplasia <i>MEUNIER A , Vilain C , Abramowicz M - Bruxelles</i>
T022	A variant rs613872 in TCF4 gene is responsible for the higher risk for Fuchs endothelial corneal dystrophy development- the results of study in Polish patients. <i>UDZIELA M , Oldak M , Ruszkowska E , Sciezynska A , Binczyk E , Ploski R , Szaflik J P - Warsaw</i>
T023	Prospective study about activity of emergency unit in the Department of Ophthalmology (Nancy, University Hospital, France) <i>BAUDOT A , Ameloot F , Trechot F , Angioi K - Gondreville</i>
T024	Is there a seasonal relationship with idiopathic anterior uveitis presentation? <i>SAUNDERS D , Schulz C , Lockwood A - Portsmouth</i>
T025	Frequency of refractive errors and binocular vision anomalies in children with learning disability <i>YEKTA A A , Khabazkhoob M , Hashemi H , Shadalouee Z , Ostadimoghaddam H , Rezvan F , Azimi A , Heravian J , Yekta R , Davari Ashteyani R - Mahhad</i>
T026	Homocysteine and risk of wet age-related macular degeneration: a meta-analysis <i>PINNA A , Zaccacheddu F , Boscia F , Solinas G - Sassari</i>



15:15 - 16:00 | POSTER AREA

COS: Cornea / Ocular Surface

FUCHSLUGER T , GICQUEL JJ

T027		The inhibitory effect of Itraconazole on Corneal neovascularization in Rabbits <i>YANG S , Won JY , Lee H S , Joo C K , Chung S K - Seoul</i>
T028	<i>rf</i>	Three dimensional meibography for diagnosis of dry eye syndrome <i>BYUNY S , Yoo Y S , Eom T J , Na K S , Joo C K - Seoul</i>
T029		The use of matrix therapy in the Treatment of corneal perforation <i>LAZREG S - Dar el Beida</i>
T030		An unusual germ responsible for fungal keratitis: Metarrhizium Anisopliae <i>ZAIDI M , Bazard M C , Dorin J , Machouart M , Angioi K - Vandoeuvre les Nancy</i>
T031	★	Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye. <i>CIMBOLINI N , Antonelli S , Mauro V , Feraille L , Elena P P - La Gaudé</i>
T032		Correlation of Osmolarity Measurements with Signs and Symptoms in the Norwegian Dry Eye Clinic <i>BADIAN R A , Eidet J R , Ræder S , Uttheim Ø , Chen X , Stojanovic A , Uttheim T P - Oslo</i>
T033		A case of significant refractive change in nodular posterior scleritis <i>YOON S , Jeong H , Kim H , You T - Jeonju</i>
T034	★	Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing <i>DAULL P , Feraille L , Elena P P , Garrigue J S - Evry</i>
T035		From devastation to restoration: trichosporon asahii can be beaten <i>AYDIN YAZY , Yildirim N , Oz Y , Sahin A , Yaz Y - Eskisehir</i>
T036		Blepharitis and thin corneal thickness : An unexpected association <i>TRECHOT F , Conaert J B , Perone J M , Angioi K - Nancy</i>
T037	★	Safety and Efficacy of a Polyethylene Glycol/Propylene Glycol Based Lubricant Eye Drop in Patients with Dry Eye. <i>LABETOULLE M , Messmer E , Ogundele A , Mouriaux F , Baudouin C - Le Kremlin Bicêtre</i>
T038	★	Clinical Efficacy of an Oil-based Lubricant Eye Drop in Dry Eye Patients with Lipid Deficiency. <i>LABETOULLE M , Maurino V , Ogundele A , Rossi G C M , Van der Meulen I , Mrukwa-Kominek E , Galarreta D , Boehringer D , Baudouin C - Le Kremlin Bicêtre</i>
T039		Semi-automated reconstruction of inflammatory infiltration in infectious keratitis <i>SMEDOWSKI A , Tarnawska D , Wylegala E - Katowice</i>
T040		Experience with the monoclonal anti IgE antibody Omalizumab in severe refractory vernal keratoconjunctivitis in children <i>DOAN S , Amat F , Gabison E , Just J , Cochereau I - Paris</i>
T041		Assessment of the size spectrum of epithelial lesions of punctuate superficial keratitis during dry eye <i>COURRIER E , Lepinet T , Hor G , He Z , Chikh M , Thuret G , Gain P - Saint Priest en Jarez</i>
T042		The inhibitory effect of Itraconazole on Corneal neovascularization in Rabbits <i>WON JY , Chung S K - Seoul</i>
T043		Long-term results of the phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. <i>BEHAEGEL J , Ni Dhubhgaill S , Koppen C , Tassignon M J , Zakaria N - Brussels</i>



15:15 - 16:00 | POSTER AREA

COS: Cornea / Ocular Surface

T044	Analysis of the efficacy of the tissue regenerating agent (RGTA) 0.01% poly-carboxymethylglucose sulfate in the treatment of neurotrophic corneal ulcers and persistent epithelial defects <i>DEL BUEY M A , Casas P , Caramello C , Esteban O , Martinez M , Sánchez N , Pinilla I , Lanchares E - Zaragoza</i>
T045	Ocular Sarcoidosis Surgery as the most effective option to avoid blindness <i>MARTINEZ M , Del Buey M A , Perez I , Idoate A , Sánchez J I , Ascaso J , Cristóbal J A - Zaragoza</i>
T046 ★	Study of Xailin night physical Properties versus marketed ocular lubricant products <i>PILOTAZ F , Pecout A , Do M - Sophia Antipolis</i>
T047 ★	Study of XAILIN HA Physical Properties versus Marketed Hyaluronate Based Ocular Lubricants <i>PILOTAZ F , Saldo J , Boix M - Sophia Antipolis</i>
T048	Eyelid disorders evaluation in the Ophthalmic current practice in Belgium, Denmark, France, Netherland, Portugal and Turkey: The Meibum Study <i>DIAZ VALLE D , Doan S , Ya mur M , Benitez del Castillo J M - Madrid</i>
T049	Neurotrophic keratitis (NK) in carotid cavernous fistulae (CCF) <i>STEPHAN S , Rouger H , Doan S , Lamirel C , Cochereau I , Gabison E - Paris</i>
T050	Meibomian Gland Dysfunction (MGD) and Tear Cytokines after Cataract Surgery according to Preoperative Meibomian Gland Status <i>JUNG J W , Cho D , Kyoung Yul S - Incheon</i>
T051	Dry Eye Disease Therapy: who are the non-responders? <i>EIDET J R , Ræder S , Chen X , Badian R , Utheim Ø , Utheim T P - Oslo</i>
T052	Utility of peripheral lamellar corneal graft in PUK with corneal perforation treatment <i>SANCHEZ MARIN J I , Del Buey M A , Pérez I , Almenara C , Esteban O , Martínez M , Idoate A , Ascaso F J - Zaragoza</i>
T053	Advancing age does not strongly correlate with symptoms and signs of Dry Eye Disease in a large Norwegian cohort <i>BADIAN R A , Eidet J R , Ræder S , Utheim Ø , Chen X , Stojanovic A , Utheim T P - Oslo</i>
T054	Healing of a resistant neurotrophic corneal ulcer using a new matrix therapy agent (RGTA): A case report <i>Zghal I , ZAHAF A , Fekih O , Zayani M , Bouguila H , Nacef L - Tunis</i>
T055	Corneal nerve activity during ocular inflammatory processes <i>LUNA C , Quirce S , Belmonte C , Gallar J , Acosta M C - San Juan de Alicante</i>
T056	Corneal surface temperature and tear secretion in young and adult aqueous tear deficient guinea pigs <i>GALLAR J , Luna C , Alonso E , Revert R , Quirce S , Aracil A , Belmonte C , Acosta M C - San Juan de Alicante</i>
T057 ★	The Effect of Ikervis® (1mg/mL Ciclosporin cationic emulsion) on severe keratitis in patients with dry eye disease participating in a phase III study <i>LEONARDI A , Labetoulle M , Ismail D , Garrigue J S , Rancho L , Brignole-Baudouin F , Amrane M , Baudouin C - Evry</i>
T058	Posterior corneal anatomy in a newborn baby <i>FARAJ L , Yeung A , Said D , Branch M , El Alfy M , Dua H - Nottingham</i>
T059	Microfluidic in vitro Drug Release from Contact Lens Materials <i>FILIBE H P , Paradiso P , Valente A R B , Mata J L G , Saramago B , Henriques J M , Serro A P - Lisbon</i>



15:15 - 16:00 | POSTER AREA

COS: Cornea / Ocular Surface

T060	Comparison between i-gel and endotracheal tube in corneal grafts: a randomized clinical trial <i>GUERRIER G, Rondet S, Hallal D, Levy J, Boutboul D, Sjögren L, Legeais J M, Nicolau R, Mehanna C, Bourges J L, Samama C M S - Paris</i>
T061	Investigating the blue sclera in osteogenesis imperfecta by in vivo confocal microscopy. <i>JULLIENNE R, Brehon A, Perrot J L, Forest F, Cinotti E, Labeille B, Peoc'h M, Thuret G, Gain P - Saint-Etienne</i>
T062	Upgrading wide field contact specular microscope <i>HOR G, Gavet Y, Gain P, Thuret G, Bernard A, Pinoli J C - Saint Priest en Jarez</i>
T063	Genotype and phenotype correlation of monogenic corneal dystrophies in population of central Poland <i>UDZIELA M, Oldak M, Scieczynska A, Ploski R, Szaflik J P - Warsaw</i>
T064	Visual acuity increases up to 7 years after Descemet Stripping Automated Endothelial Keratoplasty <i>HANSEN M S, Correll M H, Julian H O - Hillerød</i>
T065	Assessment of corneal layers thickness with spectral-domain optical coherence tomography <i>SEGURA F, López de la Fuente C, Sánchez-Cano A, Orduna E, Del Buey M A, Pinilla I - Zaragoza</i>
T066	Immediate Effect of Ultraviolet-A Collagen CXL Therapy on Biomechanics and Histology of Human Cornea <i>DEL BUEY M A, Lanchares E, Calvo B, Lavilla L, Almenara C, Pérez I, Idoate A, Pinilla I, Ascaso J, Cristóbal J A - Zaragoza</i>
T067	Ocular Chronic Graft Versus Host Disease after Bone Marrow Transplantation <i>JEPPESEN H, Sengeloev H, Lindegaard J, Julian H, Prause J U, Heegaard S - Copenhagen</i>
T068	New insights into the proliferative capacities of rabbit corneal endothelial cells <i>CROUZET E, He Z, Forest F, Perrache C, Piselli S, Peoc'h M, Gain P, Thuret G - Saint Priest en Jarez</i>
T069	Topical treatment with a new matrix therapy agent (RGTA, CACICOL) improves epithelial wound healing after penetrating keratoplasty in a rabbit model <i>CROUZET E, He Z, Olmiere C, Perrache C, Piselli S, Jullienne R, Gain P, Thuret G - Saint Priest en Jarez</i>
T070	Ex vivo porcine corneal storage using an innovative bioreactor <i>GUINDOLET D, HE Z, Bernard A, Rageade D, Piselli S, Perrache C, Forest F, Peoc'h M, Gain P, Gabison E, Thuret G - Paris</i>
T071	Comparison of corneal topographic indices of keratoconus versus normal eyes by using pentacam imaging <i>YEKTA A A, Khabazkhoob M, Hashemi H, Bakhshi S, Ostadimoghaddam H, Heravian J, Rezvan F, Yekta R - Mahhad</i>
T072	Ocular surface improvement after conjunctivochalasis (CCH) surgery. <i>CARAMELLO C M, Mateo Orobía A, Peiró C, Del Buey M, Pérez Navarro I, Almenara C, Esteban O, Ascaso J, Cristóbal J - Zaragoza</i>
T073	Transfer of molecules into the endothelial cells of whole human corneas using carbon nanoparticles activated by femtosecond laser <i>JUMELLE C, Mauclair C, Houzet J, Barnard A, He Z, Piselli S, Perrache C, Gain P, Thuret G - Saint Priest en Jarez</i>
T074	Pore size assessment during corneal endothelial cell permeabilization by femtosecond laser-activated carbon nanoparticles <i>JUMELLE C, Mauclair C, Houzet J, Bernard A, He Z, Piselli S, Perrache C, Gain P, Thuret G - Saint Priest en Jarez</i>



15:15 - 16:00 | POSTER AREA

COS: Cornea / Ocular Surface

T075		Corneal Analysis before Cataract Surgery; Significance as the Clue for Unexplained Visual Complaint After Surgery <i>KIM J , Lee D , Lee J H , Choi J Y , Yeom J H - Goyang</i>
T076		Long-term results orthokeratological therapy in patients with myopia <i>BUSHUYEVA N , Maliieva O - Odessa</i>
T077	★	The effect of trehalose 3% as adjuvant therapy on Lasik procedure. <i>MATEO OROBIA A J , Cristobal Bescos J A , Casas Pascual P , Lafuente Ojeda N , Perez Garcia D , Peiro Embid C , Korobko Kulikova V , Del Buey Sayas M A , Lavilla Garcia L - Zaragoza</i>
T078		Sterile corneal keratolysis in the rat at 300 nm <i>KRONSCHLAGER M , Talebizadeh N , Yu Z , Löfgren S , Findl O - Vienna</i>
T079		Evaluation of the influence of corneal biomechanical properties on the central corneal curvature after a SUPRACOR procedure <i>DELBARRE M , Rambaud C , Berguiga M , Sendon D , Graber M , Froussart-Maille F - Clamart</i>
T080	rf	Intratarsal injection of kenacort in the treatment of severe cases of VKC <i>LAZREG S - Dar el Beida</i>
T081	rf	3D model of pterygium and corneal limbus: Investigating histopathology and stem cell distribution. <i>BLOM N , Andreasen A , Heegaard S , Hjortdal J , Nielsen K - Aarhus C</i>
T082	rf	Analysis of molecular mechanisms that predispose patients to develop post-PRK haze <i>RAJIV KUMAR N , Ghosh A , Shetty R , Pahuja N - Bangalore</i>
T083	rf	Corneal lenticules as an ex-vivo model to study keratocyte biology <i>SHROFF R , Shetty R , Kumar D , Ghosh A , Kumar S , Pahuja N , Ghosh A - Bangalore</i>
T084	rf	Novel role of PELI3 as a potential biomarker for Sjogren's syndrome related dry eyes <i>PILSON Q , Ni Gabhann J , Murphy C C - Dublin</i>
T085	rf	Randomised, controlled study of the efficacy and safety of a new eye-drop formulation for moderate to severe dry eye syndrome <i>DOAN S , Baudouin C , Khairallah M - Paris</i>
T086	rf	Efficacy of Dry Eye Disease Treatment based on the 2007 Report of the International Dry Eye WorkShop (DEWS) <i>UTHEIM O , Ræder S , Utheim T P , Eidet J R , Badian R , Stojanovic A , Chen X - Oslo</i>
T087	rf	Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high risk penetrating keratoplasty: a 2-year follow-up study <i>SZAFLIK J P , Major J , Izdebska J , Lao M , Szaflik J - Warszawa</i>
T088	rf	Differential molecular signature of ectatic and non-ectatic areas from Keratoconus patient corneas. <i>PAHUJA N , Rajivkumar N , Shetty R , Shroff R , Ghosh A - Bangalore</i>
T089	rf	Assessment of the performances of a handheld in vivo confocal microscope for the analysis of human corneal innervation <i>BREHON A , Perrot J L , Cinotti E , Labeille B , Grivet D , Crouzet E , Gain P , Thuret G - Saint Priest en Jarez</i>
T090	rf	Contribution of Optical Coherence Tomography (OCT) with real-time OCT of the Femtosecond laser, and per operative OCT of the microscope in deep anterior lamellar keratoplasty (DALK) for keratoconus: a new technique <i>NGUYEN DT , Stephan S , Gleize S , Cochereau I , Gabison E - Paris</i>



15:15 - 16:00 | POSTER AREA

IM: Immunology / Microbiology**WILLERMAIN F , XU H**

T091 ★	The P2X7 receptor is a potential therapeutic target for the treatment of Uveitis <i>TEMPEST-ROE S , Tam F , Taylor S - London</i>
T092	Role of macrophages in the course of an in vivo murine model of Anterior Ischemic Optic Neuropathy <i>KOKONA D , Häner N S , Ebnetter A , Zinkernagel M S - Bern</i>
T093	Contribution of virtual reality in clinical practice in ophthalmology <i>FLORES M , Mauris N , Anne Charlotte L , Thibaud M F , Saleh M - Besancon</i>
T094	Hyperreflective Dots in Spectral Domain Optical Coherence Tomography as Phenotypic Marker in Uveitis-Associated Cystoid Macular Edema <i>SELLAM A , Massamba N , Fel A , LeHoang P , Bodaghi B - Paris</i>
T095	Therapeutics course of childhood noninfectious uveitis <i>TARFAOUI N , Lala E , Uettwiller F , Marot Y , Hoarau C , Lelez M L , Arsene S , Pisella P J - Tours</i>
T096	Efficacy and safety of TOXO KO vaccine to prevent ocular toxoplasmosis in congenital murine model <i>TARFAOUI N , Morisse S , Lemee G , Dimier-Poisson I , Seche E , Pisella P J - Tours</i>
T097	Occult non-metallic intraocular foreign body causing recurrent anterior uveitis <i>MORREALE BUBELLA R - Agrigento</i>
T098 rf	Changes in lamina cribrosa and prelaminar tissue in anterior ischemic optic neuropathy <i>MUNOZ - NEGRETE F J , Rebolleda G , García-Montesinos J , Oblanca-Llamazares N , De Juan V , De Dompablo E - Madrid</i>
T099 rf	The added value of undiluted vitreous biopsy samples processed by the Cellient® tissue processor (Hologic) in unsolved uveitis. <i>VAN CALSTER J , Van Ginderdeuren R - Leuven</i>
T100 ★ rf	APMPPE as a window on systemic granulomatous inflammation <i>LABALETTE P , Bouabane I , Maurage C A - Lille</i>
T101 rf	Relapsing Polychondritis and its Orbital Manifestations <i>TEO L , Choo CT - Singapore</i>



16:00 - 17:30 | HERMES

RV: Diabetic retinopathy and macular edema

The pathogenesis of diabetic retinopathy and macular edema will be detailed. Speakers will present diabetic classification and the interest for screening and follow-up of our patients. Macular complications will be detailed as well as the different therapeutic options. Clinical cases of diabetic retinopathy with or without diabetic macular edema will be discussed with the audience. These cases will define the role and the pros and cons of different therapeutic options.

CREUZOT C , MIDENA E

2511	16:00	Pathogenesis of diabetic retinopathy and macular edema <i>BEHAR-COHEN F - Paris</i>
2512	16:18	Classification of diabetic retinopathy : from screening to diagnosis <i>WIEDEMANN P - Leipzig</i>
2513	16:36	Macular complication: from edema to ischemia <i>MIDENA E - Padova</i>
2514	16:54	Therapeutic options: how does it work? <i>POURNARAS C J - Genève</i>
2515	17:12	Clinical cases <i>CREUZOT C - Dijon</i>



16:00 - 17:30 | RHODES 1

RV: Free paper session - AMD

LEYS A , LAWRENSON J

2521		16:00	Dietary interventions for age-related macular degeneration: a review of the evidence <i>LAWRENSON J , Evans J - London</i>
2522		16:12	Prevalence of age-related macular diseases in an old French population (the MONTRACHET Study) <i>DE LAZZER A , Dossarps D , Gabrielle P H , Pallot C , Daniel S , Binquet C , Tzourio C , Bron A M , Creuzot C - Dijon</i>
2523		16:24	Subretinal drusenoid deposits in an elderly population with age-related macular degeneration (MONTRACHET study: Maculopathy, Optic Nerve, nuTRition, neurovasCular and HEarT diseases) <i>GABRIELLE P H , DeLazzer A , Koehrer P , Devilliers H , Arnoult L , Danielle S , Binquet C , Tzourio C , Bron A M , Creuzot C - Dijon</i>
2524		16:36	Lens status and macular pigment optical density in an old French population (MONTRACHET's study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases) <i>FLECK O , Koehrer P , Alassane S , Binquet C , Bretillon L , Acar N , Tzourio C , Bron A M , Creuzot C - Dijon</i>
2525	<i>rf</i>	16:48	The Protective Effect of Anti-blue Lens Against Photo-induced Cell Death <i>YU W Y , Shan S W , To C H , Chan H H L - Hong Kong</i>
2526	<i>rf</i>	16:54	Age Macular Degeneration-Lipidomic Study: Relevance and interest of Lipidomic study in screening, follow-up and etiopathogeny of AMD <i>GONZALEZ C , Bertrand-Michel J - Toulouse</i>
2527	<i>rf</i>	17:00	Endophthalmitis associated with intravitreal Ranbimab: Microbiology and visual outcomes. <i>PENWARDEN A , Weston K , Lockwood A - Portsmouth</i>
2528	<i>rf</i>	17:06	Microbiology of conjunctiva sac in intravitreal injections. <i>GRZYBOWSKI A , Gaca-Wysocka M , Paluch M - Olsztyn</i>



16:00 - 17:30 | RHODES 2

G: New and/or underdiagnosed entities in glaucoma

This SIS will address a variety of topics, all associated with raised IOP or glaucoma that are either recently described or underdiagnosed.

STEVENS A-M , KESTELYN P

2531	16:00	Bilateral acute iris transillumination <i>TUGAL-TUTKUN I - Istanbul</i>
2532	16:22	Cystoid macular oedema in endstage glaucoma <i>BIFRARE D - Sion</i>
2533	16:44	Radius Maumenee Syndrome <i>KESTELYN P - Gent</i>
2534	17:06	Drug induced glaucoma: old and new drugs <i>LAMBRECHT P - Gent</i>



16:00 - 17:30 | RHODES 3

G: Free paper session - Imaging and biomechanics**CORDEIRO MF , CORDEIRO SOUSA D**

2541	16:00	Influence of intraocular pressure in anterior lamina cribrosa depth – a prospective observational study in a healthy Portuguese population <i>CORDEIRO SOUSA D , Leal I , Pinto Ferreira N , Pinto J , Abegao Pinto L , Pinto F , Marques-Neves C - Lisbon</i>
2542	16:12	Intra and inter-rater agreement of anterior lamina cribrosa depth measurements using enhanced-depth imaging optical coherence tomography <i>LEAL I , Cordeiro Sousa D , Couceiro R , Barata A , Abegao Pinto L , Pinto F , Marques-Neves C - Lisbon</i>
2543	16:24	Evaluation of the lamina crivosa thickness and depth, the prelaminar nerve tissue thickness and the Bruch's membrane opening-based minimum rim width in eyes with and without primary open-angle glaucoma: an enhanced depth imaging OCT study of the optic nerve head and the correlation between anatomy and function <i>GAMA I , Almeida L , Gonçalves I , Monteiro-Grillo M - Lisbon</i>
2544	 16:36	Pigment epithelium central limit - Inner limit of the retina, Minimal Distance, PIMD, a morphometrical variable for glaucoma follow-up <i>SANDBERG MELIN C , Malmberg F , Malmqvist L , Talebizadeh N , Yu Z , Söderberg P - Uppsala</i>
2545	16:48	Subjective versus objective vertical cup-disc-ratio assessment in open angle glaucoma patients. <i>VANDEWALLE E , Willekens K , Van Keer K , Abegao Pinto L , Stalmans I - Leuven</i>
2546 ★	17:00	Gender specific IOP measurement using induced corneal vibration analysis - a multicenter clinical trial <i>BITOUN P , Bouafia K , Khoeir Z , Haouchine B , Hammoud S , Chapelle P , Chambard J P , Jourot P , Lachkar Y , Benzacken L - Paris</i>



16:00 - 17:30 | RHODES 4

COS: Free paper session - Ocular surface anatomy updates

BORDERIE V , RUGGERI A

2551	16:00	Three-dimensional structure of the mammalian limbal stem cell niche <i>BORDERIE V , Grieve K , Ghoubay D , Georgeon C , Thouvenin O , Bouheraoua N , Pâques M - Paris</i>
2552	16:12	Assessing the microstructures of the human cornea using Gabor-Domain optical coherence microscopy with large field of view and high resolution <i>THURET G , Tankam P , He Z , Lanis M , Canavesi C , Lepinet T , Hindman H , Topham D , Gain P , Rolland J P - Saint Etienne</i>
2553	16:24	Posterior corneal surface: new insights in curvature and astigmatism <i>PATEL S , Wacker K - Rochester</i>
2554	16:36	Computerized analysis of human corneal endothelium morphology <i>RUGGERI A , Scarpa F - Padua</i>
2555	rf 16:48	Differential molecular signature of ectatic and non-ectatic areas from Keratoconus patient corneas. <i>PAHUJA N , Rajivkumar N , Shetty R , Shroff R , Ghosh A - Bangalore</i>
2556	rf 16:54	Assessment of the performances of a handheld in vivo confocal microscope for the analysis of human corneal innervation <i>BREHON A , Perrot J L , Cinotti E , Labeille B , Grivet D , Crouzet E , Gain P , Thuret G - Saint Priest en Jarez</i>
2557	rf 17:00	Contribution of Optical Coherence Tomography (OCT) with real-time OCT of the Femtosecond laser, and per operative OCT of the microscope in deep anterior lamellar keratoplasty (DALK) for keratoconus: a new technique <i>NGUYEN DT , Stephan S , Gleize S , Cochereau I , Gabison E - Paris</i>



16:00 - 17:30 | GALLIENI 1+2

NSPH: Nystagmus and non-nystagmic abnormal spontaneous eye movements

Intermediate

This course is intended for beginners and intermediate levels. A patient presenting with spontaneous abnormal eye movements can be challenging to the clinician. Interruption of fixation can result from many types of nystagmus and non-nystagmic spontaneous abnormal eye movements. Being able to identify the various mechanisms and etiologies of disorders which can interrupt the stability of fixation is mandatory. This course aims at providing participants with a structured approach to identify correctly the most frequent and important types of spontaneous abnormal eye movements and will consist of five sections:

1. Review of the anatomical and physiological bases of stability of gaze;
2. Congenital forms of nystagmus;
3. Acquired forms of nystagmus not to be missed;
4. Alterations of stabilization of the eyes under dynamic conditions;
5. Abnormal non nystagmic spontaneous eye movements. At the end of this course participants should have acquired a systematic and practical approach to the patient with abnormal spontaneous eye movements.

BORRUAT FX , KAESER P

2561	16:00	Review of the anatomical and physiological bases of stability of gaze <i>BORRUAT FX - Lausanne</i>
2562	16:18	Congenital forms of nystagmus <i>KAESER PF - Lausanne</i>
2563	16:36	Acquired forms of nystagmus not to be missed <i>BORRUAT FX - Lausanne</i>
2564	16:54	Alterations of stabilization of the eyes under dynamic conditions <i>KAESER PF - Lausanne</i>
2565	17:12	Abnormal non nystagmic spontaneous eye movements <i>BORRUAT FX - Lausanne</i>



16:00 - 17:30 | GALLIENI 5

IM: Free paper session - Mechanisms in inflammatory disease to outcomes of novel therapies, part 1

DICK A , ABU EL ASRAR A

2571	★	16:00	Treg-based immunotherapy of non-infectious uveitis (NIU) <i>ASNAGLI H , Jacquin M , Belmonte N , Gertner-Dardenne J , Hubert M F , Sales A , Foussat A - Valbonne</i>
2572	🕒	16:12	The role of dendritic cells in non-infectious anterior uveitis <i>O'ROURKE M , Canavan M , Sweeney C , Fletcher J , Fearon U , Murphy C - Dublin</i>
2573		16:24	Interleukin 33/ST2 signaling regulates inflammatory response in choroidal stroma and ocular angiogenesis: implications for age-related macular degeneration. <i>THEODOROPOULOU S , Doyle S , Copland D , Liu J , Wu J , Campbell M , Dick A - Bristol</i>
2574		16:36	Systemic IL-1 production as a consequence of corneal HSV-1 infection – contribution to the development of Herpes Simplex Keratitis <i>MURPHY C , De Chaumont C , Shahnazaryan D , Malone C , Jefferies C , Smith S , Ni Gabhann J - Dublin</i>
2575	rf	16:48	Changes in lamina cribrosa and prelaminar tissue in anterior ischemic optic neuropathy <i>MUNOZ - NEGRETE F J , Rebolleda G , García-Montesinos J , Oblanca-Llamazares N , De Juan V , De Dompablo E - Madrid</i>
2576	rf	16:54	The added value of undiluted vitreous biopsy samples processed by the Cellient® tissue processor (Hologic) in unsolved uveitis. <i>VAN CALSTER J , Van Ginderdeuren R - Leuven</i>
2577	★ rf	17:00	APMPPE as a window on systemic granulomatous inflammation <i>LABALETTE P , Bouabane I , Maurage C A - Lille</i>
2578	rf	17:06	Relapsing Polychondritis and its Orbital Manifestations <i>TEO L , Choo CT - Singapore</i>



17:30 - 19:00 | HERMES

RV: New developments in OCT-Angiography

Optical coherence tomography angiography (OCTA), generates high-resolution, non-invasive angiograms qualitatively similar to conventional fluorescein angiography. OCTA may serve to detect abnormal microvasculature of the retinal or choroidal microvasculature either in healthy or diseased eyes.

POURNARAS C , ZOGRAFOS L

2611	17:30	Principles & Potential application of OCT-Angiography <i>COSCAS F - Creteil</i>
2612	17:48	ANGIO-OCT & DMLA (diagnosis and post-treatment follow-up) <i>COSCAS G , Lupidi M , Coscas F - Creteil</i>
2613	18:06	OCT angiography in CNV quantitative follow up <i>LUMBROSO B - Rome</i>
2614	18:24	OCT angiography for the evaluation of macular ischemic micro-angiopathies <i>POURNARAS C J , Frountzou E , Donati G - Genève</i>
2615	18:42	En Face OCT and OCT-Angiography in ocular oncology <i>ZOGRAFOS L - Lausanne</i>



17:30 - 19:00 | RHODES 1

G: Neuroprotection in glaucoma: Coming of age?

Neuroprotection has been around for a while in glaucoma - or so it seems. Following a lull in enthusiasm, there appears more optimism in the glaucoma community. In practice, early detection and treatment is likely to be essential to protect the visual system against insults and prevent progression. This future scenario will be realised once sufficiently powered clinical trials with well chosen endpoints demonstrate benefits in terms of visual function or on validated surrogate endpoints of visual function. This session will review where we are and discuss new trial designs, new endpoints and new agents and review what lessons may have been learnt from before. Although confirmation of neuroprotective effects by randomized clinical trials is needed, there is demonstration of positive non-IOP dependent effects, which may be utilized in future trials.

CORDEIRO MF , LEVIN L

2621	17:30	Is it becoming or coming of age <i>CORDEIRO M F - London</i>
2622	18:00	Are we there yet? <i>LEVIN L A - Montreal</i>
2623	18:30	To the clinic and back <i>GANDOLFI S - Parma</i>



17:30 - 19:00 | RHODES 2

COS: Corneal imaging

In the recent years significant advances in corneal imaging were obtained. The current SIS first provides an overview of currently available techniques for corneal imaging. The other three talks are related to recent innovations in the field. Optical coherence tomography (OCT) has now become a standard procedure for imaging ocular tissues. Using broadband light source unprecedented resolution can be achieved allowing to visualize many structures within the cornea including the pre- corneal tear film. Confocal in vivo microscopy is a technique which provides excellent resolution although the field of view is small. The technique has been used to visualize many details of the cornea including endothelial cells and provides the unique opportunity to study corneal nerves. Finally recent advances in assessing corneal endothelial cells are provided. This includes ex vivo assessment of endothelial cell viability, 3D end cell count for eye banks and HD 3D imaging of cells with endothelial markers.

SCHMETTERER L , GUTHOFF RF

2631	17:30	Corneal Imaging Modalities - from Basic Science to Clinical Application <i>STACHS O - Rostock</i>
2632	17:52	Corneal ultra-high resolution OCT <i>SCHMETTERER L - Vienna</i>
2633	18:14	Clinical use of in vivo confocal microscopy <i>GUTHOFF RF - Rostock</i>
2634	18:36	Recent advantages in the imaging of human corneal endothelial cells <i>THURET G - Saint Etienne</i>



17:30 - 19:00 | RHODES 3

PO: It is a masquerade! Eye cancers lurking behind innocent appearances

Eye cancer is rare as compared to most benign eye diseases. This is a diagnostic challenge in general, especially in the office of the comprehensive ophthalmologist. It becomes a particular dilemma when a malignancy takes the disguise of another eye disease, in regard to symptoms or signs, and essentially becomes its look-a-like. Such a situation is known as a masquerade syndrome, and certain eye cancers are especially prone to produce one. This symposium highlights the most common situations in which an eye cancer lurks behind an innocent appearance, hopefully helping the audience to get their diagnosis right on the first visit of their next masquerade patient.

KIVELÄ T , DESJARDINS L

2641	17:30	Masquerade syndromes in children <i>DESJARDINS L , Cassoux N - Paris</i>
2642	17:48	Blepharitis, chalazion, sty - or rather not? <i>LOEFFLER K - Bonn</i>
2643	18:06	Photopsia, floaters, cataract - a systematic approach to correct diagnosis <i>TALL M - Helsinki</i>
2644	18:24	Uveitis - the classic masquerade in adults <i>KIVELÄ T - Helsinki</i>
2645	18:42	It is a masquerade! A potpourri of rapid cases <i>KIVELÄ T - Helsinki</i>



17:30 - 19:00 | RHODES 4

NSPH: An update on aniridia

Aniridia is a panocular disease. This rare bilateral ocular disorder occurs at a frequency of approximately 1 in 80 000. About one third of these aniridia are sporadic, with many variable expressivities of the features. PAX6 gene anomalies with 11p13 mutations or deletion are involved in aniridia. PAX6 mutations result in alterations in corneal cytokeratin expression, cell adhesion and glycoconjugate expression. Syndromic manifestations in aniridia patients with PAX6 point mutations will be described. Ocular anomalies in aniridia commonly associates limbal insufficiency, cataract, glaucoma, foveal aplasia with nystagmus and ptosis. Potential mechanism of limbal stem cell insufficiency will be exposed. Physiopathology of cornea fate or PAX6 and corneal homeostasia will be exposed. Innovation with therapeutic options will be discussed as medical treatment, limbal stem cell transplant technology or pluripotent stem cells.

BREMOND-GIGNAC D , LAUDERDALE J

2651	17:30	Limbal stem cell transplant technology <i>LAUDERDALE J - Georgia</i>
2652	17:45	PAX6 and corneal homeostasia <i>GABISON E - Paris</i>
2653	18:00	Syndromic manifestations in aniridia patients with PAX6 point mutations <i>CALVAS P , Chassaing N , Kaplan J , Rozet J M - Toulouse</i>
2654	18:15	Pluripotent stem cells, cornea fate and physiopathology <i>ABERDAM D - Paris</i>
2655	18:30	Aniridia and ocular surface: new insight (part 1) <i>BREMOND-GIGNAC D - Amiens</i>
2656	18:45	Aniridia and ocular surface: new insight (part 2) <i>CHIAMBARETTA F - Clermont Ferrand</i>



17:30 - 19:00 | GALLIENI 1+2

RV: Free paper session - Retinal vasculopathy

LEYS A , BAILLIF S

2661	17:30	Lack of correlation between calcium activity in perivascular cells and prostaglandin induced changes in the tone of porcine retinal arterioles in vitro <i>KUDRYAVTSEVA O , Bek T - Aarhus</i>
2662	<i>rf</i> 17:42	New generation analysis of thrombin generation in retinal vein thrombosis <i>FRUSCHELLI M , Capozzoli M , Scapellato C , Calzoni P , Puccetti L - Siena</i>
2663	<i>* rf</i> 17:48	Functional Expression of Toll-Like Receptors in Human Retinal and Choroidal Vascular Endothelial Cells <i>STEWART E , Wei R , Branch M , Sidney L , Amoaku W - Nottingham</i>
2664	17:54	Abnormal lymphatic-like differentiation and endothelial progenitor cell activation in hemi retinal vein occlusion <i>LOUKOVAARA S , Gucciardo E , Repo P , Lohi J , Salven P , Lehti K - Helsinki</i>
2665	<i>*</i> 18:06	Two-year, Prospective, Multicenter Study of the Use of Dexamethasone Intravitreal Implant for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in France <i>GUALINO V , Korobelnik J F , Kodjikian L , Delcourt C , Leaback R , Pinchinat S , Velard M E - Montauban</i>
2666	<i>*</i> 18:18	Visual Acuity (VA) Outcomes and Impact of Baseline (BL) Perfusion Status in VIBRANT <i>FELTGEN N , Asmus F - Göttingen</i>
2667	18:30	Treatment of circumscribed choroidal haemangioma in 2015 <i>MASCHI C , Thariat J , Baillif S , Caujolle J P - Nice</i>



17:30 - 19:00 | GALLIENI 5

ACB: RPE Transplantation. From lab to the clinic

Retinal pigment epithelial (RPE) cells have a critical role in the pathogenesis of many common retinal diseases. Therefore they have been regarded as important tools for the replacement therapy. The rapid technological development in the regenerative medicine has made RPE transplantations a clinically relevant option to treat retinal diseases in the future. This RPE SIS will focus in the critical topics of the development of this technology from laboratories to the clinics like differentiation of the RPE cells from hESC and iPSC, regulatory and clinical aspects like recruited biomaterial scaffolds, surgical techniques and safety issues.

UUSITALO H , KAARNIRANTA K

2671	17:30	Introduction to the stem cell derived transplants <i>SKOTTMAN H - Tampere</i>
2672	17:48	Induced to cure: Engineering iPS cell derived RPE scaffolds to treat degenerative eye diseases <i>BHARTI K - Bethesda</i>
2673	18:06	Subretinal implantation surgery and follow up in pig model <i>KIILGAARD J F - Copenhagen</i>
2674	18:24	Subretinal implantation of human stem cell-derived RPE on ultrathin carriers in rabbits <i>STANZEL B V - Vienna</i>
2675	18:42	Regulation of cell-based medicinal products <i>LODGE A - London</i>



19:00 - 20:30 | HERMES

How to create a new generation of glaucoma patient ?

NORDMANN J

2711	19:00	New paradigms in Glaucome? <i>NORDMANN J - Paris</i>
2712	19:20	Can OCT be enough for glaucoma management? <i>NORDMANN J - Paris</i>
2713	19:40	Efficacy, Safety, Observance: What is the optimal balance ? <i>THYGESEN J - Glostrup</i>
2714	20:00	Shall we wait Ocular surface disease to prescribe preservative free (PF) products in glaucoma ? <i>SHORTTA - London</i>

EVER 2015
Friday, Oct 9





8:00 - 8:30 | HERMES
Coffee and Croissants



8:30 - 10:00 | HERMES
RV: Degenerative myopia

Intermediate

Myopic disease can lead to severe visual impairment. This course aims to describe epidemiology of myopia and the recent genetic markers related to high myopia. Then macular complications, either medical or surgical, will be presented. Characteristics of retinal detachment linked to myopia will be considered. Finally, clinical cases will overview the different presentations of visual impairment in high myopic eyes.

CREUZOT C , LEVEZIEL N

3111	8:30	Epidemiology and genetic in degenerative myopia <i>LEVEZIEL N - Poitiers</i>
3112	8:48	Macular diseases in myopia <i>CREUZOT C - Dijon</i>
3113	9:06	Macular surgical diseases in myopia <i>POURNARAS JA - Lausanne</i>
3114	9:24	Retinal detachment <i>BERROD J P , Conart J B - Nancy</i>
3115	9:42	Clinical cases (all) <i>CREUZOT C - Dijon</i>



8:30 - 10:00 | RHODES 1
G: Autonomic dysfunction in glaucoma

The known mechanisms behind glaucomatous damage have extended beyond intraocular pressure (IOP) to include those related to an underlying vascular dysfunction. One of the possible explanation for this vascular dysfunction is an impairment of the autonomic nervous system (ANS). This nervous structure is of paramount importance in regulating overall visceral activity and promoting that the proper response to a specific stimulus exists. Accordingly, a number of validated tests exist to determine whether an ANS dysfunction exists and to what extent. As glaucoma patients have been reported to exhibit both ocular and systemic signs of ANS dysfunction, this information may be of value to glaucoma management. This information could potentially be of use in early diagnosis, diagnostic confirmation and as prognostic value, particularly in patients where disease is progressing with an otherwise normal range IOP.

MARQUES-NEVES C , SCHMETTERER L

3121	8:30	Ocular Autonomic Regulation <i>ROCHA DE SOUSA A , Barbosa-Breda J - Porto</i>
3122	8:48	Ocular tests and interpretation <i>MARQUES-NEVES C - Lisbon</i>
3123	9:06	Ocular autonomic dysfunction in glaucoma <i>VANDEWALLE E - Leuven</i>
3124	9:24	Systemic dysfunction in glaucoma <i>SCHMETTERER L - Vienna</i>
3125	9:42	Clinical relevance of ANS dysfunction in glaucoma management <i>ABEGAO PINTO L - Lisbon</i>



8:30 - 10:00 | RHODES 2

COS: Comprehensive lamellar keratoplasty

Endothelial keratoplasty is the mainstay in the management of corneal pathology leading to endothelial decompensation. Different techniques and modifications have evolved and the process is on-going. In this SIS we cover the full range of the procedures available supported by published evidence, so that the surgeon can understand the pros and cons of each technique and choose the one best suited for the patient and clinical indication. This will include Descemets stripping endothelial keratoplasty (DSEK) and ultrathin DSEK; Descemets membrane endothelial keratoplasty (DMEK) and Pre-Descemets endothelial keratoplasty (PDEK). The outcomes of each will be discussed and compared in the context of the learning curve, eye banking considerations regarding donor tissue required for each and post-operative issues related to graft detachment. The role of penetrating keratoplasty (PK) in modern day corneal transplantation and the strategies for enhancing graft survival will be covered as PK is performed more and more in cases with greater risk of failure. All speakers have been instructed to make their talk well illustrated; evidence based and cover practical applications supported by sound basic and clinical science.

DUA HS , SAID D

3131	8:30	DALK versus PK for keratokonus <i>BORDERIE V - Paris</i>
3132	8:48	Ultrathin DSAEK: The Present Status <i>BUSIN M - Forli</i>
3133	9:06	Descemets membrane endothelial keratoplasty (DMEK) <i>KATAMISHT - Cairo</i>
3134 ★	9:24	Pre-Descemets Endothelial Keratoplasty (PDEK) <i>DUA H S - Nottingham</i>
3135	9:42	There is still a place for Penetrating Keratoplasty (PK) <i>SAID D - Maadi,Cairo</i>



8:30 - 10:00 | RHODES 3

PO: Eyelid tumors

Intermediate

Eyelid problems range from benign, to malignant. Fortunately, most eyelid disorders are not vision- threatening or life-threatening. Recognition and diagnosis of these problems are crucial to their proper management. For example, malignant eyelid tumors may be associated with lash loss and erosion of normal eyelid structures. Traditional surgical treatment of non-melanoma skin cancer includes excision with subsequent surgical margins, the "security" margins leading to determine the theoretical level of recurrences. Thus, some authors favor a clinical excision margin of 4 mm for basal cell carcinoma and 6 mm for squamous cell carcinoma. However, such "security" margins could not be applied in all cases of eyelids tumors for anatomic and functional considerations because such recommendations may lead to severe ocular complications. Thus the best assurance of minimal excision with complete excision is obtained by extemporaneous examination of the resection margins by frozen section or by surgery in two times. Knowledge of basis of reconstruction is important to avoid complications.

MOURIAUX F , LOEFFLER K

3141	8:30	Benign or Malignant? Clinical features <i>LASUDRY J - Brussels</i>
3142	8:52	Clinico-pathologic correlations of unusual lesions of eyelid tumors <i>LOEFFLER K - Bonn</i>
3143	9:14	Which margins for which tumors? <i>MOURIAUX F - Rennes</i>
3144	9:36	Basis of eyelid reconstruction after tumor resection <i>BRISCOE D - Savion</i>



8:30 - 10:00 | RHODES 4

LC: Posterior capsular opacification

Our SIS will cover subjects such as cell migration and fibrosis, treatment with different drug delivery methods and the prevention of capsular opacification for accommodative lens refilling.

BARRAQUER R I , MICHAEL R

3151 ★	8:30	Introduction and overview <i>SPALTON D - London</i>
3152	8:48	TGF beta and fibrosis-ironing out the wrinkles <i>ELDRED J , Wormstone M - Norwich</i>
3153	9:06	Migration of lens epithelial cells and IOL drug soaking <i>WERTHEIMER C , Kueres A , Mayer W , Liegl R , Eibl-Lindner K - Reichertshofen</i>
3154	9:24	Sealed-capsule irrigation with distilled deionized water to prevent posterior capsule opacification <i>REKAS M , Klu A , Kosatka M - Warsaw</i>
3155 ★	9:42	Capsular opacification and accommodative lens refilling <i>KOOPMANS S - Groningen</i>



8:30 - 10:00 | GALLIENI 1+2

MBGE: Free paper session**LISKOVA P , VOTRUBA M**

3161	8:30	Understanding and perceptions of inherited eye diseases and attitudes to genetic testing and gene therapy in a primary eye care setting <i>GANNE P , Votruba M , Garrioch R - Ipswich</i>
3162	8:42	Genetic variants in the TNFA are associated with Korean Dry Eye Disease <i>YANG S , Na K S , Mok J W , Ju H J , Joo C K - Seoul</i>
3163	8:54	Investigation of genotype-phenotype correlation of TGFBI mutations reveals c.1868G>A; p.(Gly623Asp) is associated with a variable clinical phenotype, including epithelial basement membrane dystrophy <i>EVANS C , Davidson A , Carnt N , Veli N , Tuft S , Hardcastle A - London</i>
3164	9:06	Target region sequencing in sporadic congenital cataracts reveals a new genotype-phenotype relation for the GALK1 gene <i>LI D , Yang J , Ye H , Tang Y , Luo Y , Lu Y - Shanghai</i>
3165	9:18	Ocular fundus changes in patients with Down syndrome and pulmonary hypertension <i>LEYS A , Delcroix M , Willems A , Wirix M , Nijs I - Leuven</i>
3166 <i>rf</i>	9:30	Two Sisters with Congenital Blindness caused by Osteoporosis-pseudoglioma Syndrome due to new Mutations in the LPR5 Gene <i>WELINDER L , Robitaille J M , Boerkoel C F , Rupps R , Lyons C - Aalborg</i>



8:30 - 10:00 | GALLIENI 5

NSPH: GOA Symposium : Tears in allergy: update



Allergic ocular surface diseases affect subjects of all ages and increased all over the world with evolution of environment. These pathologies could lead to ulcers and sight-threatening corneal complications. Identification of inflammatory mediators in the tear fluid have been studied for a better understanding of the immune mechanisms involved in the ocular surface inflammation. Quantitative and qualitative characterization of the peptidoma of human tears will be developed and detailed in specific allergic keratoconjunctivitis as vernal keratoconjunctivitis. A possible disease marker may lead to identification of potential targets for therapeutic interventions. An update on severe ocular allergic disease and their treatment with current options will be reviewed with practical aspects and diverse clinical cases considering quality of life of the children and adults.

BREMOND-GIGNAC D , FAUQUERT J

3171	8:30	Allergic mediators in tears: what's new? <i>LEONARDI A - Padova</i>
3172	9:00	Healing and corneal ulcers <i>GABISON E - Paris</i>
3173	9:30	Immuno modulation <i>CALDER V - London</i>



10:10 - 10:50 | HERMES

Keynote Lecture by Reza DANA


Introduction by Thomas FUCHSLUGER

Translational applications in corneal and ocular surface diseases

DANA R - Boston MA

Summary

The field of Cornea and Ocular Surface has made significant advances in the recent past. Compared to our colleagues in Retina and Glaucoma where the principal leaps forward have been in pharmaco-therapy, in Cornea our primary advances have been in the realm of microsurgery and new technologies (e.g., DSEK/DMEK, femtosecond). Nevertheless, significant work has also been done in understanding the pathophysiology of common corneal and ocular surface disorders, with translational applications in our clinics. This talk will provide a short summary of some of the translational research performed by our team in understanding the pathogenic mechanisms and novel treatment options for corneal neovascularization, graft-versus-host disease (GVHD), and dry eye syndrome



Award of the EVER Certificate of Honour

Biography Reza Dana:

Dr. Reza Dana, Senior Scientist, W Clement Stone Scholar, The Schepens Eye Research Institute; Claes Dohlman Chair in Ophthalmology, Professor of Ophthalmology at Harvard Medical School; Director, Cornea & Refractive Surgery, Massachusetts Eye & Ear Infirmary; Vice Chairman of Harvard Department of Ophthalmology and Director of the Harvard Medical School Cornea Center of Excellence. Dr. Dana completed his bachelor's, graduate, and medical education at Johns Hopkins and performed his residency at the Illinois Eye and Ear Infirmary, followed by fellowships in Cornea and External Diseases at the Wills Eye Hospital, in Uveitis at the Massachusetts Eye and Ear, and in Ocular and Transplantation Immunology at The Schepens Eye Research Institute, Harvard Medical School. Dr. Dana, a 'Gold Fellow' of the Association for Research in Vision and Ophthalmology (ARVO), has authored over 230 peer-reviewed articles and over 100 reviews and book chapters, and has delivered more than 200 invited and named lectures worldwide. He has been the recipient of multiple awards, including the Special Scholar Award, Physician-Scientist Award, Lew R. Wasserman Award, and the Senior Scientific Investigator Award from Research to Prevent Blindness, the Cogan Award from ARVO, the LSU Chancellor's Award in Neuroscience and Ophthalmology, and the Alcon Research Institute Award. Dr. Dana is Associate Editor of IOVS, and is on the editorial board of the journals Cornea and The Ocular Surface. In addition to his basic laboratory investigations, Dr. Dana leads a large translational research program at Mass. Eye and Ear that has received a number of IND permits from the FDA in just the last few years. Apart from his many clinical trainees, Dr. Dana has trained over 90 fellows and students from 30 countries in his laboratory to date.

Dr. Dana's principal research interests are in determining the molecular and cellular regulation of ocular immunity. The aims of Dr. Dana's research program are to (1) unravel the molecular and cellular processes that are responsible for initiating and sustaining immuno-inflammatory responses in the cornea and anterior segment, and thereby (2) develop specific molecular targeting strategies to promote mechanisms that engender immune unresponsiveness without placing the eye or the patient at risk of toxicity or secondary infections. Areas of investigation include transplantation, angiogenesis, stem cells, and dry eye disease. Dr. Dana's research is supported by several federal grants.



11:00 - 12:30 | HERMES

RV: Lessons taught by imaging about atrophy in retinal disease

A large number of imaging technics are at our disposal since ten years or so. The progressive mastery of fundus autofluorescence clearly helped the differential diagnosis, separating atrophy resulting from heredo degeneration from that resulting age related degeneration. ICG angiography did improve our knowledge in discerning specific features of choriocapillaris atrophy or Haller layer atrophy. OCT and even more en face OCT provided us with additional information on the initial site of dysfunction in showing the morphology of the different retinal layers. The last to arrive in the clinic Angio OCT promises to complete the clinical aspect of the tissue alterations and the respective role of different vascular layers. The advent of Adaptive Optics opens new avenues in our understanding of the pathogenesis of atrophy and provides the possibility to use biological markers. In addition, the emerging approaches may allow to identify new diseases. The increase of knowledge obtained with all the means used in the daily life will be presented by the teams with most expertise in each field. The confrontation of all informations obtained may result in the identification of reliable prognostic markers for evaluation of clinical trial results.

SOUBRANE G

3211 ★	11:00	Adaptive Optics <i>PAQUES M - Paris</i>
3212	11:18	Lessons talk by imaging about atrophy in retinal disease: Fundus autofluorescence <i>LOIS N - Belfast</i>
3213	11:36	ICG <i>STAURENGHI G - Milan</i>
3214	11:54	En face OCT <i>SCEMAMA TIMSIT C , Mauget-Fajsse M , Wolff B - Paris</i>
3215	12:12	OCT angiography of the choriocapillaris and choroid <i>COSCAS G , LUPIDI M , COSCAS F - Creteil</i>



11:00 - 12:30 | RHODES 1

G: Drug delivery and the eye

Effective delivery of drugs for the treatment of ocular disorders is a challenge. Many potential active agents fail to progress because of not reaching their target. The unique anatomical and physiological barriers of the eye restrict the passage of drugs to the back of the eye, including . the corneal epithelium, the blood-retinal barrier, systemic absorption, and drainage through the nasolacrimal ducts. The only mode of delivery currently for ant-VEGF treatments is through intravitreal delivery. These injections have put a strain on health service providers around the world. However, nanotechnology and small molecule advances mean that potentially intraocular injections may be a thing of the past. A different problem is encountered in glaucoma where often it is the task of daily eye-drop instillation that is associated with poor compliance. Again, advances in sustained release delivery promise to be potentially very useful.

CORDEIRO M F , SCHMETTERER L

3221	11:00	Ocular lubrication <i>SCHMETTERER L - Vienna</i>
3222	11:22	New and old drug delivery systems <i>WILSON C - Robroyston - Glasgow</i>
3223	11:44	Recent advances in drug delivery to the retina <i>DAVIS B - London</i>
3224	12:06	Development pathway <i>CORDEIRO M F - London</i>



11:00 - 12:30 | RHODES 2

COS: Corneal wound healing

This session will Focus on pathologies of the corneal Strom and the orneal Epithelium and will state- of-the-art present therapeutical Options.

BEUERMAN R , MELLER D

3231	11:00	Limbal stem cell niche - New insights into structural and molecular composition <i>SCHLOTZER-SCHREHARDT U - Erlangen</i>
3232	11:18	The epithelial-stromal TGFBI corneal dystrophies <i>LISCH W - Hanau</i>
3233	11:36	Mechanisms of Stromal Fibrosis <i>BEUERMAN R - Singapore</i>
3234	11:54	Limbal stem cells and their application in ocular surface reconstruction <i>MELLER D - Essen</i>
3235	12:12	Biomaterials for ocular surface reconstruction and lamellar keratoplasty <i>FUCHSLUGER T - Erlangen</i>



11:00 - 12:30 | RHODES 3

EOVS: Doctor, I can't see, but you can't see why (Medically unexplained visual loss)

The SIS will address the challenging clinical problem of Medically Unexplained Visual Loss (MUVL). The content of the SIS will address the Initial Consultation, pointing out those elements of the routine clinical examination that require particular attention and how to attempt the distinction between non- organic and organic visual loss. The potential retinal and neuro-ophthalmic causes of MUVL will be discussed by an ophthalmologist and neurologist respectively, paying particular attention to disorders that may be mistaken for non-organic visual loss. Finally, the role of electrophysiology in providing objective assessment of visual pathway function, both retinal and intracranial, will be addressed using a case-based approach.

HOLDER G

3241	11:00	The Initial Consultation – when and how to suspect non-organic visual loss <i>SPILEERS W - Leuven</i>
3242	11:22	Potential retinal causes: when and how to investigate <i>LEROY B P - Ghent</i>
3243 ★	11:44	Neuro-ophthalmic considerations and investigations <i>KAWASAKI A - Lausanne</i>
3244	12:06	The role of electrophysiology <i>HOLDER G - London</i>



11:00 - 12:30 | RHODES 4

LC: Free paper session**LÖFGREN S , BEIKO G**

3251		11:00	α B-Crystallin Phosphorylation as a Precursor to Cataractogenesis <i>THORNELL E , Ecroyd H , Aquilina A - Wollongong</i>
3252		11:12	Endothelial cell loss after phacoemulsification according to different anterior chamber depths measured by IOL master <i>HWANG H , Lyu B , Yim H , Lee N - Incheon</i>
3253		11:24	Changes of intraocular pressure and cornea biomechanical properties after cataract phacoemulsification. <i>YUGAY M , Ryabtzeva A - Moscow</i>
3254	★	11:36	Increased Uptake of Intracameral Antibiotic Prophylaxis in Europe <i>BARRY P - Dublin</i>
3255		11:48	Impact of intracameral Cefuroxime on post-operative endophthalmitis in Languedoc Roussillon, France from 2010 to 2014 <i>DAIEN V , Papinaud L , Lacombe S , Daures J P , Villain M - Montpellier</i>
3256	rf	12:00	Anterior chamber and refractive parameters in diabetic patients according to metabolic status <i>COSTA L , Cardigos J , Vicente A , Borges B , Ferreira J , Cunha J P , Amado D - Lisbon</i>



11:00 - 12:30 | GALLIENI 1+2

MBGE: Ionizing radiation and cataract

The ocular lens is recognized as one of the most radio-sensitive tissues in the human body and cataracts are known to be initiated by exposures to relatively low doses of ionizing radiation. Recent new work on survivors of the Hiroshima atomic bomb and the Chernobyl atomic power plant together with epidemiological work on radiation technologists suggests that the question of the threshold dose for cataract development is open again. We will discuss recent findings on human cataracts together with mouse models.

GRAW J , WEGENER A

3261		11:00	Radiation-induced cataracts: governmental safety aspects <i>AINSBURY E - Oxford</i>
3262		11:22	Scheimpflug analysis in an epidemiological study <i>WEGENER A - Bonn</i>
3263		11:44	The EURALOC Project <i>STRUELENS L - Mol</i>
3264		12:06	Lifetime study in mice for radiation-induced cataracts <i>DALKE C , Rößler U , Neff F , Greiter M , Gomolka M , Hornhardt S , Unger K , Garrett L , Rosemann M , Kempf S , Azimzadeh O , Wurst W , Aubele M , Zitzelsberger H , Hölter S , Tapio S , Hoeschen C , Kulka U , Atkinson M , Graw J - Muenchen</i>



11:00 - 12:30 | GALLIENI 5

NSPH: An ophthalmological look at history

Studying history of ophthalmology we acknowledge the past of our profession, but also better understand the origins of our present knowledge. We can also often analyze the process of scientific discoveries and the progress in medical sciences. The eye has been often used in art as a symbol of the most delicate and important organ of human body, sometimes as a window to the soul. During the session unknown early descriptions of retinopathy in onchocerciasis, and military ophthalmia during the Napoleonic campaign will be presented. Moreover, obsession of the eyes in Luis Buñuel's work and the biography of Friedrich Wegener will be discussed.

GRZYBOWSKIA , ASCASO F

3271	11:00	The obsession of the eyes in Luis Buñuel's work (Spain, 1900- Mexico, 1983) <i>ASCASO F - Zaragoza</i>
3272	11:22	The history of the description of retinopathy in onchocerciasis <i>KESTELYN P - Gent</i>
3273	11:44	Military ophthalmia and the Napoleonic campaign in Egypt. <i>DE LAEY J J - Gent</i>
3274	12:06	Wegener's granulomatosis – should we change the name of the disease? <i>GRZYBOWSKIA A - Poznan</i>



12:30 - 13:30 | RHODES 2

Macular edema: from basic science to clinical evidences**DOT C**

12:30	Blocking VEGF and PIGF : what is the interest in clinical practice ? <i>DOT C - Lyon</i>
12:50	Systemic exposure to anti-VEGF : what is the reality ? <i>LEVY B - Paris</i>
13:10	From basics to clinical evidences : Overview of efficacy & safety across macular edema indications (RVO & DME) <i>ZAMBROWSKI O - Créteil</i>



12:30 - 13:30 | RHODES 3

**A rare breakthrough in mitochondrial medicine:
changing the patient journey in LHON**

12:30	Introducing a rare breakthrough in mitochondrial medicine
12:35	Optic neurodegeneration – the time to act is now <i>GUEVEN N - Hobart</i>
12:50	Reaching key milestones in LHON – the idebenone clinical development program <i>METZ G - Liestal</i>
13:00	Changing the patient journey in LHON: the evidence <i>KLOPSTOCK - München</i>
13:20	Q&A with panel



13:30 - 15:00 | HERMES

RV: FAN : Fluorescein Angiography Club**LEYS A ,VELDMAN E**

Cases with retinal imaging are presented and discussed with a panel.

Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.

Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org



13:30 - 15:00 | RHODES 1

G: The Obergurgl optic nerve conference 2014: neuroinflammation

The optic nerve conference in Obergurgl, which is supported by EVER, explores the current state of our understanding of optic nerve degeneration, such as in glaucoma. To stimulate ideas and discussion, leading experts from a variety of fields will emphasize a cross-sectional, interdisciplinary approach. The conference brings together clinicians and basic scientists from different fields and will highlight translational research providing a platform for networking and stimulating discussions. The Focus area 2014 of the Obergurgl conference was "Neuroinflammation". In this SIG, some of the topics of the Obergurgl conference will be presented at EVER. Jonathan Crowston, Franz Grus, Keith Martin Conference Organizers, Obergurgl Optic Nerve Conference

GRUS F , MARTIN K , CROWSTON J

3421	13:30	Autophagy in neurodegeneration and inflammation and novel modulators of macroautophagy <i>BEHL C - Mainz</i>
3422 ★	13:48	Innate immunity in age-related retinal degeneration <i>LUHMANN U - Basel</i>
3423	14:06	Heterogeneity of retina Müller glia and their possible role neuroprotecting retinal ganglion cells <i>VECINO E - Vizcaya</i>
3424	14:24	Retinal innate immune activation in health and disease <i>XU H - Belfast</i>
3425	14:42	Beta II tubulin as molecular marker of intraocular pressure in endothelial cells <i>PROKOSCH-WILLING V - Münster</i>



13:30 - 15:00 | RHODES 2

COS quartett immunodiagnostica Research Award Session



FUCHSLUGER T

3 grants supported by quartett for best paper in COS

- Translational Research Award
- Basic Science Research Award
- Clinical Research Award

The papers will be chosen during the congress and the grants will be handed over during quartett immunodiagnostica Research Award Session



13:30 - 15:00 | RHODES 3

PO: Free paper session

HEEGAARD S , MOULIN A

3441	13:30	Improving the overall diagnosis of eyelid margin tumours with in vivo reflectance confocal microscopy <i>GRIVET D , Singer A , Forest F , Cinotti E , Douchet C , Labeille B , Perrot J L , Cambazard F , Dumollard J M , Peoc'h M , Gain P , Thuret G - Saint-Etienne</i>
3442	13:42	New management of peri-ocular basal cell carcinoma using in vivo and ex vivo confocal microscopes <i>ESPINASSE M , Grivet D , Perrot J L , Cinotti E , Labeille B , Forest F , Gain P , Thuret G - Saint-Etienne</i>
3443	13:54	Cyclin kinase inhibitor p27 is downregulated in conjunctival melanoma <i>MOULIN A , Schalenbourg A , Zografos L , Nicolas M - Lausanne</i>
3444	14:06	Looking for the best mouse model to study retinoblastoma <i>LEMAITRE S , Poyer F , Cassoux N , Fréneaux P , Thomas C - Paris</i>
3445	14:18	Orbital T-cell lymphoblastic lymphoma <i>HEEGAARD S , Stenman L - Copenhagen</i>
3446	14:30	The effect of PAXgene fixation on preservation of morphology and nucleic acids in microdissected retinal tissue <i>EDWARD D , Liu Y - Baltimore</i>



F13:30 - 15:00 | RHODES 4

NSPH: Free paper session

PARSA C , GRZYBOWSKI A

3451		13:30	Optic coherence tomography in analyzes of optic nerve and macula in neuro-ophthalmological patients <i>COSTA L , Vicente A , Anjos R , Santos A , Ferreira J , Amado D , Cunha J P - Lisbon</i>
3452		13:42	Optic nerve Drüsens in black patients : a case series of 16 patients <i>SUSTRONCK P , Jean-Charles A , Benzekri R , Merle H - Fort de France</i>
3453	★	13:54	Treatment of Leber's hereditary optic neuropathy with EPI-743: the Brazilian experience <i>KARANJIA R , Ganti A , Chu E , Wagschal T , Belfort- Jr. R , Moraes- Filho M , Salomao S , Chicani F , Guy M , Sadun A - Pasadena</i>
3454	🕒	14:06	The influence of lingering fusional adaptation on the Bielschowsky head tilt test in superior oblique paresis <i>IRSCH K , Guyton D , Ying H - Paris</i>
3455	rf	14:18	Optic disc swelling : Prospective study of sixty-seven patients <i>SITBON C , Fel A , Bodaghi B , Le Hoang P , TOUITOU V - Paris</i>
3456	rf	14:24	Nonarteritic anterior ischemic optic neuropathy (NAION): A misnomer. A non-ischemic papillopathy caused by vitreous separation <i>PARSA C , Hoyt W - Paris</i>
3457	rf	14:30	Ophthalmic insert for pupillary mydriasis in neonates <i>BREMOND-GIGNAC D , Jacqz-Aigrain E , Abdoul H , Beresniak A , Baud O , Alberti C - Paris</i>
3458	rf	14:36	Homonymous hemimacular thinning in retrochiasmal lesions <i>CUNHA J P , Proença R , Dias-Santos A , Vicente A , Anjos R , Costa L , Cardigos J , Ferreira J , Amado D - Lisbon</i>



13:30 - 15:00 | GALLIENI 1+2

MBGE: Cataract genetics

Cataracts are a major disorder at the eye. It becomes evident that at least in developed countries genetic congenital cataracts are due to mutations either present in a family over generations or appearing de novo in the germ line; recessive mutations become obvious in regions with a larger portion of consanguinity. In this SIS we will discuss recent findings on novel cataract-causing genes in humans and mice. Moreover, we will discuss also the advantage of next-generation sequencing in disease-specific applications.

GRAW J

3461		13:30	Mutations in Connexin-encoding genes <i>BEYER E , Berthoud V - Chicago, IL</i>
3462		13:52	Mutation in the Ercc2 gene of the mouse causes cataracts <i>GRAW J , Kunze S , Dalke C , Fuchs H , Klatfen M , Sabrautzki S , Hrabé de Angelis M - Neuherberg</i>
3463		14:14	Whole exome sequencing in patients with congenital cataracts <i>LISKOVA P - Prague</i>
3464		14:36	Gene panels and genomic testing for childhood cataract and lens dislocation disorders <i>BLACK G C , Hall G , Ramsden S , Lloyd I C - Manchester</i>



13:30 - 15:00 | GALLIENI 5

EOVS: Free paper session - Oculophysiology assessments**LEINONEN M , WEBER M**

3471	13:30	Light-Induced Retinopathy in neonatal rats: A new retinal degeneration slow model <i>LACHAPELLE P , Polosa A , Ait Igrine W , Chevrolat L A , Bessaklia B - Montreal Quebec</i>
3472 *	13:42	Clinical evaluation of video imaging technology during visual field exams <i>CHARLIER J , Zanlonghi X , Defoort-Dhellemmes S - Perenchies</i>
3473 *	13:54	Using reaction time in visual search and decision making task to measure visual field thresholds in multifixation perimetry <i>LEINONEN M , Mäntysalo T , Sampinen K , Ojala M - Turku</i>
3474	14:06	Electrophysiological ON and OFF responses in Autosomal Dominant Optic Atrophy <i>MORNY E , Margrain T , Binns A , Votruba M - Cardiff</i>
3475	14:18	Apparent Contradictions in Pupillomotor, Sensory Visual and Electrodiagnostic Findings in Chiasmal Compression <i>KRASTEL H , Landauer M , Diehm T , Kubarko A , Schlichtenbrede F - Neckargemünd</i>
3476	14:30	Choroidal thickness changes in response to defocus in emmetropia and in myopia <i>WEBER M , Esmaeelpour M , Drexler W , Findl O - Vienna</i>



15:00 - 15:45 | HERMES

G: Glaucoma**BLOOM P , SUNARIC MEGEVAND G , VIDAL-SANZ M**

- | | | |
|-------------|-------------|---|
| F001 | rf | Receptor-targeted liposome-peptide-siRNA nanoparticles represent a novel and efficient siRNA delivery system to prevent conjunctival fibrosis
<i>YU-WAI-MAN C , Tagalakis A , Manunta M , Hart S L , Khaw P T - London</i> |
| F002 | rf | Leuven Eye Study - Baseline and methods
<i>ABEGAO PINTO L , Willekens K , Van Keer K , Shibesh A , Vandewalle E , Molenberghs G , Stalmans I - Lisbon</i> |
| F003 | rf | Biomechanical properties of eyes with asymmetrical glaucoma defect
<i>CELLINI M , GIZZI C , Finzi A , Campos E C - Bologna</i> |
| F004 | * rf | Multicenter clinical trial of high-intensity focused ultrasound treatment in glaucoma patients without previous filtering surgery
<i>APTEL F , Denis P , Rouland J F , Renard J P , Bron A - Laxou</i> |
| F005 | * rf | Comparison of preservative-free latanoprost and bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial
<i>STALMANS I , Cordeiro F , Hommer A , Oddone F , Ribeiro L , Sunaric Mégevand G , Rossetti L - Leuven</i> |
| F006 | rf | Double-hump sign on gonioscopy: definitive plateau iris? A cross-sectional study using ultrasound biomicroscopy
<i>CORDEIRO SOUSA D , Leal I , Caiado F , Goncalves I , Reina M , Marques-Neves C , Prior Filipe H , Abegao Pinto L - Lisbon</i> |
| F007 | rf | How accurate are optometrist referrals for glaucoma in the NICE era?
<i>BOBAT H , Begum S , Lockwood A , Kirwan J F - Portsmouth</i> |
| F008 | rf | A pilot study of survey on patient satisfaction and its meaning in an Glaucoma outpatient
<i>POURJAVAN S , Vanhaecht K - Brussels</i> |
| F009 | | Corneal and optic nerve head biomechanical changes after deep sclerectomy
<i>MUNOZ - NEGRETE F J , Rebolledo G , Díez L , Oblanca-Llamazares N , De Juan V , Casas-Llera P - Madrid</i> |
| F010 | | Selective laser trabeculoplasty: Results on intraocular pressure and number of topical antiglaucoma medications
<i>BONNEL S , Fenolland J R , Marill A F , Gaillard R , Rosenberg R , Theillac V , Mazharian A , Mouinga A , Giraud J M , Renard J P - Paris</i> |
| F011 | * | Primary open angle glaucoma treated by high intensity focused ultrasound (HIFU) with the 2nd generation probe
<i>ROULAND J F , Aptel F - Lille</i> |
| F012 | | Glaucoma patient satisfaction after switching from preserved treatment to preservative-free latanoprost; results from the PASSY survey in three European countries
<i>MUNOZ - NEGRETE F J , Lemij H , Erb C - Madrid</i> |
| F013 | | Intraocular pressure in Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
<i>PINNA A , Blasetti F , Campesi I , Scanu B , Carru C - Sassari</i> |
| F014 | | Normal tension glaucoma associated with lamina cribrosa defects and complicated of maculopathy: A case report
<i>BESOMBES G , Bachetti P , Labalette P , Rouland J F - Lille</i> |
| F015 | | A high oxygen demand in normal tension glaucoma
<i>TURKSEVER C , Todorova M , Orguel S - Baselland</i> |
| F016 | | Estimated cerebrospinal fluid pressure and trans-lamina cribrosa pressure difference in open angle glaucoma. The Korea National Health and Nutrition Examination Survey 2009-2012
<i>LEE S H , Kwak S W , Kang E M , Hong S , Seong G J , Kim C Y - Seoul</i> |
| F017 | | Comparison of Humphrey visual field perimetry and new invented PC-based visual field testing system in healthy people and glaucoma patients.
<i>KIM Y G , Lee J , Lee B , Kim S , Lee N , Kim S , Park J , You H , Kang J H - Seoul</i> |



15:00 - 15:45 | HERMES

G: Glaucoma

F018	Glaucoma patient satisfaction regarding tolerance to their prostaglandin treatment: results from the GOAL (Glaucoma patients treated with prOstaglandins; sAtisfaction evaLuation) survey in Europe. <i>CLARKE J , Stalmans I , Lemij H , Baudouin C - London</i>
F019	Tarsal inflammatory response after topical prostaglandin analogues treatment - pilot study. <i>TRZECIECKA A , Paterno J , Toropainen E , Wylegala E , Kaarniranta K , Smedowski A - Kuopio</i>
F020	Glaucomatocyclitic crisis, a rare cause of unilateral ocular hypertension <i>OZCAN A A , Sariyeva A - Adana</i>
F021	Risk of glaucoma and treatment with systemic antihypertensive treatment - A nationwide study <i>HORWITZ A , Jeppesen J , Torp-Pedersen C , Kolko M - Copenhagen</i>
F022	Dexamethasone induced glaucoma as part of chemotherapy for T cell lymphoblastic lymphoma. <i>LOCKWOOD A J , Mitchell A , Gray J , May K - Southampton</i>
F023	Reproducibility of intraocular pressure self-measurement by ICare Home rebound tonometer and comparison with Goldman applanation tonometer <i>GAILLARD R , Fenolland J R , Bonnel S , Rosenberg R , Marill A F , Bostanci K , Giraud J M , Renard J P - Paris</i>
F024	Generic Drugs- are they as good as brand-names? <i>KOLKO M , Ali N , Jensen P K - Roskilde</i>
F025	Cystic macular edema induced by Latanoprost <i>PEREZ I , Ascaso F J , Caramello C , Almenara C , Esteban O , Martinez M , Sánchez J I , Idoate A , Nuñez E - Zaragoza</i>
F026	The pathophysiology of pseudoexfoliation syndrome is affected by interaction of TGF-β1 and LOXL1 <i>LIRAVI P , Zenkel M , Kruse F E , Schlötzer-Schrehardt U - Erlangen</i>
F027	Effects of recurring intraocular pressure elevations on the retina and the autoimmune component <i>TEISTER J , Gramlich O , Neumann M , Tao X , Pfeiffer N , Grus F - Mainz</i>
F028	Association of microRNA DGCR8 and XPO5 gene polymorphisms with the risk of primary open angle glaucoma occurrence <i>SZAFLIK J P , Majsterek I , Molasy M , Walczak A , Przybyłowska-Sygut K , Szymanek K , Szaflik J - Warszawa</i>
F029	Angle evaluation after cataract operation using Swept-Source OCT in elder Asian <i>LEE W , Bae H , Kim C Y , Seong G J - Seoul</i>
F030	Repeatability of retinal nerve fiber layer reflectance intensity measurement in glaucoma <i>GARDINER S , Demirel S , Reynaud J , Fortune B - Portland</i>
F031	Comparison of Optical Coherence Tomography Measurement Reproducibility between Children and Adults <i>KIM S H , Chung H K , Han Y G , Oh S - Seoul</i>
F032	Surgical outcomes of Ahmed glaucoma valve implantation in pseudoexfoliative glaucoma. <i>KIM G A , Ko J , Bae H , Hong S , Kim C Y - Seoul</i>
F033 ★	Complementary effects of PIGF inhibition and MMC in the improvement of surgical outcome after glaucoma filtration surgery <i>VAN BERGENT , Jonckx B , Moons L , Feyen J , Stalmans I - Heverlee</i>
F034	Longterm outcomes of cyclodiode treatment for patients with neovascular glaucoma <i>WESTON K , Lockwood A , Penwarden A , Kirwan J - Portsmouth</i>
F035	Surgically induced corneal astigmatism after fornix-based trabeculectomy <i>VAN KEER K , Willekens K , Abegão Pinto L , Delbeke H , Vandewalle E , Stalmans I - Leuven</i>
F036	Changes in choroidal thickness after intraocular pressure reduction following trabeculectomy <i>KADZIAUSKIENE A , Kuoliene K , Galgauskas S , Asoklis R - Vilnius</i>



15:00 - 15:45 | POSTER AREA

PBP: Physiology / Biochemistry / Pharmacology**OSBORNE N , SCHMETTERER L**

F037		Nanomedicine and Ophthalmology: looking forward <i>CORDEIRO SOUSA D , Ferreira Q , Araujo M , Morgado J , Ferreira J , Leal I , Abegao Pinto L , Marques-Neves C - Lisbon</i>
F038		Quantification of total retinal blood flow via dual-beam bidirectional Doppler optical coherence tomography for the assessment of neurovascular coupling <i>ASCHINGER G , Werkmeister R , Garhöfer G , Schmetterer L - Vienna</i>
F039		Combination of Resveratrol with omega-3 fatty acids synergize to counteract VEGF-R pathway in sick retinal pigment epithelium cells mimicking AMD <i>CHALONS P , Scagliarini A , Courtaut F , Olmière C , Delmas D - Dijon</i>
F040		Inhibition of micro-fibrillar associated protein 4 as a potential therapy targeting choroidal neovascularisation in age related macular degeneration <i>BLACKLEY Z , Ved N , Schlosser A , Holmskov U , Bates D O , Sorensen G L - Nottingham</i>
F041		Rescue of photoreceptor degeneration by progesterone in an animal model of retinitis pigmentosa <i>MIRANDA M , Benlloch-Navarro S , Trachsel-Moncho L C , Ramírez DT , López-Pedrajas R , Almansa I , Silvestre D - Moncada</i>
F042		Neuroprotection as a therapeutic target in diabetic retinopathy: a basic approach <i>DAL MONTE M , Amato R , Biagioni M , Cammalleri M , Casini G - Pisa</i>
F043		Suprachoroidal pocket to collect drugs for treatment of ocular diseases <i>RODRIGO M J , Prieto E , Idiope M , García-Martin E , Otin S , Polo V - Zaragoza</i>
F044		In-vivo microdialysis as a new technique to assess ocular pharmacokinetics of topically applied drugs in a rabbit model <i>GARHOFER G , Klaus R , Jäger W , Zeitlinger M , Richter-Mütsch S , Schmetterer L - Vienna</i>
F045		Angiotensin Receptor Blockade in Retinopathy of Prematurity: An Experimental Study <i>NATH M , Kumar A , Chandra P , Singh B , Deorari A K , Velpandian T - New Delhi</i>
F046		Ghrelin inhibits choroid-retinal cell migration, proliferation and in vitro angiogenesis, under a high glucose environment <i>ROCHA DE SOUSA A , Silva-Gomes R , Conceição G , Moleiro A , Santos C , Leite-Moreira A - Porto</i>
F047		The diameter regulation of retinal arterioles during systemic hypoxia is impaired in diabetic patients without retinopathy <i>PETERSEN L , Bek T - Aarhus</i>



15:00 - 15:45 | POSTER AREA

EOVS: Electrophysiology, Physiological Optics, Vision Sciences

LEROY B , PUELL M

F048	Clinical evaluation of Nidek autorefractometer AR-360A <i>STOOR K , Karvonen E , Liinamaa J , Saarela V - Oulu</i>
F049	Assessment of deviation angle and oblique muscle function in strabismus patients using analysis of two-dimensional eye globe pictures in diagnostic gaze positions <i>BUSHUYEVA N , Romanenko D - Odessa</i>
F050	 Testing of an automated tablet-based method for the determination of low contrast near visual acuity in ophthalmic patients <i>MIRZA N , Tahir H J , Wang Y , Parry N R A , Murray I J , Aslam T M - Manchester</i>
F051	Assessment of interlinked double staircase acuity test <i>GIULVEZAN S , Gallagher K , Davies N - London</i>
F052	 Significance of Camouflage, Chromatic Acuity and Contour in the Design of Pseudoisochromatic Plates <i>KRASTEL H , Schultze-Lutter S , Mothes N , Udodov E , Kahlert C , Jonas J B - Neckargemünd</i>
F053	Comparability and reproducibility of four wavefront aberrometers for measuring lower and higher order aberrations in pseudophakic eyes <i>NGUYEN P M , Hirnschall N , Doeller B , Schuschitz S , Varsits R , Findl O - Wien</i>
F054	The Repeatability of straylight measurements using the C-Quant in young and older adults <i>PUELL M , Barrio A R , Antona B - Madrid</i>
F055	Mesopic Visual Acuity in Type2 Diabetes without Retinopathy <i>ALDAHAM S , Martín-Ridura M D C , Barrio A R , Antona B , Carballo-Álvarez J , Puell M C - Madrid</i>
F056	Analysis of Mp-1 audio-biofeedback impact on fixation in low vision patient with maculopathy. <i>SATO G , RIZZO R , Villani G M , Camerucci C - Padova</i>
F057	Frequency-Doubling Perimetry in Type2 Diabetes without Retinopathy <i>ALDAHAM S , Martín-Ridura M D C , Pérez-Carrasco M J , Palomo-Álvarez C , Carballo-Álvarez J , Puell M C - Madrid</i>
F058	Presbyopia compensation: looking for cortical predictors <i>IMBEAU L , Majzoub S , Thillay A , Bonnet-Brilhault F , Pisella P J , Batty M - Tours</i>
F059	Three family cases with Retinitis pigmentosa rod-cone dystrophy with autosomal dominant inheritance <i>KOEV K - Sofia</i>
F060	Aplication of low-level Laser therapy (LLLT) in patients with Retinitis Pigmentosa (RP) <i>KOEV K - Sofia</i>
F061	Female heterozygotes of X-linked ocular disease in the era of molecular diagnostics <i>KREPS E O , De Zaeytijd J , De Baere E , Leroy B P - Ghent</i>
F062	Multifocal electroretinogram and en-face OCT in patients who underwent retinal detachment surgery <i>RICOUARD F , Bigan G , Tumahai P , Flores M , Castelbou M , Delbosc B , Saleh M - Besancon</i>
F063	The STZ-induced diabetic rat as a model for studying neuronal pathologies of diabetic retinopathy <i>HERRMANN R , Zippel N , Haller J , Streicher R - Biberach an der Riss</i>
F064	Evidence for a new model of the human eye - a holographic laser system, biophotonics. The holographic view <i>MANU M D , Plesu G - Iasi</i>
F065	Bioluminescence - Biological Laser Phenomenon initiated by eye. Biophotonic tests. <i>MANU M D - Iasi</i>
F066	Modulation of the contrast response function of V1 neurons by the pulvinar <i>CASANOVA C , Lai J , Thomas S - Montreal</i>



15:00 - 15:45 | POSTER AREA

LC: Lens and Cataract**LÖFGREN S , KRONSCHLÄGER M**

F067	Evaluation of a portable manual stretching device to simulate accommodation <i>D'ANTIN J C , Pinilla Cortés L , Montenegro G A , Barraquer R I , Michael R - Barcelona</i>
F068	Objective assessment of cataract: Comparison between the Lens Opacities Classification System III and a Scheimpflug camera <i>BIRKELDH U , Domínguez-Vicent A , Laurell C G , Brautaset R , Nilsson M - Stockholm</i>
F069	Cataract surgery in adult patients with uveitis <i>BACQUET J L , Fel A , Butel N , Remond A L , Le Hoang P , Bodaghi B - Paris</i>
F070	Anterior segment changes after femtosecond cataract surgery measured with optical coherence tomography and scheimpflug imaging technology <i>PEREZ CARRASCO M J , Fernández-Cuenca S , Lorente-Hevia M P , Alvarez de Rementería L , Aldaham S , Puell M C - Madrid</i>
F071	<i>rf</i> Anterior chamber and refractive parameters in diabetic patients according to metabolic status <i>COSTA L , Cardigos J , Vicente A , Borges B , Ferreira J , Cunha J P , Amado D - Lisbon</i>
F072	New Parameter for Predicting the Postoperative IOL Position: Preoperative Lens Equator Depth measured By Three-Dimensional Anterior Segment Optical Coherence Tomography <i>HWANG KY , Joo C K , Yoon GY - Daejeon</i>
F073	Impact of a pre-cut on clear cornea incision architecture in cataract surgery <i>DRASCHL P , Hirnschall N , Doeller B , Nguyen P M , Findl O - Vienna</i>
F074	Small pupil and pupil dilatation methods. Comparative study in cataract surgery <i>CARAMELLO C M , Del Buey M , Cristóbal J , Mateo J , Martínez Velez M , Sanchez Marín J , Idoate A , Pinilla I , Casas P - Zaragoza</i>
F075	Effects of optic's shape for contraction of anterior capsulorhexis <i>MAYUMI N , Hiroyuki M , Tadashi S - Tochigi</i>
F076	Effect of Preconditioning Intraocular Lenses in Moxifloxacin Solution <i>FILIFE H P , Bozukova D , Pimenta A , Mata J L G , Colaço R , Saramago B , Serro A P - Lisbon</i>
F077	Thermal cataract induced by near infrared radiation (IRR) <i>YU Z , Schulmeister K , Talebizadeh N , Kronschräger M , Söderberg P - Uppsala</i>



15:00 - 15:45 | POSTER AREA

PO: Poster session: Pathology / Oncology in Poster area

KILIC E , VAN GINDERDEUREN R

F078		Uveal melanoma and renal cell carcinoma both metastatic to the liver <i>TURUNEN J , Markkinen S , Wilska R , Kivelä T - Helsinki</i>
F079		Clinical Experience with the Ruthenium- plaque Brachytherapy in Case of Choroidal Melanoma <i>GRAJEWSKI L , Kneifel C , Ciernik I , Ebrahimi F , Krause L - Dessau</i>
F080	<i>rf</i>	The Liverpool Uveal Melanoma Prognosticator Online (LUMPO) for prognosing metastasis free survival in the absence of cytogenetic data after ruthenium brachytherapy for uveal melanoma <i>ROSPOND-KUBIAK I , Wroblewska-Zierhoffer M , Twardosz-Pawlik H , Kociecki - Poznan</i>
F081		3D Sphere cultures of uveal melanoma reveal a molecular signature with a potential target for cancer therapy <i>NESS C , Garred Ø , Eide N , Bærlund T , Nicolaissen B , Moe M C , Noer A - Oslo</i>
F082		Intravitreal chemotherapy in advanced retinoblastoma:results and complications <i>HADJISTILIANOUT , Borri M , De Francesco S , Sparagna C - Sienna</i>
F083		Clinical characteristics and surgical outcomes of mesectodermal leiomyoma of the ciliary body and choroid <i>PARK H J , Lee J H , Lee S C - Seoul</i>
F084		Case report of ring ciliary body and choroidal lymphoma. <i>BOGDALI A , Markiewicz A , Jakubowska B , Romanowska-Dixon B - Krakow</i>
F085	<i>rf</i>	Immunohistochemical characterization of a retinal hamartoma <i>VAN GINDERDEUREN R , Stalmans P - Leuven</i>
F086		New device to applanate full thickness eyelid tumours for ex vivo confocal microscopy <i>GRIVET D , Cinotti E , Perrot J L , Labeille B , Cambazard F , Bernard A , Forest F , Gain P , Thuret G - Saint-Etienne</i>
F087		A case report of eyelid basal cell carcinoma with orbital invasion : an alternative to exenteration <i>JEANCOLAS A L , Maalouf J , Baudot A , Ameloot F , George J L , Angioi K - Vandoeuvre les Nancy</i>



15:00 - 15:45 | POSTER AREA

NSPH: Neuro-ophthalmology / Strabismology / Paediatric / History**GRZYBOWSKIA , BOSCHIA**

F088	Reduced retinal nerve fibre layer thickness in multiple sclerosis patients with and without history of optic neuritis <i>BIRKELDH U , Wahlberg-Ramsay M , Hietala A , Brautaset R , Nilsson M - Stockholm</i>
F089	Retinal thickness in children with anisohypermetropic amblyopia <i>TOMO N , Nahoko O - Kashihara</i>
F090	Seasonal variation of the pupil light reflex <i>KOURTI P , Münch M , Collomb S , Kawasaki A - Lausanne</i>
F091	Evaluation of the retinal nerve fiber layer thickness and its relation to visual evoked potentials in multiple sclerosis <i>STRUPAITE R , Mockeviciute E , Kizlaitiene R , Budrys V , Liveikiene A , Mamontovaite G , Cimbaldas A , Asoklis R - Vilnius</i>
F092	Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease <i>SATUE M , RODRIGO M J , Mateo A , Otin S , Bambo M P , Fuertes I , Pablo L , Garcia-Martin E - Zaragoza</i>
F093	Effects of smoking during pregnancy on retinopathy of prematurity <i>RODRIGO M J , Fernández S , De la Mata G , Ara M , Prieto E , González-Viejo I , Ferrer C , Pueyo V - Zaragoza</i>
F094	Visual functions in children with congenital myopia and with amblyopia with the same refraction. <i>BOYCHUK I , Mukhina A - Odessa</i>
F095	Stereovision in patients with intermittent exotropia before and after surgical treatment <i>BOYCHUK I , Tarak A - Odessa</i>
F096	Quantitative assessment of fixational saccades in school children. A new method. <i>LARSEN D A , Bek T - Århus C</i>
F097	Comparison of effective group and refractory group to alternative patch treatment in overcorrected intermittent exotropia <i>LEE S J , Kim J Y , Park J M - Busan</i>
F098	Ptosis and diplopia after incidental botulinum powder exposure <i>CHO M - Seoul</i>
F099	Consecutive esotropia in contralateral recess-resect for recurrent intermittent exotropia after unilateral recess-resect <i>CHO S Y , Lee S Y - Gyeongju</i>
F100	<i>rf</i> Ophthalmic insert for pupillary mydriasis in neonates <i>BREMOND-GIGNAC D , Jacqz-Aigrain E , Abdoul H , Beresniak A , Baud O , Alberti C - Paris</i>
F101	Comparison of long-term surgical outcomes of 2-muscle surgery in intermittent exotropia: Bilateral vs Unilateral <i>CHO S Y , Lee S Y , Bang S P , Lee Y C - Gyeongju</i>
F102	Diplopia as presenting sign of Turcot syndrome <i>NINCLAUS V , Walreadt S , Baert E , Laureys G , De Zaeytijd J - Gent</i>
F103	Double depressor palsy after bilateral paramedian thalamus infarction <i>KIM S J , Lee S - Busan</i>
F104	Correlation between peripapillary retinal thickness and serum level of vascular endothelial growth factor in patients with POEMS syndrome <i>YOKOUCHI H , Baba T , Oshitari T , Yamamoto S - Chiba</i>



15:00 - 15:45 | POSTER AREA

NSPH: Neuro-ophthalmology / Strabismology / Paediatric / History

F105		Late ocular changes after closantel (Flukiver) poisoning <i>ASOKLIS R , Augyte A , Cimbaldas A - Vilnius</i>
F106		Sarcoidosis of orbita and central nervous system presenting as a non-arteritic ischemic optic neuropathy. <i>DE BRUYN D , Ninclaus V , Leroy B , De Schryver I , De Zaeytijd J - Ghent</i>
F107		Optic disc drusen with subretinal hemorrhage <i>HALFELD FURTADO DE MENDONCA R , De Oliveira Maia JR. O - Rome</i>
F108	★	Clinical experience with Idebenone (Raxone®) in the treatment of patients with Leber's Hereditary Optic Neuropathy (LHON) <i>METZ G , Klopstock T , Gallenmüller C , Catarino C , Von Livonius B , Lob F , Meier T - Liestal</i>
F109	rf	Nonarteritic anterior ischemic optic neuropathy (NAION): A misnomer. A non-ischemic papillopathy caused by vitreous separation <i>PARSA C , Hoyt W - Paris</i>
F110	rf	Optic disc swelling : Prospective study of sixty-seven patients <i>SITBON C , Fel A , Bodaghi B , Le Hoang P , Tuitou V - Paris</i>
F111		The Damato Multifixation Campimetry Online (DMCO) - A possible visual field test to detect neurological visual field defects <i>STEENBERG AT , Olsen A S , Pinborg L H , Kolko M - Copenhagen</i>
F112	rf	Homonymous hemimacular thinning in retrochiasmal lesions <i>CUNHA J P , Proença R , Dias-Santos A , Vicente A , Anjos R , Costa L , Cardigos J , Ferreira J , Amado D - Lisbon</i>



15:45 - 16:15

Section Business Meetings

- ACB Gallieni 5
- COS Rhodes 2
- EOVS Rhodes 1
- G Rhodes 1
- IM..... Rhodes 4
- LC Hermes
- MBGE..... Gallieni 1 & 2
- NSHP Rhodes 2
- PO Rhodes 3
- PBP..... Rhodes 3
- RV..... Hermes

Agenda

1. Report of the chair of section
2. Report of the programme secretary
3. Next year's meeting:
 - nomination of the 2016 section programme secretary (different from the section chair)
 - proposals of 2016 Special Interest Symposia (SIS)
 - proposals of 2016 Courses
 - proposals for 2017 Keynote speakers
4. Comment on the EVER activities
5. Other business

In addition to the agenda, the sections IM and PBP will nominate at least 2 candidates for section chair 2016-2021.



16:20 - 17:50 | HERMES

RV: Vitreoretinal macular interface in various macular pathologies

Vitreoretinal macular interface disorders are of great interest since the introduction of vitreolysis as an alternative to surgical approach. Their association to different macular pathologies will be discussed separately, as idiopathic condition, diabetes, venous occlusions and High myopia.

POURNARAS JA , LE MERY

3511	16:20	Evaluation of the vitreoretinal interface <i>GUALINO V - Montauban</i>
3512 ★	16:38	Vitreoretinal traction syndrome <i>LE MERY - Paris</i>
3513	16:56	Diabetic maculopathy <i>POURNARAS JA - Lausanne</i>
3514	17:14	Venous occlusions <i>PAQUES M - Paris</i>
3515	17:32	High myopia <i>STANGOS A - Geneva</i>



16:20 - 17:50 | RHODES 1

G: Healthcare delivery - The traditional role of the doctor is changing

Financial restrictions in healthcare delivery, imposed by the economical and social factors, leads inevitably to innovation in the organization of the care. The professionals should perform more efficiently, less expensive and overcome the challenges of maintaining the quality of care. There is a trend for disruptions of healthcare professions, as specialists concentrate on curing the most complex and sickest patients, the "less-skilled" practitioners could take on more complex role (Christensen C, Harvard Business Review, 2000). Our SIS concentrates on "Lean management", "disruptive innovations in healthcare" and "patient-centeredness". The lecture of the first speaker, the CEO (non-medical professional) of the University Hospitals in Brussels concentrates on the challenges that a university hospitals encounters because of the governmental restrictions. The medical professionals explain the changing role of the specialists. Very interesting SIS to attend which gives new insights of organization of the healthcare for the professionals.

POURJAVAN S , KOTECHA A

3521	16:20	Healthcare delivery, not just about the doctor and the patient <i>MAZY R - Bruxelles</i>
3522	16:38	The evolving role of nurses and allied health professionals in the management of age-related macula degeneration <i>HAMILTON R , Mapani A , DaCosta J , Pavesio C , Flanagan D - London</i>
3523	16:56	Optometrists and the management of glaucoma; the Rotterdam experience <i>LEMIJ H - Rotterdam</i>
3524	17:14	Can ophthalmic technicians be used to deliver glaucoma care? <i>KOTECHA A - London</i>
3525	17:32	Patient-focused glaucoma care delivery, maintaining quality despite cost limitation <i>POURJAVAN S - Brussels</i>



16:20 - 17:50 | RHODES 2

COS: Immune regulation in cornea and ocular surface

This session will present new insights into the role of immune Regulation on physiology and pathology of cornea and ocular surface.

DANA R , SABAN D

3531	16:20	Corneal nerves maintain the immune privilege of the cornea <i>HAMRAH P - Wellesley</i>
3532	16:38	Immune Responses at the Ocular Surface <i>SABAN D R - Durham</i>
3533	16:56	Immunomodulation in allergic eye disease <i>CALDER V - London</i>
3534 ★	17:14	Tregs in corneal health and disease <i>DANA R - Boston MA</i>
3535	17:32	The Role of Antigen Presenting Cells in the Pathophysiology of Dry Eye <i>STERN M E - Irvine</i>



16:20 - 17:50 | RHODES 3

PO: Ocular lymphomas

Lymphoproliferative diseases may affect the eye and the adnexae under two main patterns: on the one hand, high-grade, B-cell lymphomas affecting the vitreous, retina and central nervous system, and low-grade, 'MALT' lymphomas affecting the orbit and palpebral tissue on the other. The scope of this SIS is to bring together pathologists, clinical haematologists, orbital and retino-vitreous surgeons to focus on the histological, clinical, surgical and medical issues of ocular lymphomas in 2015.

ROBERT PY , COUPLAND S

3541	16:20	Update on lymphoma diagnostic <i>COUPLAND S - Liverpool</i>
3542	16:38	Vitreoretinal Lymphomas <i>CASSOUX N - Paris</i>
3543	16:56	Orbital and palpebral lymphomas <i>ROBERT PY , Flausse R - Limoges</i>
3544	17:14	Imaging and Biopsies <i>VAN GINDERDEUREN R - Leuven</i>
3545	17:32	Medical treatment of Lymphoma in 2015 <i>BORDESSOULE D - Limoges</i>



16:20 - 17:50 | RHODES 4

LC: Oxidation and defense in the ocular lens

First, experimental evidence for apoptosis in the lens after in vivo oxidative stress will be presented. Then, the spatial distribution of active caspase-3 in the lens and its response to in vivo oxidative stress after exposure to UVR will be reviewed. Subsequently, response in the immunoproteasome in human lens epithelial cells during oxidative stress will be reviewed. Thereafter, the role of estrogen as an antioxidant in the lens will be presented based on experimental and clinical data. Finally, evidence for protection against in vivo oxidative stress with the extrinsic antioxidant caffeine will be presented.

SÖDERBERG P , ZETTERBERG M

3551	16:20	Apoptosis in the lens after oxidative stress induced by in vivo exposure to UVR <i>GALICHANIN K - Stockholm</i>
3552	16:38	Active caspase-3 in the lens and its response to oxidative stress induced by in vivo exposure to UVR <i>TALEBIZADEH N - Uppsala</i>
3553	16:56	The immunoproteasome in human lens epithelial cells during oxidative stress <i>PETERSEN A , Zetterberg M - Göteborg</i>
3554	17:14	Estrogen as an antioxidant in the lens <i>ZETTERBERG M - Mölndal</i>
3555	17:32	Caffeine, an in vivo oxidation protectant in the lens <i>KRONSCHLAGER M , Yu Z , Talebizadeh N , Söderberg P - Freiburg</i>



16:20 - 17:50 | GALLIENI 1+2

MBGE: Identification of novel mouse models for hereditary eye disorders

The mouse is one of the most frequently used models for genetic eye diseases. Therefore, it is of particular importance to have standardized phenotyping procedures allowing a fast and reliable diagnosis of genetic defects affecting the eye. Therefore, several mouse phenotyping centers have been established and are coordinated on an international level (International Mouse Phenotyping Consortium -IMPC; <http://www.mousephenotype.org/>). In Europe, four mouse clinics (Munich, Strasbourg, Harwell and Cambridge) exist and are screening for eye disorders. We would like to discuss the different strategies to identify as many eye disorders in the mouse as possible on the most efficient way under high-throughput conditions. Moreover, selected recent findings will be reported which can be used as models for several hereditary eye disorders.

GRAW J

3561	16:20	Novel mouse phenotypes identified in the eye screen of the German Mouse Clinic <i>AMARIE O V , Fuchs H , Gailus-Durner V , Hrab de Angelis M , Graw J - Neuherberg</i>
3562	16:42	Eye diseases identified in the ENU-Ageing Screen <i>JACKSON I , Starbuck B , McKie L , Banks G , Blease A , Simon M , Wisby L , Cross S , Nolan P , Brown S , Potter P - Edinburgh</i>
3563	17:04	The eye screen design in Czech Centre for Phenogenomics and selected models for eye diseases <i>ANTOSOVA B , Smolikova J , Zilova L , Lachova J , Bendova M , Machon O , Kozmik Z - Prague</i>
3564	17:26	Angiography reveals novel features of the retinal vasculature in mice <i>RUBERTE J - Ceradanyola del Valles</i>



16:20 - 17:50 | GALLIENI 5

G: Free paper session - Experimental glaucoma

STALMANS I , BRON A

3571	 16:20	The Effect of Hypertension on Intraocular Pressure and Apoptosis of Retinal Ganglion Cell Through ET-1 Signaling Pathway Activation in Trabecular Meshwork of Hypertension Rat Model <i>PRAYITNANINGSIH S , Sujuti H , Abdullah Hamid A , Permatasari N , Aris Widodo M - Malang</i>
3572	16:32	TrkB signaling in Müller glia stimulates neuroprotection after optic nerve injury <i>HARADAT , Namekata K , Guo X , Kimura A , Harada C - Tokyo</i>
3573	16:44	Downregulating the Myocardin-related transcription factor/ Serum response factor (MRTF/ SRF) pathway is a novel therapeutic approach to prevent post-surgical fibrosis in glaucoma. <i>YU-WAI-MAN C , Treisman R , Khaw PT , Bailly M - London</i>
3574	16:56	In vivo modified peripheral glia enhance regenerative capacity in a rat retina <i>SMEDOWSKI A , Pietrucha-Dutczak M , Kaarniranta K , Lewin-Kowalik J - Katowice</i>
3575	17:08	MMP-9 null mice display elevated IOP due to reduced aqueous humor drainage from the trabecular meshwork <i>DE GROEF L , Siwakoti A , Geeraerts E , Billen J , Stalmans I , West-Mays J , Moons L - Leuven</i>
3576	17:20	Neuroprotective modifications in retinal Müller cells due to oxidative stress and energy restriction <i>TOFT-KEHLER A K , Gurunbaram R , Brændstrup C , Desler C , Rasmussen L , Skytt D , Kolko M - Copenhagen</i>



17:55 - 18:30 | HERMES
EVER General Assembly



1. President's address by Bart Leroy
 2. Minutes of the General Assembly 2014
 3. Report of the Secretary General, Catherine Creuzot
 4. Report of the Programme Secretary, Marcela Votruba
 5. Report of the Treasurer, Steffen Heegaard :
 - approval of the accounts 2014
 - discharge to the directors
 - approval budget for 2015
 6. Results of the elections
 7. Presentation of the board 2016
 8. Future congresses
 9. Miscellanea
 10. Handover of chain of office
-



20:00 - 23:00 | NEGRESCO

EVER Congress dinner in Negresco



EVER 2015
Saturday, Oct 10





8:00 - 8:30 | HERMES

Coffee and Croissants



8:30 - 10:00 | HERMES

RV: Diabetic macular edema in vitrectomized eyes

Conventional theory explains that poor visual outcomes following surgical treatment of proliferative diabetic retinopathy are the result of macular ischemia, long standing traction retinal detachment of the macula or advanced fibrovascular proliferation beyond surgical repair. In some cases, cystoid macular edema (CME) may be a prominent finding on optical coherence tomography (OCT) and may account for the observed limited visual outcomes following pars plana vitrectomy (PPV) surgery. In the present SIS, we present the spectrum of conditions where CME has been reported after PPV, the importance of imaging technology in the management of CME and will concentrate on CME post PPV surgery in diabetic patients. Pharmacokinetic data and clinical efficacy data of treatment with anti- VEGF agents and periocular and intravitreal steroids are presented for the management of CME in diabetic vitrectomized eyes.

XIROUT , ZAMBARAKJI H

4111	8:30	Introduction: DME in vitrectomized eyes <i>XIROUT - Glyfada</i>
4112	8:48	Imaging of DME in vitrectomized eyes <i>POURNARAS JA - Lausanne</i>
4113	9:06	Pharmacokinetics of anti-VEGF and steroid agents in vitrectomized eyes with diabetic macular edema <i>PAPASTEFANOU V - London</i>
4114	9:24	The role of Anti-VEGFs in the management of DME in vitrectomized eyes <i>KOURENTIS C - Athens</i>
4115	9:42	Steroids agents in the management of vitrectomized eyes with diabetic macular edema <i>ZAMBARAKJI H , Papastefanou V , Dooley I - London</i>



8:30 - 10:00 | RHODES 1

Subspecialty exam and diploma in Europe: Why, when and how


The EBO has gained worldwide respect for its efforts on harmonizing education and training in general ophthalmology within Europe. The comprehensive EBO Diploma examination, organised annually since 1995, awards successful candidates the title of the Fellow of the European Board of Ophthalmology (FEBO), and is the most evident result of such efforts. More recently the EBO has established a Subspecialty European Board of Ophthalmology Diploma Examination with the goal to increase standards of knowledge and care in various subspecialties. The EBO is realising this goal by close collaboration with different European ophthalmological subspecialty societies who are actively taking part in the organization and realization of the EBO Subspecialty Examinations allowing an official and standardized evaluation and awarding of knowledge in various specialties. The first of these subspecialty examinations to be introduced is in the field of glaucoma and is developed in close collaboration with the European Glaucoma Society (EGS). The goals, the organisation and requirements to sit the subspecialty exam as well as the first experience with the FEBO-Glaucoma exam and Diploma will be presented.

RINGENS P , GRUPCHEVA H

4121	8:30	Why do we need a subspecialty exam? <i>ACLIMANDOS W - London</i>
4122	8:48	What are the general requirements for candidates to sit the exam <i>MIDENA E - Padova</i>
4123	9:06	How does EBO manage expertise of MCQ's ? <i>TASSIGNON M - J - Edegem</i>
4124	9:24	EBO-EGS exam in glaucoma ; our first experience in 2015 ? <i>SUNARIC MEGEVAND G - Geneva</i>
4125	9:42	Future plans: Exams in retina, paediatrics, cataract and cornea <i>CREUZOT C - Dijon</i>



8:30 - 10:00 | RHODES 2

COS: Infectious keratitis

This session will give focus on the pathology and promoting new therapies of infectious Keratitis.

GRIFFITH M , BEUERMAN R

4131	8:30	Infectious keratitis and the distribution in Asia <i>BEUERMAN R - Singapore</i>
4132	8:52	Prevention of herpes simplex stromal keratitis by a glycoprotein B-specific monoclonal <i>BAUER D , Dirks M , Kasper M , Buch A , Dittmer U , Giebel B , Wildschütz L , Busch M , Goergens A , Schneeweis K E , Eis-Hübinger A M , Sodeik B , Heiligenhaus A , Roggendorf M , Krawczyk A - Muenster</i>
4133	9:14	Peptide versus gene therapy: Cathelicidin LL-37 and HSV-1 corneal infection <i>GRIFFITH M , Lee C J , Buznyk O - Linköping</i>
4134	9:36	Antibiotic resistance and new types of antimicrobials <i>BEUERMAN R - Singapore</i>



8:30 - 10:00 | RHODES 3

PO: OOG Ocular Oncology Group 1

DESJARDINS L , KIVELÄ T

4141	8:30	Uveal melanoma and other cancers <i>DESJARDINS L , Villaret J , Cassoux N , LumbrosoLeRouic L , Levy C , Plancher C , Savignoni A - Paris</i>
4142	8:42	Uveal melanoma in Finnish patients with congenital ocular melanocytosis <i>MAMUNUR R , Kivelä T - Helsinki</i>
4143	8:54	Spectral-domain EDI-OCT in small uveal melanoma and «pseudomelanomas» <i>SAAKYAN S , Neroev V , Myakoshina E , Zaitseva O - Moscow</i>
4144	9:06	BAP1 correlates with metastasis in polyploid uveal melanoma <i>KILIC E , Yavuziyigitoglu S , Mensink H , Vaarwater J , Naus N , Paridaens D , De Klein A - Rotterdam</i>
4145	9:18	Proteomic analysis of the uveal melanoma (UM) secretome reveals novel insights and potential biomarkers <i>ANGI M , Kalirai H , Coupland S - Liverpool</i>
4146	9:30	Selecting uveal melanoma for PRAME-TCRT cell immunotherapy <i>JAGER M J , Krijgsman D , Luyten G P M , Luk S J , Van der Velden P , Heemskerk M H M - Oegstgeest</i>



8:30 - 10:00 | RHODES 4

IM: Free paper session - Mechanisms in inflammatory disease to outcomes of novel therapies, part 2

HEISSIGEROVA J , WILLERMAIN F

4151	8:30	Comparison of retinal and choroidal involvement in tuberculous chorioretinitis in a non-endemic area. <i>MASSY R , Herbot C P - Sierre</i>
4152 ★	8:42	Impact of disease modifying anti-rheumatic drugs (DMARDs) on the uveitis risk in juvenile idiopathic arthritis <i>TAPPEINER C , Klotsche J , Schenck S , Niewerth M , Minden K , Heiligenhaus A - Bern</i>
4153	8:54	Effect of dexamethasone intravitreal implant in the treatment of noninfectious uveitis <i>FRERE A , Janssens X , Makhoul D , Judice L , Postelmans L , Lefèbvre P , Caspers L , Willermain F - Brussels</i>
4154 ★	9:06	Sarilumab for the treatment of posterior segment non-infectious uveitis (NIU): The SATURN (SARIL-NIU) study <i>HEISSIGEROVA J , Sundaram P A , Erickson K , Varona R , Corp-dit-Genti V , Vitti R , Buggage R , Rihova E , Nguyen Q D - Prague 2</i>
4155 ★	9:18	Long-Term Safety of Intravitreal Sirolimus for the Treatment of Non-infectious Uveitis (NIU) of the Posterior Segment: 12-Month SAKURA Study 1 Results <i>BODAGHI B , Pavesio C , Alfredo A C , Valentine M E - Paris</i>
4156	9:30	Ophthalmologic manifestations of the granulomatosis with polyangiitis (Wegener) <i>TOUTEE A , Tuitou V , Bodaghi B , Lehoang P , Saadoun D , Hie M , Schoindre Y - Le Kremlin Bicetre</i>



8:30 - 10:00 | GALLIENI 1+2

NSPH: ABC in retina structure and function

Beginner

An understanding of the anatomy and physiology of the retina are essential in order to help in the diagnoses and treatment of various types of retinal diseases. Generally, only a limited amount of information is available in ophthalmic textbooks with the reader being unaware of more recent advances. The aim of this course is therefore to provide some more in-depth information on retinal structure and function to hopefully facilitate in an understanding in, for example, imaging diagnostic technologies like OCT and adaptive optics. Moreover, the newer available methods that include gene and stem cell treatments are aimed at preserving specific retinal cell-types and this requires knowledge related to the functional and morphological relationship between neurons, glial cells and the retinal vascular. In addition, an understanding of the relationship between retinal physiology and circadian rhythms cannot be ignored. The course should benefit clinicians, basic scientists and physiologists and will concentrate on retinal glial cells, the important relationship between photoreceptors and retinal pigment epithelial cells, the significance of ganglion melanopsin cells and the unique characteristics of the ON/OFF pathway of the retina.

GRZYBOWSKIA , OSBORNE N

4161	8:30	General structure of the retina <i>GRZYBOWSKI A - Poznan</i>
4162	8:48	Retinal vasculature structure and function <i>SCHMETTERER L - Vienna</i>
4163	9:06	The RPE/photoreceptor complex <i>OSBORNE N - Oxford</i>
4164	9:24	Retinal glial cells <i>REICHENBACH A - Leipzig</i>
4165	9:42	The On/OFF system pathway of the retina <i>CASTELO-BRANCO M - Coimbra</i>



8:30 - 10:00 | GALLIENI 5

ACB: Free paper session - Molecular and morphological studies in ocular diseases

PETROVSKI G , KOLKO M

4171		8:30	MicroRNA-124 regulates transforming growth factor 1-induced epithelial-mesenchymal transition in the retinal pigment epithelium by Down-regulating expression of the RhoG <i>JUN J H , Joo C K - Daegu</i>
4172		8:42	Spontaneous and mechanically induced Ca ²⁺ activity changes in hESC-RPE cells during maturation <i>ABU KHAMIDAKH A , Juuti-Uusitalo K , Caetano dos Santos F , Skottman H , Hyttinen J - Tampere</i>
4173		8:54	Inflammasome activation by UVB irradiation in human corneal epithelial cells <i>KAUPPINEN A , Korhonen E , Piippo N , Hytti M , Kaarniranta K - Kuopio</i>
4174		9:06	Anatomical digital image analysis of the angle and optic nerve – a novel method for glaucoma imaging <i>RUSSELL G , Szabó A , Sziklai P , Facskó A , Kolko M , Petrovski G - Cheshire</i>
4175	<i>rf</i>	9:18	Fisetin and Luteolin decrease inflammation and oxidative stress-induced cytotoxicity in ARPE-19 cells <i>HYTTI M , Piippo N , Korhonen E , Kaarniranta K , Kauppinen A - Kuopio</i>
4176	<i>rf</i>	9:24	cis-Urocanic acid prevents inflammation and cell death in UVB-treated ARPE-19 cells <i>KORHONEN E , Piippo N , Hytti M , Kaarniranta K , Kauppinen A - Kuopio</i>
4177	<i>rf</i>	9:30	Anterior lens epithelium in cataract patients with retinitis pigmentosa - scanning and transmission electron microscopy study <i>ANDJELIC S , Drašlar K , Hvala A , Hawlina M - Ljubljana</i>
4178	<i>rf</i>	9:36	The study of needle tip aspirates and entry sites after intravitreal injections with different needle types <i>LYTVYNCHUK L , Savytska I , Sergiienko A , Binder S , Petrovski G - Lviv</i>



10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous**CHIQUET C , WIEDEMANN P , LOEWENSTEIN A**

S001		Posterior vitreous detachment: more a case of the fibronectin interface than the inner limiting membrane? <i>ETIENNE I , Jonckx B , Feyen J - Leuven</i>
S002	<i>rf</i>	Improvement in retinal vessel oxygen saturation after vitrectomy <i>LIM S L , Tan L , Perera S - Singapore</i>
S003	<i>rf</i>	Imaging of intravitreal injected solution dispersion. <i>WILLEKENS K , Reyns G , Jonckx B , Feyen J H M , Yewei L , Coudyzer W , Yicheng N , Stalmans P - Leuven</i>
S004		23-Gauge versus 25-Gauge Vitrectomy for Proliferative Diabetic Retinopathy: A Comparison of Surgical Outcomes <i>MAGILL H , Guthrie G , Steel D - London</i>
S005		Preoperative intravitreal bevacizumab effects on the course of Pars Plana vitrectomy in diabetic vitreous hemorrhage <i>ZAHAF A , Zghal I , Fekih O , Zayani M , Mahjoub A , Bouguila H , Nacef L - Tunis</i>
S006		Management of Acute Submacular Haemorrhage: Royal Free Hospital Experience <i>SIM S Y , Elhousseini Z , Maragos I , Asaria R - London</i>
S007		Management of Unexplained Haemorrhagic PVD at Southampton Eye Casualty Clinic <i>SHALABY A , Tossounis C , Andrew M - Southampton</i>
S008		Resolution of postoperative macular hole with topical nepafenac: a case report <i>IDOATE A , Honrrubia A , Ascaso J , Cristobal J A , Perez I , Almenara C , Esteban O , Martinez M , Sanchez J I - Zaragoza</i>
S009	<i>rf</i>	The use of intraoperative spectral domain optic coherence tomography in vitreoretinal surgery: The evaluation of efficacy. <i>LYTVYNCHUK L , Glittenberg C , Binder S - Lviv</i>
S010	<i>rf</i>	epiretinal membrane peeling for eyes with asteroid hyalosis: a case-control study <i>MOUNA A , Conart J B , Kurun S , Ameloot F , Berrod J P - Vandoeuvre les Nancy</i>
S011		Project RESET. REtinal Surgery systEm for Training <i>COTIN S , Keppi J J , Allard J , Bessard R , Courtecuisse H , Gaucher D - Strasbourg</i>
S012		Clinical outcome of YAG laser vitreolysis (Ultra Q Reflex®) for the treatment of floaters <i>KIM E , Kim H K , Yoo T Y - Jeonju</i>
S013		Ampiginous choroiditis: heterogeneity in 2 cases <i>VANDEPUTTE J , Lambrecht P , Leroy B P , De Schryver I , De Zaeytijd J - Ghent</i>
S014		Wide-Field Angiography in the management of retinal vasculitis <i>EL MATRI HASSAIRI A , Chebil A , Bouladi M , Kort F , El Matri L - Tunis</i>
S015		Toxoplasma chorioretinitis: value of polymerase chain reaction and intraocular antibody production in a patient with negative anti-Toxoplasma gondii serology <i>ROELS D , Nerinckx F , Leroy B P , Padalko E , De Schryver I - Ghent</i>
S016		Intravitreal Cysticercosis <i>HALFELD FURTADO DE MENDONCA R , De Oliveira Maia JR. O - Rome</i>
S017		Choroidal thickness in patients with central serous chorioretinopathy: Assessment of haller's and sattler's layers <i>KIM S W , Chung Y R , Kim J W , Lee K - Seoul</i>
S018		Our experience with anti-VEGF treatment on central serous retinopathy <i>PAPAVASILEIOU E , Younis S - London</i>



10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S019		Mineralocorticoid receptor's antagonists in treatment of central serous chorioretinopathy <i>ROMANOWSKA DIXON B , Karska-Basta I , Pocij-Marciak W , Ozog-Baran J , Kubicka-Trzaska A - Krakow</i>
S020		Oral eplerenone as a first line treatment in chronic central serous chorioretinopathy : A case series evaluation <i>SENDON D , Graber M , Chiche A , Rambaud C , Berguiga M , Delbarre M , Froussart-Maille F - Paris</i>
S021		Novel SRPK1 inhibitors specifically target alternative splicing in human primary retinal epithelial cells <i>ROWLINSON J , Batson J , Toop H , Allen C , Gibbons B , Babaei-Jadidi R , Zhang J , Wearmouth S , Knapp S , Morris J , Bates D - Nottingham</i>
S022		Association between drusen and blood test results in a colony of 1,174 monkeys <i>NISHIGUCHI K , Yokoyama Y , Fujii Y , Furukawa T , Ono F , Shimozaawa N , Togo M , Suzuki M , Nakazawa T - Sendai</i>
S023	<i>rf</i>	Age Macular Degeneration-Lipidomic Study: Relevance and interest of Lipidomic study in screening, follow-up and etiopathogeny of AMD <i>GONZALEZ C , Bertrand-Michel J - Toulouse</i>
S024		AMD Drusenoid deposits "L" Lipid type, characterization, structural analysis with multimodal imaging and morphology-structural software <i>GONZALEZ C , Lay B - Toulouse</i>
S025		AMD Drusenoid deposits "P", Protein-Cellular Type : Characterization and Evolution. Multimodal imaging and OCT, OCT en Face, Evaluation and Interest. <i>GONZALEZ C - Toulouse</i>
S026		Long term outcomes in a real life setting treatment by anti-vascular endothelial growth factor for wet age-related macular degeneration <i>HAOUAS M , Girmens J F , Thuret G , Gain P , Paques M , Sahel J A - Saint-Etienne</i>
S027		Efficacy of intravitreal Aflibercept in patients with neovascular AMD who were previously treated with Ranibizumab based on a Treat and Extend protocol <i>TURKSEVER C , Prunte C , Hatz K - Baselland</i>
S028		Visual outcome following treatment with aflibercept in patients with neovascular age-related macular degeneration. <i>SANDER B , Rasmussen A , Lund-Andersen H - Glostrup</i>
S029	<i>rf</i>	The protective effect of anti-blue lens against photo-induced cell death <i>YU WY , Shan S W , To C H , Chan H H L - Hong Kong</i>
S030	<i>rf</i>	Microbiology of conjunctiva sac in intravitreal injections. <i>GRZYBOWSKI A , Gaca-Wysocka M , Paluch M - Olsztyn</i>
S031	<i>rf</i>	Endophthalmitis associated with intravitreal Ranibizumab: Microbiology and visual outcomes. <i>PENWARDEN A , Weston K , Lockwood A - Portsmouth</i>
S032	<i>* rf</i>	Functional Expression of Toll-Like Receptors in Human Retinal and Choroidal Vascular Endothelial Cells <i>STEWART E , Wei R , Branch M , Sidney L , Amoaku W - Nottingham</i>
S033		Spontaneous oscillations in the diameter of retinal arterioles from normal persons decrease with age. <i>RAGUNATHAN S , Taborsky J , Bek T - Aarhus</i>
S034		Real Time, In Vivo Analysis of the Onset of Retinogenesis: Assessment of the Retinal Vascular Plexus, Electrophysiological Response and Architecture in Neonatal Mice <i>DENIRO M , AIQahtani A , AIAhmar S , AIMohanna F - Riyadh</i>



10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S035	Effects of selective retina therapy on retinal oxygen saturation compared to conventional photocoagulation in rabbits <i>KIM J R , Roh Y J - Seoul</i>
S036	The effects of nitroglycerine and COX-inhibition on retinal vessel diameters during hypoxia <i>KAYA M , Petersen L , Bek T - Aarhus</i>
S037	Lack of tone response in retinal arterioles secondary to electrical field stimulation <i>KRATHOLM N , Simonsen U , Jensen P S , Kringelholm S , Bek T - Aarhus C</i>
S038 <i>rf</i>	New generation analysis of thrombin generation in retinal vein thrombosis <i>FRUSCHELLI M , Capozzoli M , Scapellato C , Calzoni P , Puccetti L - Siena</i>
S039	Comparison of the lamina cribrosa thickness of patients with unilateral branch retinal vein occlusion and normal subjects <i>SAGONG M , Lim S H , Kim M , Chang W - Daegu</i>
S040	Effect of intravitreal bevacizumab on choroidal thickness in eyes with retinal vein occlusion and diabetic macular oedema <i>KUOLIENE K , Malysko K , Cimbaldas A , Asoklis R - Vilnius</i>
S041	Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion <i>ALMENARA MICHELENA C , Ascaso F J , Idoate A , Caramello C , Sánchez J I , Berniolles J , Cristóbal J A - Zaragoza</i>
S042	Macular Infarction Following Intravitreal Triamcinolone Injection for Treatment of Central Retinal Vein Occlusion <i>KIM T K , Lee J H , Lee M Y - Gyeonggi-do</i>
S043	Retinal vein occlusion in a patient with jugular vein compression by metastasis of carcinoma of the oral tongue <i>PEREZ NAVARRO I , Ascaso F J , Sánchez J I , Esteban O , Martinez M , Del Buey M A , Núñez E - Zaragoza</i>
S044	Intraarterial thrombotic material relative of essential thrombocytaemia in a 59-year-old woman <i>ROSPOND-KUBIAK I , Oszkini G , Kociecki J - Poznan</i>
S045	Retinal Vessel Oxygen Saturation and its implications in myopia <i>HEITMAR R - Birmingham</i>
S046	Assessment of choroidal thickness in high myopic glaucomatous eyes using SD OCT <i>EL MATRI L , Chebil A , Hassairi A , Maamouri R , Kort F , Chaker N - Tunis</i>
S047	Adjunctive photodynamic therapy for type 1 choroidal neovascularization associated with thickened choroid <i>KIM N , Lee W K - Seoul</i>
S048	Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of Aflibercept: report of 4 cases <i>MALCLES A , Russo A , Agard E , El-Chehab H , Dot C - Lyon</i>
S049	Spontaneous subretinal pigment epithelium hemorrhage <i>HALFELD FURTADO DE MENDONCA R , De Oliveira Maia JR. O - Rome</i>
S050	Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT) <i>ABU EL ASRAR A , De Hertogh G , Van den Eynde K , Alam K , Van Raemdonck K , Opdenakker G , Van Damme J , Geboes K , Struyf S - Riyadh</i>
S051 <i>*</i>	Stimulation of TLR4 Increases Angiogenic and Anti-Angiogenic Gene Expression in Choroidal Endothelial Cells <i>STEWART E , Wei R , Uribe M , May S , Amoaku W - Nottingham</i>



10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S052		Development of Diabetic Retinopathy in a 22-Week Old Homozygous Ins2Akita Mouse: A Case Study <i>DENIRO M , AIQahtani A , AlAhmar S , AlMohanna F - Riyadh</i>
S053		Correlation of Different Circulating Endothelial Progenitor Cells to Stages of Diabetic Retinopathy in patients with type 2 diabetes mellitus <i>WU Z , Ty M , Wang F - Wuxi</i>
S054	★ rf	Dexamethasone Reverses the Effects of High Glucose on Human Retinal Endothelial Cells In Vitro <i>STEWART E , Saker S , Amoaku W - Nottingham</i>
S055		The effect of glucose and insulin on the susceptibility of cultured photoreceptor-like cells to hypoxia <i>LAYTON C , DE MORAES G - Greenslopes</i>
S056		Insulin-induced dilatation of porcine retinal vessels in vitro is most pronounced in precapillary arterioles <i>JENSEN P S , Bek T - Aarhus C</i>
S057		Prevalence of diabetic retinopathy in children and adolescents with type 1 diabetes in Helsinki, Finland, 7-15 years after diagnosis <i>GRASBECK S , Gräsbeck T , Miettinen P J , Summanen P A - Helsinki</i>
S058	★	Hospital prevalence of visual of visual impairment caused by diabetic retinopathy <i>ROCHA DE SOUSA A , Tavares-Ferreira J , Perestrelo S P , Lima-Ramos P , Batista A M , Santana R , Macedo A F - Porto</i>
S059		Prognostics factors of poor functionally response in ranibizumab treatment for diabetic macular edema <i>JULLIEN M , Deken-Delannoy V , Labalette P - Lille</i>
S060		Correlation of hyperreflective foci, status of photoreceptor layer, and visual acuity in diabetic macular edema <i>CHEBIL A , Ben Abdallah M , Kort F , Hassairi A , Maamouri R , El Matri L - Tunis</i>
S061	rf	Automatic method to distinguish manifestation areas of early diabetic retinopathy from image artefacts by using L*u*v* colour space <i>SUZUKI N , Yamane K - Numazu</i>
S062	rf	Choroidal Thickness and Systemic Examination in Diabetic Patients without Diabetic Retinopathy <i>CARDIGOS J , Vicente A , Costa L , Crisóstomo S , Marques N , Cunha J P , Pinto L A , Ferreira J - Lisbon</i>
S063		Evaluation of intraocular pressure, choroidal and retinal thickness measurements using optical coherence tomography in non-diabetic haemodialysis patients <i>STRUPAITE R , Skvarciany I , Noreikyte M , Mockeviciute E , Galgauskas S , Rimsevicius L , Cimbaldas A , Asoklis R - Vilnius</i>
S064		Retinal Layers Changes in Diabetic Patients without Diabetic Retinopathy <i>FERREIRA J , Vicente A , Proença R , Costa L , Dias-Santos A , Santos B , Cunha J P , Abegão-Pinto L - Lisbon</i>
S065		Heterogeneous choroidal thickness pattern in diabetic patients without diabetic retinopathy <i>VICENTE A , Costa L , Cardigos J , Santos A , Amado D , Cunha J P , Abegao Pinto L , Ferreira J - Lisbon</i>
S066		Focal choroidal changes on diabetic macular edema <i>DUARTE L , Ruão M , Gallego R - Santa Maria da Feira</i>
S067		Correlation of visual acuity and central macular thickness in diabetic macular edema <i>EL MATRI HASSAIRI A , Chebil A , Ben Abdallah M , Maamouri R , Chaker N , El Matri L - Tunis</i>



10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S068	Fundus photography as a screening method of diabetic retinopathy in children and adolescents with type 1 diabetes Outcome of the first fundus photography at the age of 9 to 17 years <i>GRASBECK T, Gräsbeck S, Miettinen P J, Summanen P A - Helsinki</i>
S069	The effect of panretinal photocoagulation and additive Intravitreal bevacizumab injections on central retinal vessel diameters in diabetic retinopathy <i>PARK J M, Lee S J - Busan</i>
S070	Intravitreal anti-VEGF treatment for refractory diabetic macular edema <i>PAPAVASILEIOU E, Quijano C, Younis S - London</i>
S071	Switching to ranibizumab for diabetic macular edema with persistent fluid on bevacizumab : Who is likely to benefit from the switch? <i>LEE J H, Lee W K - Seoul</i>
S072	Effect of intravitreal dexamethasone implant (Ozurdex®) in the glycemic control of patients with diabetic macular edema <i>AGARD E, El Chehab H, Malclès A, Russo A, Leberre J P, Mounier C, Dot C - Lyon</i>
S073	Efficacy and safety of ranibizumab in diabetic macular edema : real life study <i>HRARAT L, Fajnkuchen F, Sarda V, Grenet T, Buffet S, Chaine G, Giocanti-auregan A - Stains</i>
S074	Outcomes of using intravitreal ranibizumab to treat patients with ischaemic diabetic maculopathy. <i>BEGUM S, Lockwood A, Mourtzouko S - Portsmouth</i>
S075	Role of SD-OCT in the follow-up of a patient with macular edema associated with mucopolysaccharidosis type II (Hunter syndrome) undergoing idursulfase enzyme replacement therapy <i>SANCHEZ J I, ASCASO F J, Pérez I, Almenara C, Esteban O, Martínez M, Idoate A, Torralba M A - Zaragoza</i>
S076	Use of directional optical coherence tomography and selected landmarks to determine foveal topography and microstructure. A strategy to characterize differences between normal and exprematue cases. <i>SJOSTRAND J, Rosén R, Nilsson M, Popovic Z - Mölndal</i>
S077	Optical Coherence Tomography and Fundus Autofluorescence evaluation in an animal model of Retinal Degeneration <i>SEGURA F, Fernandez-Sanchez L, Sánchez-Cano A, Tamarit J M, Fuentes-Broto L, Del Buey M A, Cuenca N, Pinilla I - Zaragoza</i>
S078	Three optic disc pit maculopathy case studies by optical coherence tomography images supporting the role of cerebrospinal fluid in this pathology <i>MARTINEZ M, Ascaso J, Arias L, Filloy A, Almenara C, Esteban O, Del Buey M A, Cristóbal J A - Zaragoza</i>
S079	Indocyanine green angiography findings in Stargardt disease <i>EL MATRI L, Chebil A, Charfi H, Lagueche L, Hassairi A - Tunis</i>
S080	Repeatability of wide-field autofluorescence lifetime imaging at the human retina in healthy volunteers <i>KLEMM M, Dietzel A, Nagel E, Schweitzer D - Ilmenau</i>
S081	Characteristics of Artifacts Associated with Ultra-Wide Field Fundus Image <i>OH J R, Lee B, Ahn J, Kim Y H, Kim S W - Seoul</i>
S082	Agreement between ophthalmoscopy and ultrawide field image analysis in an outpatient clinic setting <i>BORDET J, Caliot J, Vardi K, Barbe C, Ducasse A, Angioi K, Arndt C - Reims</i>



10:00 - 10:45 | POSTER AREA

RV: Retina / Vitreous

S083	Wide field imaging in patients treated with vigabatrin <i>VARDI K , Brugniart C , Motte J , Ducasse A , Arndt C - Reims</i>
S084	An algorithm combining two lesion-detection methods of retinal microaneurysms for the reduction of human workload <i>OMETTO G , Bek T , Al-Diri B , Hunter A - Aarhus</i>
S085	Comparisons of retinal sensitivity obtained by microperimetry with two different fixation targets in normal individuals <i>NIZAWAT , Kitahashi M , Yamamoto S - Chiba</i>
S086	Postoperative Endophthalmitis: Incidence, Causes and Comparison Between Medical and Surgical Treatment in a United Kingdom Region in the Last 10 Years <i>SHALABY A , Di Simplicio Cherubini S , Lockwood A , Newsom R - Southampton</i>
S087	Endogenous panophthalmitis caused by sphingomonas paucimobilis ; A postpartum devastating rare condition <i>OZCAN A A , Esen E - Adana</i>
S088	Intraocular Pharmacokinetics of Povidone-iodine and the Effect of Repeat Injection with low concentration on the Experimental S. epidermidis Endophthalmitis <i>BYON I , Kim K , Yu J , Yoon I , Lee J - Yangsan</i>
S089	Tolerance of Dexamethasone intravitreal implant in GAO patients according to their initial treatment and repeated intravitreal injections. <i>VIE A L , Kodjikian L , Malcles A , Agard E , El Chehab H , Russo A , Dot C - Lyon</i>
S090	Intra-ocular pressure spike after Aflibercept and Ranibizumab intravitreal injections <i>EL CHEHAB H , Agard E , Russo A , Malcles A , Dot C - Lyon</i>
S091 ★	Background ophthalmological changes following subretinal injection in the brown norway rat <i>VEZINA M , Li C , Bussieres M - Senneville</i>
S092	Clinical guidelines for acute exposure to laser pointer radiation <i>LOFGREN S , Hengstler J , Jans E - Stockholm</i>
S093	Cystoid macular edema associated with retinitis pigmentosa resolved by a dexamethasone intravitreal implant <i>ALMENARA C , Ascaso F J , Martínez M , Pérez I , Esteban O , Bartolomé I , Cristóbal J A - Zaragoza</i>
S094	Impact of Storage Temperature on Gene Expression of Cultured ARPE-19 Cells <i>PASOVIC L , Eidet J R , Olstad O K , Chen D F , Lyberg T , Utheim T P - Oslo</i>
S095	Transcription factors involved in cell death and regeneration in AGEs exposed retinal neurons <i>OSHITARIT , Bikbova G , Yamamoto S - Chiba</i>
S096	Expression of histamine receptors in the gerbil retinal neurons <i>MIYACHI E , Imada H , Ohkuma M , Sakai K - Toyoake-shi</i>
S097 rf	Research on ophthalmic examination apparatus to diagnose multiple diseases which result in loss of eyesight <i>SUZUKI N , Yamane K - Numazu</i>
S098	Subthreshold Micropulse Yellow Laser (577nm) Photocoagulation for Subfoveal Serous Pigment Epithelium Detachment <i>PARK H - Daegu</i>



10:45 - 11:25 | HERMES

Keynote Lecture by Bitá ESMAELI

Introduction by Steffen HEEGAARD

Multidisciplinary treatments for malignant eyelid tumors: surgical and non-surgical options, sentinel lymph node biopsy, and surveillance

ESMAELI B - Houston, Texas

Summary

Malignant tumors of the eyelid are varied in their presentation and stage. Surgical treatments and reconstructive outcomes for each stage and histology will be reviewed. Adjuvant local treatments such as radiation therapy as well as non-surgical medical treatments will also be discussed. Indications and clinical cases where sentinel lymph node biopsy may be beneficial and other recent advances in the field will be reviewed.



Award of the EVER Certificate of Honour

Biography Bitá Esmaeli:

Dr Bitá Esmaeli is a Professor of Ophthalmology in the Department of Plastic Surgery at The University of Texas M. D. Anderson Cancer Center, where she has an orbital oncology and oncologic ophthalmic plastic surgery practice since 1998.

Dr Esmaeli's practice focus is surgical treatment of orbital tumors, lacrimal gland carcinomas, eyelid cancers, melanoma of eyelid and conjunctiva, and reconstructive surgery in the periocular region including lacrimal surgery.

Dr Esmaeli has authored over 160 peer-reviewed manuscripts, over 55 invited articles and book chapters, has spearheaded several clinical trials, and has participated in numerous research protocols at M. D. Anderson Cancer Center. She has received many prestigious awards and honors including the Merrill Reeh Pathology Award and the Research Award from the American Society of Ophthalmic Plastic and Reconstructive Surgery, the American Academy of Ophthalmology Senior Achievement Award, Best Doctors in America, and Top Doctors Award. Dr Esmaeli is a member of the American Ophthalmologic Society.

Dr Esmaeli's research interests include molecular signature of ocular and orbital tumors, tissue banking, eye and vision-sparing treatment strategies for orbital and adnexal cancers, and ocular side effects of cancer therapy.

Dr. Esmaeli helped establish the Ophthalmology Service as a comprehensive full-time service at M. D. Anderson Cancer Center in 1998. She served as the Director of Service from 1998 to 2001 and the Chief of Ophthalmology from 2001 to 2004. She is the Program Director for an ASOPRS-sponsored fellowship in oculoplastic surgery and orbital oncology at M. D. Anderson Cancer Center.



11:30 - 13:00 | HERMES



IM: ARVO session: Sweetening the inflammatory response to combat the rise in retinal disease

DICK A

4211	11:30	Introduction and overview <i>DICK A - Bristol</i>
4212	11:40	Parainflammation, ageing and loss of control <i>XU H - Belfast</i>
4213	12:00	Obesity, degeneration and senescence <i>SENNLAUB F - Paris</i>
4214	12:20	Feeding microglia to regulate vascular responses <i>LANGMANN T - Cologne</i>



11:30 - 13:00 | RHODES 1

G: Free paper session - Surgery and blood flow

GRIESHABER M , ABEGAO PINTO L

4221	*	11:30	Canaloplasty with the Stegmann Canal expander – two years results <i>GRIESHABER M , Schoetzu A , Stegmann R - Basel</i>
4222		11:42	Risk of trabeculectomy with an initial diagnosis of glaucoma versus ocular hypertension in Gloucestershire, UK. <i>MCNAUGHT A , Turner S , Ivanova K , Crabb D - Cheltenham</i>
4223	*	11:54	A minimally invasive approach to sub-conjunctival outflow: 1 year results of an ab-interno gelatin stent in combination with preoperative MMC injection for the treatment of primary open angle glaucoma. <i>STALMANS I , Fea A , Reitsamer H , Lavin C - Leuven</i>
4224		12:06	Glaucoma patients have a significant decrease in retrobulbar blood flow velocities during general anesthesia <i>ABEGAO PINTO L , Vandewalle E , Willekens K , Van keer K , Van Calster J , Stalmans P , Vertommen J , Deckers K , Marques-Neves C , Stalmans I - Lisbon</i>
4225	rf	12:18	Receptor-targeted liposome-peptide-siRNA nanoparticles represent a novel and efficient siRNA delivery system to prevent conjunctival fibrosis. <i>YU-WAI-MAN C , Tagalakis A , Manunta M , Hart S L , Khaw PT - London</i>
4226	rf	12:24	Leuven Eye Study - Baseline and Methods <i>ABEGAO PINTO L , Willekens K , Van Keer K , Shibesh A , Vandewalle E , Molenberghs G , Stalmans I - Lisbon</i>
4227	rf	12:30	Biomechanical properties of eyes with asymmetrical glaucoma defect <i>CELLINI M , GIZZI C , FINZI A , CAMPOS E C - Bologna</i>
4228	* rf	12:36	Multicenter Clinical Trial of High-Intensity Focused Ultrasound Treatment in Glaucoma Patients without Previous Filtering Surgery <i>APTEL F , Denis P , Rouland J F , Renard J P , Bron A - Laxou</i>



11:30 - 13:00 | RHODES 2

COS: Unmet needs and innovation in ophthalmology

This session will focus on unmet Needs and new developments in ophthalmology.

FUCHSLUGER T , STEFANSSON E

4231	11:30	Corneal neovascularization: a translational perspective <i>FERRARI G - Milan</i>
4232	11:48	New perspectives in dry eye treatment <i>BARABINO S - Sanremo</i>
4233	12:06	New developments in DMEK and endothelial cell therapy <i>FUCHSLUGER T - Erlangen</i>
4234	12:24	Non-antagonistic influences of intrastromal corneal ring on primary human microvascular endothelial cells from adult donors in a tissue culture system <i>STORSBERG J , Träg S , Messner A , Rehfeldt S , Klöpzig S , Jentzen V , Bohrisch J , Schmidt C - Potsdam</i>
4235	12:42	Information technology in ophthalmology. www.retinarisk.com <i>STEFANSSON E - Reykjavik</i>



11:30 - 13:00 | RHODES 3

PO: OOG Ocular Oncology Group 2



ANGI M , JAGER MJ

4241	11:30	Integrated multi-omic analysis of human retinoblastoma identifies novel regulatory networks <i>SURESHBABU V , Mallipatna A , Guha N , SA D , Lateef S , Gundimeda S , Padmanabhan A , Shetty R , Ghosh A - Bangalore</i>
4242	11:42	Anatomic features of choroidal naevi: Swept-source optical coherence tomography vs Enhanced depth imaging tomography. Preliminary results in 31 patients <i>PAPASTEFANO V P , Vázquez-Alfageme C , Xirou T , Degli-Esposti S , Patel P , Sagoo M S - London</i>
4243	11:54	Human choroidal nevi histopathology revisited <i>MADIGAN M C , Vader M , Ton H , Van der Velden P , Jager M - Sydney</i>
4244	<i>rf</i> 12:06	The Liverpool Uveal Melanoma Prognosticator Online (LUMPO) for prognosing metastasis free survival in the absence of cytogenetic data after ruthenium brachytherapy for uveal melanoma <i>ROSPOND-KUBIAK I , Wroblewska-Zierhoffer M , Twardosz-Pawlik H , Kociecki - Poznan</i>
4245	<i>rf</i> 12:12	Immunohistochemical characterization of a retinal hamartoma <i>VAN GINDERDEUREN R , Stalmans P - Leuven</i>



11:30 - 13:00 | RHODES 4

FRO - Belgian Fund for Research in Ophthalmology 1



CASPERS L , TASSIGNON MJ

4251	11:30	RNA sequencing in keratoconus: unraveling the molecular pathways <i>VALGAEREN H - Edegem</i>
4252	11:42	Development of micro needle for retinal vein cannulation <i>WILLEKENS K - Leuven</i>
4253	11:54	Serine proteases as potential therapeutic targets for ocular inflammation and dry eye syndrome <i>JOOSSEN C - Wilrijk</i>
4254	12:06	Automatic detection of early keratoconus using topography and biomechanical measurements in the corneal horizontal and vertical axis <i>RUIZ HIDALGO I - Edegem</i>
4255	12:18	Tissue engineering in ophthalmology: regenerating the anterior cornea using self-aligning recombinant human collagen nanoscaffolds and corneal epithelial stem cells <i>HAAGDORENS M - Edegem</i>
4256	12:30	In vitro functional characterisation of tissue engineered corneal endothelial grafts <i>VAN DEN BOGERD B - Edegem</i>
4257	12:42	An in vitro and ex vivo study into the role of Müller cells in nanoparticle-based retinal gene therapy after intravitreal injection <i>PEYNSHAERT K - Gent</i>
4258	12:54	Detailed characterization of structural, functional and behavioral changes in a laser-induced mouse model for glaucoma <i>GEERAERTS E - Leuven</i>



11:30 - 13:00 | GALLIENI 1+2

NSPH: New approaches to the prevention of myopia

High myopia is a major cause of uncorrectable visual impairment. It imposes major challenges and costs for refractive correction and for the treatment of associated pathological complications. In the last 60 years, there has been a marked increase in the prevalence of high myopia in younger generations in developed countries in East and Southeast Asia, and there are signs of similar, but less pronounced increases in North America and Europe. In some parts of the world, 70-90% of children completing high schools are now myopic, and as many as 20% may be highly myopic. It is now clear that myopia results from excessive axial elongation of the eye and this greater rate of axial elongation appears to be environmentally driven. Experimental studies have examined the biochemical mechanisms involved in regulation of axial elongation. From these studies, some options have emerged for preventing the development of myopia or slowing myopic progression.

GRZYBOWSKIA , MORGAN I

4261	11:30	Pathology of high myopia <i>OHNO-MATSUI K - Tokyo</i>
4262	11:45	Epidemiology and the protective effects of time outdoors <i>MORGAN I , Rose K - Ainslie</i>
4263	12:00	Optical reduction of peripheral hyperopic defocus <i>TORII H , Negishi K , Tsubota K - Tokyo</i>
4264	12:15	Atropine treatment <i>GRZYBOWSKI A - Poznan</i>
4265	12:30	5. 7-methylxanthine treatment <i>TRIER K - Hellerup</i>
4266	12:45	Defocus Incorporated Soft Contact (DISC) lens <i>LAM C S , Tang W C , To C H - Hong Kong</i>



11:30 - 13:00 | GALLIENI 5

RV: Free paper session - Imaging and RPE

SCHMETTERER L , LUMBROSO B

4271		11:30	The Silk-protein Sericin Induces Rapid Melanization of Cultured Retinal Pigment Epithelial Cells by Activating the NF- B Pathway <i>PASOVIC L , Utheim T P , Reppe S , Lyberg T , Olstad O K , Eidet J R - Oslo</i>
4272		11:42	Cell penetrating peptide constructs: A novel drug delivery to the eye <i>SCOTT R , Hill L , De Cogan F , O'Neill J , Logan A - Birmingham</i>
4273		11:54	The improvement of Spoke-Wheel pattern foveoschisis in a patient with X-linked retinoschisis treated with topical dorzolamide observed by high-resolution adaptive optics camera <i>GOCHO K , Akeo K , Kameya S , Yamaki K , Mizota A , Takahashi H - Inzai</i>
4274		12:06	Concordance between ophtalmologists and paramedical professionals in screening for retinal abnormalities with ultrawide field imaging <i>DURBANT E , Vardi K , Bordet J , Barbe C , Garcia T , Angioi-Duprez K , Arndt C - Reims</i>
4275	<i>rf</i>	12:18	Research on ophthalmic examination apparatus to diagnose multiple diseases which result in loss of eyesight <i>SUZUKI N , Yamane K - Numazu</i>



13:00 - 14:00 | RHODES 1

Update in the management of DME, RVO and Uveitis

CREUZOT C , BODAGHI B

13:00	Management of RVO – Update on new clinical data and recommendations of treatment <i>MATONTI F - Marseille</i>
13:15	Management of Uveitis - Update on new clinical data and recommendations of treatment <i>BODAGHI B - Paris</i>
13:30	Management of DME – Update on new clinical data and recommendations of treatment <i>CREUZOT C - Dijon</i>
13:45	Discussion: C. Creuzot, B. Bodaghi and F. Matonti



14:00 - 15:30 | HERMES

RV: Silicone oil (SiO) complications

The use of silicone oil (SiO) as an internal tamponade agent in cases of complex retinal detachment with proliferative vitreoretinopathy (PVR) has become common, but it also may lead to postoperative complications if it is not surgically removed later. This symposium will document the safety and effectiveness of intravitreal injections in the silicone oil-filled eye, the possible complications from the migration of emulsified silicone and, finally, it will provide a review and discussion of the surgical management of these conditions.

GRZYBOWSKI A , ASCASO F

4411	14:00	Safety and effectiveness of intravitreal injections in the silicone oil-filled eye <i>ASCASO F - Zaragoza</i>
4412	14:15	Silicone oil use in trauma <i>WEINBERGER D - Tel Aviv</i>
4413	14:30	Silicone oil-induced anterior segment complications <i>AVITABILET - Catania</i>
4414	14:45	Controversies on heavy SiO endotamponade <i>LE MERY - Paris</i>
4415	15:00	Complications after SiO removal <i>KILGAARD J F - Copenhagen</i>
4416	15:15	Neuronal complications of intravitreal SiO <i>GRZYBOWSKI A - Poznan</i>



14:00 - 15:30 | RHODES 1

G: Untrabitional (sic) glaucoma surgery

For almost 50 years, trabeculectomy has been considered the 'gold standard' procedure in the surgical management of the Glaucoma patient. The operation undoubtedly works well in many surgeons' hands, and over the last 20 years small changes in surgical technique have improved the safety profile of guarded sclerostomy. 'Tube' surgery has also long been widely advocated and debate rages about which of these two mainstream treatments should be the de facto surgery for glaucoma. In a continued attempt to improve the surgical risk/benefit ratio, there have more recently been advocated other surgical glaucoma procedures, which may in time take on the mantle of 'standard of care'. Our SIS presents a selection of these new treatments as a basis for a robust discussion of why and how we offer surgery to control our patients' disease with the ultimate aim of preserving their vision as effectively and safely as possible.

BLOOM P

4421 ★	14:00	Turn off the tap: Inflow surgery comes of age with ECP <i>BLOOM P , Clements C , Sharkawi E , Grieshaber M - London</i>
4422	14:22	Back to the future: The return of angle surgery <i>SHARKAWI E - Lausanne</i>
4423	14:44	Down under the sclera: Deep sclerectomy <i>CLEMENT C - Gordon</i>
4424	15:06	Coming full circle: Canal surgery with / without implants <i>GRIESHABER M - Basel</i>



14:00 - 15:30 | RHODES 2

COS: Toric intraocular lenses – Calculation and clinical aspects

This session covers diagnostics, calculation, patient selection, pre- and postoperative care in lens replacement by toric iol.

LANGENBUCHER A , SZENTMARY N

4431	14:00	Indications, patient selection, pre- and postoperative patient care <i>SZENTMARY N - Homburg/Saar</i>
4432	14:18	Instrument assisted diagnostics – biometry, topography and wave-front analysis <i>EPPIGT , Spira C , Seitz B , Szentmáry N , Langenbacher A - Homburg/Saar</i>
4433	14:36	How to calculate toric intraocular lenses in clinical practice? <i>LANGENBUCHER A , Szentmáry N , Seitz B , Spira C , Eppig T - Homburg</i>
4434	14:54	Intraoperative optical coherence tomography (iOCT) in toric IOL implantation. <i>WYLEGALA E - Katowice</i>
4435	15:12	Surgical aspects of toric lens implantation, from perioperative marking to axis re-adjustment <i>BARRAQUER R I - Barcelona</i>



14:00 - 15:30 | RHODES 3

PO: OOG Ocular Oncology Group 3

ZOGRAFOS L , ROMANOWSKA DIXON B

4441	14:00	Correlation between radiation dose and damage to optic disc and macula in eyes treated with ruthenium brachytherapy <i>ESPENSEN C A , Fog L S , Klemp K , Aznar M C , Specht L , Kiilgaard J F - Copenhagen</i>
4442	14:12	Dexamethasone 0.7-mg intravitreal implant in patients with radiation macular edema after proton beam therapy for choroidal melanoma : 2-year results. <i>BAILLIF S , Maschi C , Caujolle J P - Nice</i>
4443	14:24	Radiation complications, Toxic Tumor Syndrome prevention <i>ROMANOWSKA DIXON B , Kubicka-Trzaska A , Morawski K , Bogdali A , Markiewicz A - Krakow</i>
4444	14:36	Proton beam irradiation of choroidal hemangiomas after unsuccessful photodynamic therapy <i>ZOGRAFOS L , Schalenbourg A - Lausanne</i>
4445	14:48	Stereotactic radiation therapy of diffuse choroidal hemangioma in Sturge-Weber syndrome <i>SCHALENBOURG A , Zografos L , Pica A - Lausanne</i>
4446	15:00	Choroidal osteoma in deep range imaging OCT (DRI-OCT) <i>MARKIEWICZ A , Romanowska-Dixon B , Bogdali A , Jakubowska B - Kraków</i>



14:00 - 15:30 | RHODES 4

FRO - Belgian Fund for Research in Ophthalmology 2**CASPERS L , TASSIGNON MJ**

4451	14:00	An innovative mouse model for retinal alpha-synucleinopathy: taking a new look on Parkinson's disease <i>DE GROEF L - Leuven</i>
4452	14:12	Unraveling the molecular and cellular mechanisms underlying deleterious ROCK signaling in neuronal survival and axonal growth <i>LEFEVERE E - Leuven</i>
4453	14:24	Identification of the gene signature of retinal endothelial cells during classical experimental autoimmune uveitis, Th1- and Th17-dependent uveitis <i>LIPSKI D - Brussels</i>
4454	14:36	Development of a portable retinal oximeter using a hyperspectral image sensor <i>VAN KEER K - Leuven</i>
4455	14:48	3D printed human recombinant collagen scaffolds for corneal tissue engineering: determination of cell-scaffold interactions <i>MATTHYSSEN S - Antwerpen</i>
4456	15:00	Functional characterization of RCBTB1 as novel disease gene for syndromic retinal dystrophies <i>ASCARI G - Ghent</i>
4457	15:12	Integrated transcriptomics and genomics to identify hidden genetic variation of FRMD7 or novel candidate genes in idiopathic infantile nystagmus <i>ALMOALLEM B - Ghent</i>
4458	15:24	Role of the transcription factor TonEBP/NFAT5 in the inflammatory response induced by hyperosmolar stress in RPE cells <i>LIBERT S - Anderlecht - Brussels</i>



14:00 - 15:30 | GALLIENI 1+2

NSPH: Orbit meets neuro-ophthalmology

Actualised management for different neuro-orbit disorders like optic nerve, intra orbital tumours and Graves' orbitopathy will be discussed by a panel of experienced speakers with different backgrounds.

BOSCHIA , BALDESCHI L

4461	14:00	Acute exophthalmos in children <i>DE POTTER P - Bruxelles</i>
4462	14:22	Update in management of optic nerve glioma (part 2) <i>PARSA C - Paris</i>
4463	14:44	A novel method for measuring outcome of orbital decompression in Graves' orbitopathy <i>BALDESCHI L - Bruxelles</i>
4464	15:06	Orbital implantation of biocompatible magnets for the treatment of intractable nystagmus <i>VERITY D H , Kennard C , Pankhurst Q , Geoffrey E R - Tadworth - Surrey</i>



14:00 - 15:30 | GALLIENI 5

G: Free paper session - Clinical aspects of glaucoma

KOLKO M , GARDINER S

4471	14:00	The prevalence and incidence of glaucoma in Denmark in a fifteen year period: A nationwide study <i>KOLKO M , Horwitz A , Thygesen J , Jeppesen J , Torp-Pedersen C - Roskilde</i>
4472	14:12	Optic nerve head hemorrhage and vitreous traction. <i>WILLEKENS K , Pinto L A , Vandewalle E , Stalmans P , Stalmans I - Leuven</i>
4473	14:24	Localized changes in retinal nerve fiber layer reflectance intensity are related to localized functional loss in glaucoma <i>GARDINER S , Demirel S , Reynaud J , Fortune B - Portland</i>
4474	14:36	Visual field screening by opticians with Damato Multifixation Campimetry Online (DMCO) <i>OLSEN A S , Damato B , La Cour M , Kolko M - Copenhagen</i>
4475	* rf 14:48	Comparison of preservative-free latanoprost and bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial. <i>STALMANS I , Cordeiro F , Hommer A , Oddone F , Ribeiro L , Sunaric Mégevand G , Rossetti L - Leuven</i>
4476	rf 14:54	Double-hump sign on gonioscopy: definitive plateau iris? A cross-sectional study using ultrasound biomicroscopy <i>CORDEIRO SOUSA D , Leal I , Caiado F , Goncalves I , Reina M , Marques-Neves C , Prior Filipe H , Abegao Pinto L - Lisbon</i>
4477	rf 15:00	How accurate are optometrist referrals for glaucoma in the NICE era? <i>BOBAT H , Begum S , Lockwood A , Kirwan J F - Portsmouth</i>
4478	rf 15:06	A pilot study of survey on patient satisfaction and its meaning in an Glaucoma outpatient <i>POURJAVAN S , Vanhaecht K - Brussels</i>



15:30 - 16:00 | HERMES

Prize award ceremony and conclusion of the congress

Chair : Aki Kawasaki, President EVER 2016

Introduction by Marcela Votruba, Programme Secretary

Travel awards presentation by the section chairs

Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2015 Bart Leroy



EVER Award Ceremony 2014



EVER Award Ceremony 2014



EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH

OCTOBER 5-8

www.ever.be

**EVER
2016**

NICE
in France





www.ever-f.eu

Awardees of the
EVERf Research Fellowships 2015

- Dr. Sepehr FEIZI, Iran
host institute: Queens Medical Centre, Nottingham, UK
- Dr. Sabina SAPETA, Poland
host institute: Medical University of Vienna, Austria

*European Association for Vision and
Eye Research Foundation*

European University Professors of Ophthalmology


EUPO 2016

Neuro-ophthalmology and Strabismus



October 7-8, 2016
Nice, France

In conjunction with EVER 2016
www.eupo.eu



Members of EVER
receive FREE online
access to *Acta
Ophthalmologica*
as part of their
membership.



Acta Ophthalmologica

Edited by: Einar Stefánsson

Why should you read the journal?

- Top class research - our impact factor now stands at 2.844*, with a ranking of 13/57 in the ISI Ophthalmology category
- Coverage that's relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye
- Official publication of EVER, Dutch and all five Nordic Ophthalmological Societies

Visit www.actaophthalmologica.com
for more information

*2014 JCR, Thomson Reuters

WILEY

183803

SOE2017



EUROPEAN SOCIETY OF OPHTHALMOLOGY
10-13 JUNE 2017 | BARCELONA, SPAIN

**SEE YOU IN
BARCELONA**
www.soe2017.org



Diploma Examination 2016


EBOD 2016

Applications open October 2015

Website: ebo-online.org




New Books in Ophthalmology



ESASO Course Series, Vol. 6

Cornea


Editor: Güell, J.L. (Barcelona)
VIII + 136 p., 85 fig., 81 in color,
7 tab., soft cover, 2015
CHF 98.00 / EUR 92.00 / USD 115.00
ISBN 978-3-318-05452-1
e-ISBN 978-3-318-05453-8



ESASO Course Series, Vol. 5

Orbital Surgery

Editors: Medel, R. (Barcelona); Vásquez, L.M. (Barcelona)
VIII + 92 p., 75 fig., 70 in color,
3 tab., soft cover, 2014
CHF 98.00 / EUR 92.00 / USD 115.00
ISBN 978-3-318-02605-4



ESASO Course Series, Vol. 4

Optical Coherence Tomography

Editors: Coscas, G. (Créteil/Paris); Loewenstein, A. (Tel Aviv); Bandello F. (Milan)
XII + 134 p., 137 fig., 97 in color,
9 tab., soft cover, 2014
CHF 98.00 / EUR 92.00 / USD 115.00
ISBN 978-3-318-02563-7




Developments in Ophthalmology,
Vol. 55

Retinal Pharmacotherapeutics

Will be published November 2015

Editors: Nguyen, Q.D.; Do, D. (Omaha, Nebr.); Farah, M.E. (São Paulo); Mieler, W.F. (Chicago, Ill.); Rodrigues, E.B. (São Paulo)
CHF 269.00 / EUR 251.00 / USD 316.00
ISBN 978-3-318-05564-1
e-ISBN 978-3-318-05565-8



Developments in Ophthalmology,
Vol. 54

Microincision Vitrectomy Surgery Emerging Techniques and Technology

Editors: Oh, H. (Amagasaki); Oshima, Y. (Tokyo)
XII + 268 p., 143 fig., 125 in color,
10 tab., hard cover, 2014
CHF 224.00 / EUR 209.00 / USD 264.00
ISBN 978-3-318-02660-3



Developments in Ophthalmology,
Vol. 53

Cell-Based Therapy for Retinal Degenerative Disease

Editors: Casaroli-Marano, R.P. (Barcelona); Zarbin M.A. (Newark, N.J.)
XII + 206 p., 55 fig., 41 in color, 6 tab.,
hard cover, 2014
CHF 198.00 / EUR 154.00 / USD 233.00
ISBN 978-3-318-02584-2

Journals

Ocular Oncology and Pathology

www.karger.com/ooop

Ophthalmologica

www.karger.com/oph

Ophthalmic Research

www.karger.com/ore

Open access, online only, peer reviewed

Case Reports in Ophthalmology

www.karger.com/cop



For further information and easy ordering please go to
www.karger.com/ophthalmology

KARGER 125 YEARS

S. Karger AG
P.O. Box
CH-4009 Basel
(Switzerland)

Tel. +41 61 306 11 11
Fax +41 61 306 12 34
karger@karger.com



Advancing mitochondrial medicine
in neuro-ophthalmology

Join us at our symposium at the EVER 2015 Congress:

**A rare breakthrough in
mitochondrial medicine:
changing the patient
journey in LHON**



Friday 9 October, 12:30–13:30
Acropolis Convention Center

For more information, please visit us at our booth at EVER or go to www.santhera.com




ARVO Asia

**Bridging disciplines and
disparities:** Connecting eye
research with health outcomes

**February 5 – 8, 2017
Brisbane Convention and
Exhibition Centre
Brisbane, Australia**

arvo.org/arvo-asia



ABEGAO PINTO, L.: 3125, 4224, 4226, F002
 ABERDAM, D.: 2654
 ABU EL ASRAR, A.: 2218, 2451, S050
 ABU KHAMIDAKH, A.: 4172
 ACLIMANDOS, W.: 4121
 AGARD, E.: S072
 AHMED, F.: 1122
 AINSBURY, L.: 3261
 AL-SHABRAWAY, M.: 2452
 ALDAHAM, S.: F055, F057
 ALMENARA MICHELENA, C.: S041, S093
 ALMOALLEM, B.: 4457
 AMADIO, M.: T005, T008
 AMARIE, O.: 3561
 ANDJELIC, S.: 4177, T014
 ANDROUDI, S.: 1132
 ANGI, M.: 4145
 ANTOSOVA, B.: 3563
 APTEL, F.: 4228, F004
 ARJAMAA, O.: T004
 ASCARI, G.: 4456
 ASCASO, F.: 3271, 4411
 ASCHINGER, G.: F038
 ASNAGLI, H.: 2571
 ASOKLIS, R.: F105
 AUDO, I.: 1253
 AUFFARTH, G.: 1365
 AVITABILE, T.: 4413
 AYDIN YAZ, Y.: T035
 BACQUET, J.: F069
 BADIAN, R.A.: T032, T053
 BAILLIF, S.: 4442
 BALDESCHI, L.: 4463
 BARABINO, S.: 4232
 BARBONI, P.: 2263
 BARRAQUER, R.I.: 4435
 BARRY, P.: 3254
 BATSON, J.: 2241
 BAUDOT, A.: T023
 BAUDOUIN, C.: 2331
 BAUER, D.: 4132
 BEGUM, S.: S074
 BEHAEGEL, J.: T043
 BEHAR-COHEN, F.: 2511
 BEHL, C.: 3421
 BEIKO, G.: 1363
 BERROD, J.: 2414, 3114
 BESOMBES, G.: F014
 BEUERMAN, R.: 2271, 3233, 4131, 4134
 BEYER, E.: 3461
 BHARTI, K.: 2672
 BIFRARE, D.: 2532
 BIRKELDH, U.: F068, F088
 BITOUN, P.: 2546

BLACK, G.C.: 1252, 3464
 BLACKLEY, Z.: F040
 BLOM, N.: 1346, T081
 BLOOM, P.: 4421
 BOBAT, H.: 4477, F007
 BODAGHI, B.: 1235, 2157, 4155
 BOGDALI, A.: F084
 BONNEAU, D.: 2264
 BONNEL, S.: F010
 BORDERIE, V.: 2551, 3131
 BORDESSOULE, D.: 3545
 BORDET, J.: S082
 BORRUAT, FX.: 2164, 2561, 2563, 2565
 BOSCHI, A.: 2163
 BOYCHUK, I.: F094, F095
 BREHON, A.: 2556, T089
 BREMOND-GIGNAC, D.: 2655, 3457, F100
 BRISCOE, D.: 3144
 BRON, A.J.: 2234
 BUI QUOC, E.: 2443
 BUSHUYEVA, N.: F049, T076
 BUSIN, M.: 3132
 BYON, I.: S088
 BYUN, Y.: 2236, T028
 CAHUZAC, A.: 2113
 CALDER, V.: 3173, 3533
 CALONGE, M.: 2272
 CALVAS, P.: 2653
 CARAMELLO, C.M.: F074, T072
 CARDIGOS, J.: 2215, S062
 CARELLI, V.: 2463
 CARRASQUILLO, K.G.: 2472
 CASANOVA, C.: F066
 CASSOUX, N.: 1221, 1224, 3542
 CASTELO-BRANCO, M.: 4165
 CELLINI, M.: 4227, F003
 CHALONS, P.: F039
 CHARLIER, J.: 3472
 CHAUHAN, B.: 1321
 CHEBIL, A.: S060, T016
 CHIAMBARETTA, F.: 2656
 CHO, M.: F098
 CHO, S.Y.: F099, F101
 CIMBOLINI, N.: T031
 CLARKE, J.: F018
 CLEMENT, C.: 4423
 CORDEIRO SOUSA, D.: 2541, 4476, F006, F037
 CORDEIRO, M.F.: 2621, 3224
 COSCAS, F.: 2611
 COSCAS, G.: 2612, 3215
 COSTA, L.: 3256, 3451, F071
 COUPLAND, S.: 3541
 COURRIER, E.: T041
 CRABB, D.: 2224

CRAWLEY, L.: 1121
 CREUZOT, C.: 2515, 3112, 3115, 4125
 CROUZET, E.: T068, T069
 CUNHA, J.: 3458, F112
 D'ANTIN, J.C.: F067
 DAIEN, V.: 3255
 DAL MONTE, M.: F042
 DALKE, C.: 3264
 DANA, R.: 3534
 DAULL, P.: T034
 DAVIDSON, A.: 1331
 DAVIS, B.: 3223
 DE BATS, F.: 2112
 DE BLESER, E.: T020
 DE BRUYN, D.: F106
 DE GROEF, L.: 3575, 4451
 DE LAEY, J.J.: 3273
 DE LAZZER, A.: 2522
 DE POTTER, P.: 4461
 DEL BUEY, M.A.: T044, T066
 DELBARRE, M.: T079
 DENIRO, M.: S034, S052
 DESCHASSE, C.: 2413
 DESJARDINS, L.: 1223, 2641, 4141
 DIAMOND, J.: 1124
 DIAZ VALLE, D.: 2333, T048
 DICK, A.: 1131, 1136, 4211
 DOAN, S.: 2237, T040, T085
 DOBROWOLSKI, D.: 1242
 DRASCHL, P.: F073
 DUA, H.S.: 1143, 1145, 1352, 3134
 DUARTE, L.: S066
 DURBANT, E.: 4274
 EDWARD, D.: 3446
 EIDET, J.R.: 2231, T051
 EL CHEHAB, H.: S090
 EL MATRI, L.: S046, S079
 ELDRED, J.: 3152
 EPPIG, T.: 4432
 ESPENSEN, C.A.: 4441
 ESPINASSE, M.: 3442
 ESTEBAN, O.: T009, T012
 ETIENNE, I.: S001
 EVANS, C.: 3163
 FARAJ, L.: 1344, T058
 FELTGEN, N.: 2666
 FERRARA, V.: 1212
 FERRARI, G.: 4231
 FERREIRA, J.: 1113, 2214, S064
 FILIPE, H.: 2243, F076, T059
 FLECK, O.: 2524
 FLORES, M.: T093
 FRÈRE, A.: 4153
 FRUSCHELLI, M.: 2662, S038
 FUCHSLUGER, T.: 3235, 4233
 GABISON, E.: 2652, 3172
 GABRIELLE, P.: 2523
 GAILLARD, R.: F023
 GALICHANIN, K.: 3551
 GALLAR, J.: T056
 GAMA, I.: 2543
 GANDOLFI, S.: 2623
 GANNE, P.: 3161
 GARDINER, S.: 4473, F030
 GARHÖFER, G.: 2143, F044
 GARWAY-HEATH, D.: 1322
 GEERAERTS, E.: 4258
 GHULAM, M.: 2453
 GIULVEZAN, S.: F051
 GOCHO, K.: 4273
 GONZALEZ, C.: 2526, S023, S024, S025
 GRAJEWSKI, L.: F079
 GRÄSBECK, S.: S057
 GRÄSBECK, T.: S068
 GRAW, J.: 3462
 GRIESHABER, M.: 4221, 4424
 GRIFFITH, M.: 4133
 GRIVET, D.: 3441, F086
 GRUENERT, A.: 2434
 GRZYBOWSKI, A.: 1361, 2528, 3274, 4161, 4264, 4416, S030
 GUALINO, V.: 2665, 3511
 GUERRIER, G.: T060
 GUINDOLET, D.: 2432, T070
 GUTHOFF, R.F.: 2133, 2633
 HAAGDORENS, M.: 4255
 HABIBI, I.: T017
 HADJISTILIANOU, T.: F082
 HALFELD FURTADO DE MENDONCA, R.: F107, S016, S049
 HAMEL, C.: 1251
 HAMILTON, R.: 3522
 HAMRAH, P.: 3531
 HAOUAS, M.: S026
 HARADA, T.: 3572
 HASSAIRI, A.: S014, S067
 HE, Z.: 2431
 HEEGAARD, S.: 3445
 HEISSIGEROVA, J.: 4154
 HEITMAR, R.: S045
 HERBORT, C.P.: 1135, 1234, 2154
 HERRMANN, R.: F063
 HIROTAKA, Y.: F104
 HOLDER, G.: 1254, 3244
 HOMMER, A.: 2122
 HOR, G.: T062
 HORWITZ, A.: F021
 HOUTMAN, A.C.: 2441

HRARAT, L.: S073
HUDSON, C.: 2144
HWANG, H.: 3252
HWANG, K.Y.: F072
HYTTI, M.: 4175, T001
IDOATE, A.: S008
IMBEAU, L.: F058
IRSCH, K.: 3454
ISMAIL, D.: T057
JACKSON, I.: 3562
JAGER, M.J.: 4146
JEANCOLAS, A.: F087
JENSEN, P.S.: S056
JEPPESEN, H.: T067
JOHNSTON, R.: 2225
JOOSSEN, C.: 4253
JULIENNE, R.: T061
JULLIEN, M.: S059
JUMELLE, C.: T073, T074
JUN, J.H.: 4171
JUNG, J.W.: T050
KABURAKI, T.: 2155
KADZIAUSKIENE, A.: F036
KAESER, P.: 2562, 2564
KARANJIA, R.: 3453
KATAMISH, T.: 1142, 3133
KAUPPINEN, A.: 4173
KAWASAKI, A.: 1151, 3243
KAYA, M.: S036
KEPPI, J.: S011
KESTELYN, P.: 2533, 3272
KHAIRALLAH, M.: 1233
KHAN, A.: 1333
KIILGAARD, J.F.: 2673, 4415
KILIC, E.: 4144
KIM, E.: S012
KIM, G.A.: F032
KIM, J.: T075
KIM, J.R.: S035
KIM, N.: S047
KIM, S.E.: 1341
KIM, S.H.: F031
KIM, S.W.: S017
KIM, T.K.: S042
KIM, Y.G.: F017
KISSELEVA, T.: 2134
KIVELÄ, T.: 1222, 1353, 2644, 2645
KIVINEN, N.: T007
KLEMM, M.: S080
KNOP, E.: 2471
KOEV, K.: F059, F060
KOKONA, D.: T092
KOLKO, M.: 4471, F024
KOOPMANS, S.: 3155

KORHONEN, E.: 4176, T002
KOTECHA, A.: 2221, 3524
KOURENTIS, C.: 4114
KOURTI, P.: F090
KRASTEL, H.: 3475, F052
KRATHOLM, N.: S037
KREPS, E.: F061
KRONSCHLÄGER, M.: 3555, T078
KUDRYAVTSEVA, O.: 2661
KUOLIENE, K.: S040
LABALETTE, P.: 2577, T100
LABETOULLE, M.: T037, T038
LACHAPELLE, P.: 3471
LAGALI, N.: 2173
LAM, C.: 4266
LAMBRECHT, P.: 2534
LANGENBUCHER, A.: 4433
LANGMANN, T.: 4214
LARSEN, D.A.: F096
LARSEN, L.M.: 2212
LASUDRY, J.: 3141
LAUDERDALE, J.: 2651
LAWRENSON, J.: 2521
LAYTON, C.: S055
LAZREG, S.: 1345, T029, T080
LE MER, Y.: 3512, 4414
LEAL, I.: 2542
LEE, J.H.: S071
LEE, S.H.: F016
LEE, S.J.: F097
LEE, W.: F029
LEFEVERE, E.: 4452
LEINONEN, M.: 3473
LEMAITRE, S.: 3444
LEMIJ, H.: 3523
LENAERS, G.: 2462
LEONARDI, A.: 3171
LEROY, B.: 1255, 3242
LEVEZIEL, N.: 3111
LEVIN, L.: 2622
LEYS, A.: 3165
LEYSEN, I.: 2475
LI, D.: 3164
LIBERT, S.: 4458
LIM, S.L.: 2415, S002
LIPSKI, D.: 4453
LIRAVI, P.: F026
LISCH, W.: 3232
LISKOVA, P.: 1334, 3463
LOCKWOOD, A.: F022
LODGE, A.: 2675
LOEFFLER, K.: 2642, 3142
LÖFGREN, S.: S092
LOIS, N.: 3212

LONGSTAFF, S.: 1123
 LOPEZ TORRES, L.T.: T019
 LOUKOVAARA, S.: 2664
 LUMBROSO, B.: 2613
 LUNA, C.: T055
 LYNCH, A.: 2433
 LYTVYNCHUK, L.: 2417, 4178, S009, T015
 MADIGAN, M.: 4243
 MAGILL, H.: S004
 MALCLES, A.: S048
 MAMUNUR, R.: 4142
 MANCZAK, H.: 2476
 MANU, M.D.: F064, F065
 MARKIEWICZ, A.: 4446
 MARQUES-NEVES, C.: 3122
 MARTINEZ, M.: S078, T045
 MARTINUZZI, A.: 2261
 MARUYAMA, K.: 2156
 MASCHI, C.: 2667
 MASSY, R.: 4151
 MATEO OROBIA, A.J.: T077
 MATHIS, T.: 2111
 MATSUSHIMA, H.: 1364
 MATTHYSSEN, S.: 4455
 MAYUMI, N.: F075
 MAZY, R.: 3521
 MCNAUGHT, A.: 2223, 4222
 MEKKI, M.B.: 2474
 MELLER, D.: 3234
 METZ, G.: F108
 MEUNIER, A.: T021
 MIDENA, E.: 2513, 4122
 MILLERET, C.: 2442
 MIRANDA, M.: F041
 MIRZA, N.: F050
 MIYACHI, E.: S096
 MOE, M.: 2174
 MOORE, T.: 2172
 MORGAN, I.: 4262
 MORGAN, J.E.: 2421
 MORNLY, E.: 3474
 MORREALE BUBELLA, R.: T097
 MOULIN, A.: 3443
 MOUNA, A.: 2418, S010
 MOURIAUX, F.: 3143
 MUNOZ - NEGRETE, F.J.: 2575, F009, F012, T098
 MURA, M.: 1214
 MURPHY, C.: 2574
 NATH, M.: F045
 NERI, P.: 1133
 NESS, C.: F081
 NEVES, C.: 1111
 NGUYEN, D.: 2557, T090
 NGUYEN, P.: F053
 NI GABHANN, J.: 2232
 NINCLAUS, V.: F102
 NISHIGUCHI, K.: S022
 NIZAWA, T.: S085
 NORDMANN, J.: 2711, 2712
 NORK, T.M.: 2423
 NORMANDO, E.M.: 1323
 NOWINSKA, A.: 1244
 NUBILE, M.: 1141
 NYKTER, M.: 2274
 O'ROURKE, M.: 2572
 OH, J.R.: S081
 OHNO-MATSUI, K.: 2161, 4261
 OLSEN, A.S.: 4474
 OMETTO, G.: S084
 OPDENAKKER, G.: 2251
 OSBORNE, N.: 2141, 4163
 OSHITARI, T.: S095
 OZCAN, A.A.: F020, S087
 PAHUJA, N.: 2555, T088
 PAPASTEFANOU, V.: 4113, 4242
 PAPAVALASILEIOU, E.: S018, S070
 PAQUES, M.: 3211, 3514
 PARK, H.: S098
 PARK, H.J.: F083
 PARK, J.M.: S069
 PARSA, C.: 1153, 3456, 4462, F109
 PASOVIC, L.: 4271, S094
 PATEL, S.: 2553
 PATERNO, J.: T003
 PENWARDEN, A.: 2527, S031
 PEREZ CARRASCO, M.J.: F070
 PEREZ NAVARRO, I.: F025, S043
 PETERSEN, A.: 3553
 PETERSEN, L.: 2245, F047
 PETROVSKI, G.: 2175
 PEYNSHAERT, K.: 4257
 PIIPPO, N.: T006
 PILOTAZ, F.: T046, T047
 PILSON, Q.: 2235, T084
 PINNA, A.: F013, T026
 PISELLA, P.J.: 2332
 PLEYER, U.: 1134, 1232, 1351
 POURJAVAN, S.: 3525, 4478, F008
 POURNARAS, C.: 2514, 2614
 POURNARAS, J.: 1215, 3113, 3513, 4112
 PRAYITNANINGSIH, S.: 3571
 PROKOSCH-WILLING, V.: 3425
 PUELL, M.: F054
 RAGEADE, D.: 2435
 RAGUNATHAN, S.: S033
 RAJIV KUMAR, N.: 1347, T082
 RAMAZANOVA, K.: 2132
 REICHENBACH, A.: 4164

REKAS, M.: 3154
 RICOUARD, F.: F062
 ROBERT, P.Y.: 3543
 ROCHA DE SOUSA, A.: 2242, 2411, 3121, F046, S058
 RODRIGO, M.J.: F043, F093
 ROELS, D.: S015
 ROMANOWSKA DIXON, B.: 4443, S019
 ROSPOND-KUBIAK, I.: 4244, F080, S044
 ROULAND, J.F.: F011
 ROWLINSON, J.: S021
 RUBERTE, J.: 3564
 RUGGERI, A.: 2554
 RUIZ HIDALGO, I.: 4254
 RUSSELL, G.: 4174
 SAAKYAN, S.: 4143
 SABAN, D.: 3532
 SADUN, A.: 2265
 SAGONG, M.: S039
 SAID, D.: 1144, 3135
 SÁNCHEZ MARÍN, J.I.: S075, T052
 SANDBERG MELIN, C.: 2544
 SANDER, B.: S028
 SATO, G.: F056
 SATUE, M.: F092
 SAUNDERS, D.: T024
 SCEMAMA TIMSIT, C.: 2114, 3214
 SCHALENBOURG, A.: 4445
 SCHLOTZER-SCHREHARDT, U.: 3231
 SCHMETTERER, L.: 2131, 2334, 2632, 3124, 3221, 4162
 SCHMIDL, D.: 1374
 SCHORNACK, M.: 2473
 SCHULZ, C.: 2412
 SCOTT, R.: 4272
 SEGURA CALVO, F.: S077, T065
 SELLAM, A.: T094
 SENDON, D.: S020
 SENNLAUB, F.: 4213
 SHALABY, A.: S007, S086
 SHARKAWI, E.: 4422
 SHORTT, A.: 2714
 SHROFF, R.: 1348, T083
 SIM, S.Y.: S006
 SIMCOCK, P.: 1213
 SIMO, R.: 1112, 2253
 SIN, M.: 1373
 SITBON, C.: 3455, F110
 SJÖSTRAND, J.: S076
 SKOTTMAN, H.: 2171, 2671
 SMEDOWSKI, A.: 1243, 3574, T013, T039
 SPALTON, D.: 1362, 3151
 SPILEERS, W.: 3241
 STACHS, O.: 2631
 STALMANS, I.: 2124, 4223, 4475, F005
 STANGOS, A.: 3515
 STANZEL, B.: 2674
 STAPPLER, T.: 1211
 STAURENGHI, G.: 2211, 3213
 STEENSBERG, A.T.: F111
 STEFANSSON, E.: 1354, 1371, 4235
 STEPHAN, S.: T049
 STERN, M.E.: 3535
 STEWART, E.: 2217, 2663, S032, S051, S054
 STOOR, K.: F048
 STORMLY HANSEN, M.: T064
 STORSBERG, J.: 4234
 STRUELENS, L.: 3263
 STRUPAITE, R.: F091, S063
 STRUYF, S.: 2252
 SU JIN, K.: F103, T011
 SUNARIC MEGEVAND, G.: 2123, 4124
 SURESHBABU, V.: 4241
 SUSTRONCK, P.: 3452
 SUZUKI, N.: 2216, 4275, S061, S097
 SZAFLIK, J.P.: 2436, F028, T087
 SZATMARY, G.: 1152
 SZENTMARY, N.: 4431
 TAKASE, H.: 2153
 TAKEUCHI, M.: 2151, 2454
 TALEBIZADEH, N.: 3552
 TALL, M.: 2643
 TAPPEINER, C.: 4152
 TARFAOUI, N.: T095, T096
 TASSIGNON, M.J.: 4123
 TEISTER, J.: F027
 TEMPEST-ROE, S.: T091
 TEN TUSSCHER, M.: 2444
 TEO, L.: 2578, T101
 THEODOROPOULOU, S.: 2573
 THORNELL, E.: 3251
 THURET, G.: 2552, 2634
 THYGESEN, J.: 2713
 TODOROVA, M.: 1372
 TOFT-KEHLER, A.K.: 3576
 TOMO, N.: F089
 TORII, H.: 4263
 TOUTÉE, A.: 4156
 TRAVERSO, C.E.: 2121
 TRECHOT, F.: T036
 TRIER, K.: 4265
 TRZECIECKA, A.: F019
 TUFT, S.: 1332
 TUGAL-TUTKUN, I.: 2152, 2531
 TURKSEVER, C.: F015, S027
 TURUNEN, J.: F078
 TUULONEN, A.: 2125, 2222
 UDZIELA, M.: T022, T063
 UETA, M.: 1342
 UTHEIM, O.: 2238, T086

UUSITALO, H.: 2273
 UZZAN, J.: 2115
 VALGAEREN, H.: 4251
 VAN BERGEN, T.: F033
 VAN CALSTER, J.: 2576, T099
 VAN DEN BOGERD, B.: 4256
 VAN GINDERDEUREN, R.: 3544, 4245, F085
 VAN KEER, K.: 2244, 4454, F035
 VANDEPUTTE, J.: S013
 VANDEWALLE, E.: 2545, 3123
 VARDI, K.: S083
 VECINO, E.: 3423
 VENUGOPAL, R.: 1343
 VERITY, D.: 4464
 VEZINA, M.: S091
 VICENTE, A.: 2213, S065
 VIDAL-SANZ, M.: 2422
 VIE, A.L.: S089
 SIGNAL-CLERMONT, C.: 2465
 VOHRA, R.: T010
 VUJOSEVIC, S.: 1114
 WEBER, M.: 3476
 WEGENER, A.: 3262
 WEINBERGER, D.: 4412
 WELINDER, L.: 3166, T018
 WERKMEISTER, R.: 2142
 WERTHEIMER, C.: 3153
 WESTON, K.: F034
 WIEDEMANN, P.: 2512
 WILLEKENS, K.: 2416, 4252, 4472, S003
 WILLERMAIN, F.: 1231
 WILLSHIRE, C.: 2233
 WILSON, C.: 3222
 WISSINGER, B.: 2461
 WON, J.Y.: T042
 WOWRA, B.: 1245
 WU, Z.: S053
 WYLEGALA, E.: 1241, 1246, 4434
 XIROU, T.: 4111
 XU, H.: 2254, 3424, 4212
 YANG, S.: 3162, T027
 YEKTA, A.A.: T025, T071
 YOON, S.: T033
 YU-WAI-MAN, C.: 3573, 4225, F001
 YU-WAI-MAN, P.: 2162, 2262, 2464
 YU, W.Y.: 2525, S029
 YU, Z.: F077
 YUGAY, M.: 3253
 ZAHAF, A.: S005, T054
 ZAIDI, M.: T030
 ZAMBARAKJI, H.: 4115
 ZETTERBERG, M.: 3554
 ZOGRAFOS, L.: 1225, 2615, 4444

The ARVO Annual Meeting brings together 11,000 global researchers to explore cutting-edge science, collaborate with their peers and connect with people who will ultimately benefit from the work.

ARVO 2016

RESEARCH: A VISION FOR HOPE
MAY 1 – 5 | SEATTLE, WASH.



Abstract submission:
Oct. 15 – Dec. 4, 2015

 **ARVO**
The Association for Research
in Vision and Ophthalmology

arvo.org/am

- AALTONEN, V.: T004
ABDOUL, H.: 3457, F100
ABDULLAH HAMID, A.: 3571
ABEGÃO PINTO, L.: 2541, 2542, 2545, 4476, F006, F037, S065, **3125**, **4224**, **4226**, **F002**, 1113, 2213, 2214, 2244, F035, S064
ABERDAM, D.: **2654**
ABRAMOWICZ, M.: T021
ABU EL ASRAR, A.: 2252, 2453, **2218**, **2451**, **S050**
ABU KHAMIDAKH, A.: **4172**
ACAR, N.: 2524
ACOSTA, M.C.: T055, T056
ACQUART, S.: 2435
ADZHEMYAN, N.: 2134
AGARD, E.: **S072**, S048, S089, S090
AGARWAL, T.: 1343
AHEARNE, M.: 2433
AHMED, F.: **1122**
AHN, J.: S081
AIKIO, M.: T007
AINSBURY, E.: **3261**
AIT IGRINE, W.: 3471
AKEO, K.: 4273
AL-DIRI, B.: S084
AL-SHABRAWAY, M.: **2452**
ALAHMAR, S.: S034, S052
ALAM, K.: 2218, S050
ALASSANE, S.: 2524
ALBERT, R.: 1344
ALBERTI, C.: 3457, F100
ALDAHAM, S.: F070, **F055**, **F057**
ALFREDO, A.C.: 4155
ALI, N.: F024
ALLARD, J.: S011
ALLEN, C.: 1344, 2241, S021
ALLEN, E.: 2172
ALMANSA, I.: F041
ALMEIDA, L.: 2543
ALMENARA MICHELENA, C.: **S041**
ALMENARA, C.: **S093**, F025, S008, S075, S078, T012, T052, T066, T072
ALMOALLEM, B.: **4457**
ALMOHANNA, F.: S034, S052
ALONSO, E.: T056
ALQAHTANI, A.: S034, S052
ÁLVAREZ DE REMENTERÍA, L.: F070
ALVES, P.: 2243, 2411
AMADIO, M.: T003, T013, **T005**, **T008**
AMADO, D.: 3256, 3451, 3458, F071, F112, S065
AMARIE, O.V.: **3561**
AMAT, F.: T040
AMATI-BONNEAU, P.: 2264
AMATO, R.: F042
AMELOOT, F.: 2418, F087, S010, T023
AMOAKU, W.: 1344, 2217, 2663, S032, S051, S054
AMRANE, M.: T057
ANDJELIC, S.: **4177**, **T014**
ANDREASEN, A.: 1346, T081
ANDREW, M.: S007
ANDROUDI, S.: **1132**
ANGI, M.: **4145**
ANGIOI, K.: 4274, F087, S082, T023, T030, T036
ANJOS, R.: 3451, 3458, F112
ANNE CHARLOTTE, L.: T093
ANTONA, B.: F054, F055
ANTONELLI, S.: T031
ANTOSOVA, B.: **3563**
APTEL, F.: F011, **4228**, **F004**
AQUILINA, A.: 3251
ARA, M.: F093
ARACIL, A.: T056
ARAPI, I.: 1133
ARAUJO, M.: F037
ARIAS, L.: S078
ARIS WIDODO, M.: 3571
ARJAMAA, O.: **T004**
ARNDT, C.: 2413, 4274, S082, S083
ARNOULT, L.: 2523
ARSENE, S.: T095
ASARIA, R.: S006
ASCARI, G.: **4456**
ASCASO, F.: T012, **3271**, **4411**
ASCASO, F.J.: **S075**, F025, S041, S043, S093, T052
ASCASO, J.: S008, S078, T009, T045, T066, T072
ASCHINGER, G.: 2142, **F038**
ASLAM, T.M.: F050
ASMUS, F.: 2666
ASNAGLI, H.: **2571**
ASOKLIS, R.: F036, F091, S040, S063, **F105**
ATKINSON, M.: 3264
ATKINSON, S.: 2172
AUBELE, M.: 3264
AUDO, I.: **1253**
AUFFARTH, G.: **1365**
AUGYTE, A.: F105
AVITABILE, T.: **4413**
AYDIN YAZ, Y.: **T035**
AZIMI, A.: T025
AZIMZADEH, O.: 3264
AZNAR, M.C.: 4441
BABA, T.: F104
BABAEI-JADIDI, R.: S021
BACHETTI, P.: F014
BACQUET, J.L.: **F069**
BADIAN, R.: 2231, 2238, T051, T086
BADIAN, R.A.: **T032**, **T053**
BAE, H.: F029, F032
BÆRLAND, T.: F081
BAERT, E.: F102
BAILLIF, S.: 2667, **4442**
BAILLY, M.: 3573
BAKHSHI, S.: T071
BALDESCHI, L.: **4463**
BAMBO, M.P.: F092
BANG, S.P.: F101
BANKS, G.: 3562
BARABINO, S.: **4232**
BARATA, A.: 2542
BARBE, C.: 4274, S082
BARBONI, P.: 2463, **2263**
BARBOSA-BREDA, J.: 3121
BARNARD, A.: T073
BARRAQUER, R.I.: F067, **4435**
BARRIO, A.R.: F054, F055
BARRY, P.: **3254**
BARTOLOMÉ, I.: S093
BATES, D.: 2241, F040, S021
BATISTA, A.M.: S058
BATSON, J.: S021, **2241**
BATTY, M.: F058
BAUD, O.: 3457, F100
BAUDOT, A.: F087, **T023**
BAUDOUIN, C.: 2237, F018, T037, T038, T057, T085, **2331**
BAUER, D.: **4132**
BAZARD, M.C.: T030
BEASLEY, S.: 2452
BEGUM, S.: 2412, 4477, F007, **S074**
BEHAEGEL, J.: **T043**
BEHAR-COHEN, F.: **2511**
BEHL, C.: **3421**
BEIKO, G.: **1363**
BEK, T.: 2245, 2661, F047, F096, S033, S036, S037, S056, S084
BELAOUDMOU, R.: 2474
BELFORT-JR., R.: 3453
BELMONTE, C.: T055, T056
BELMONTE, N.: 2571
BEN ABDALLAH, M.: S060, S067
BENDOVA, M.: 3563
BENITEZ DEL CASTILLO, J.M.: T048
BENLLOCH-NAVARRO, S.: F041
BENZACKEN, L.: 2546
BENZEKRI, R.: 3452
BERESNIAK, A.: 3457, F100
BERGERSEN, L.H.: T010
BERGUIGA, M.: S020, T079
BERNARD, A.: 2432, 2435, F086, T062, T070, T074
BERNIOLLES, J.: S041
BERROD, J.: 2413
BERROD, J.P.: 2418, S010, **2414**, **3114**
BERTHOUD, V.: 3461
BERTON, M.: 1114
BERTRAND-MICHEL, J.: 2526, S023
BESOMBES, G.: **F014**
BESSAKLIA, B.: 3471
BESSARD, R.: S011
BEUERMAN, R.: **2271**, **3233**, **4131**, **4134**
BEYER, E.: **3461**
BHARTI, K.: **2672**
BIAGIONI, M.: F042
BIFRARE, D.: **2532**
BIGAN, G.: F062
BIKBOVA, G.: S095
BILLEN, J.: 3575
BINCZYK, E.: T022
BINDER, S.: 2417, 4178, S009, T015
BINI, S.: 1114
BINNS, A.: 3474
BINQUET, C.: 2522, 2523, 2524
BIRKELDH, U.: **F068**, **F088**
BITOUN, P.: **2546**
BJØRKØY, G.: T003
BLACK, G.C.: **1252**, **3464**
BLACKLEY, Z.: **F040**
BLASETTI, F.: F013
BLEASE, A.: 3562
BLOM, N.: **1346**, **T081**
BLOOM, P.: **4421**
BOBAT, H.: **4477**, **F007**
BODAGHI, B.: 3455, 4156, F069, F110, T094, **1235**, **2157**, **4155**
BOEHRINGER, D.: T038
BOERKOEL, C.F.: 3166, T018
BOGDALI, A.: 4443, 4446, **F084**
BOHRISCH, J.: 4234
BOIX, M.: T047
BONIFERT, T.: 2461
BONNEAU, D.: **2264**
BONNEL, S.: F023, **F010**
BONNET-BRILHAULT, F.: F058

- BORDERIE, V.: **2551, 3131**
 BORDESSOULE, D.: **3545**
 BORDET, J.: 4274, **S082**
 BORGES, B.: 3256, F071
 BORRI, M.: F082
 BORRUAT, FX.: **2164, 2561, 2563, 2565**
 BOSCHI, A.: **2163**
 BOSCIA, F.: T026
 BOSTANCI, K.: F023
 BOUABANE, I.: 2577, T100
 BOUAFIA, K.: 2546
 BOUGUILA, H.: S005, T054
 BOUHERAOUA, N.: 2551
 BOULADI, M.: S014
 BOURGES, J.L.: T060
 BOUTBOUL, D.: T060
 BOYCHUK, I.: **F094, F095**
 BOZUKOVA, D.: 2243, F076
 BRÆNDSTRUP, C.: 3576
 BRANCH, M.: 2663, S032, T058
 BRAUTASET, R.: F068, F088
 BREHON, A.: T061, **2556, T089**
 BREMOND-GIGNAC, D.: **2655, 3457, F100**
 BRETILLON, L.: 2524
 BRIGNOLE-BAUDOUIN, F.: T057
 BRISCOE, D.: **3144**
 BRON, A.J.: 2233, **2234**
 BRON, A.M.: 2413, 2522, 2523, 2524, 4228, F004
 BROWN, S.: 3562
 BRUGNIART, C.: S083
 BUCH, A.: 4132
 BUCKLEY, R.: 2233
 BUCOLO, C.: T008
 BUDRYS, V.: F091
 BUENING, H.: 2434
 BUFFET, S.: S073
 BUGGAGE, R.: 4154
 BUI QUOC, E.: **2443**
 BUSCH, M.: 4132
 BUSHUYEVA, N.: **F049, T076**
 BUSIN, M.: **3132**
 BUSSIERES, M.: S091
 BUTEL, N.: F069
 BUZNYK, O.: 4133
 BYON, I.: **S088**
 BYUN, Y.S.: **2236, T028**
 CAETANO DOS SANTOS, F.: 4172
 CAHUZAC, A.: 2111, 2112, **2113**
 CAIADO, F.: 4476, F006
 CALDER, V.: **3173, 3533**
 CALIOT, J.: S082
 CALONGE, M.: **2272**
 CALVAS, P.: **2653**
 CALVO, B.: T066
 CALVO, T.: T012
 CALZONI, P.: 2662, S038
 CAMBAZARD, F.: 3441, F086
 CAMERUCCI, C.: F056
 CAMMALLERI, M.: F042
 CAMPBELL, M.: 2573
 CAMPESI, I.: F013
 CAMPOS, E.C.: F003, 4227
 CANAVAN, M.: 2572
 CANAVESI, C.: 2552
 CANTATORE, P.: 2463
 CAPORALI, L.: 2463
 CAPOZZOLI, M.: 2662, S038
 CARAMELLO, C.M.: F025, S041, T044, **F074, T072**
 CARBALLO-ÁLVAREZ, J.: F055, F057
 CARDIGOS, J.: **2215, S062, 2213, 3256, 3458, F071, F112, S065**
 CARELLI, V.: 2265, **2463**
 CARNT, N.: 3163
 CARRARO, E.: 2261
 CARRASQUILLO, K.G.: **2472**
 CARRU, C.: F013
 CASANOVA, C.: **F066**
 CASAS PASCUAL, P.: T077
 CASAS-LLERA, P.: F009
 CASAS, P.: F074, T044
 CASINI, G.: F042
 CASPERS, L.: 4153
 CASSOUX, N.: 2641, 3444, 4141, **1221, 1224, 3542**
 CASTELBOU, M.: F062
 CASTELO-BRANCO, M.: **4165**
 CATARINO, C.: F108
 CAUJOLLE, J.P.: 2667, 4442
 CELLINI, M.: 4227, F003
 CHAINE, G.: S073
 CHAKER, N.: S046, S067
 CHALONS, P.: **F039**
 CHAMBARD, J.P.: 2546
 CHAN, H.H.L.: 2525, S029
 CHANDRA, P.: F045
 CHANG, W.: S039
 CHAPELLE, P.: 2546
 CHARFI, H.: S079
 CHARLIER, J.: **3472**
 CHASSAING, N.: 2653
 CHAUHAN, B.: **1321**
 CHEBIL, A.: S014, S046, S067, S079, T017, **S060, T016**
 CHEN, D.F.: S094
 CHEN, M.: 2254
 CHEN, X.: 2231, 2238, T032, T051, T053, T086
 CHEVROLAT, L.A.: 3471
 CHIAMBARETTA, F.: **2656**
 CHICANI, F.: 3453
 CHICHE, A.: S020
 CHIKH, M.: T041
 CHIQUET, C.: 2413
 CHO, D.: T050
 CHO, M.: **F098**
 CHO, S.Y.: **F099, F101**
 CHOI, J.Y.: T075
 CHOO, C.T.: 2578, T101
 CHRAPEK, O.: 1373
 CHU, E.: 3453
 CHUDIN, A.: 2134
 CHUNG, H.K.: F031
 CHUNG, S.K.: 1341, T027, T042
 CHUNG, Y.R.: S017
 CIERNIK, I.: F079
 CIMBALAS, A.: F091, F105, S040, S063
 CIMBOLINI, N.: **T031**
 CINOTTI, E.: 2556, 3441, 3442, F086, T061, T089
 CLARKE, J.: **F018**
 CLEMENT, C.: 4421, **4423**
 COCHEREAU, I.: 2557, T040, T049, T090
 COGNASSE, F.: 2431
 COGNASSE, H.: 2431
 COIMBRA, P.: 2243
 COLAÇO, R.: F076
 COLLOMB, S.: F090
 CONAERT, J.B.: 2418, T036
 CONART, J.B.: 2414, 3114, S010
 CONCEIÇÃO, G.: 2242, F046
 COPLAND, D.: 2573
 CORDEIRO SOUSA, D.: 2542, **2541, 4476, F006, F037**
 CORDEIRO, F.: 4475, F005
 CORDEIRO, M.F.: **2621, 3224**
 CORP-DIT-GENTI, V.: 4154
 CORRAL DEBRINSKI, M.: 2465
 CORREIA-PINTO JR, J.: 2411
 CORRELL, M.H.: T064
 COSCAS, F.: 2612, **2611, 3215**
 COSCAS, G.: **2612, 3215**
 COSTA, L.: 1113, 2215, 3458, F112, S062, S064, S065, **3256, 3451, F071**
 COTIN, S.: **S011**
 COUCEIRO, R.: 2542
 COUDYZER, W.: 2416, S003
 COUPLAND, S.: 4145, **3541**
 COURRIER, E.: **T041**
 COURTAUT, F.: F039
 COURTECUISE, H.: S011
 COURTNEY, D.: 2172
 CRABB, D.: 4222, **2224**
 CRAWLEY, L.: **1121**
 CREUZOT, C.: 2413, 2522, 2523, 2524, **2515, 3112, 3115, 4125**
 CRISÓSTOMO, S.: 2215, S062
 CRISTOBAL, J.: F074, S008, S041, S078, S093, T009, T012, T045, T066, T072, T077
 CROSS, S.: 3562
 CROUZET, E.: 2556, T089, **T068, T069**
 CUENCA, N.: S077
 CUNHA, J.P.: 1113, 2213, 2214, 2215, 3256, 3451, F071, S062, S064, S065, **3458, F112**
 CUPRI, S.: T008
 D'ADAMO, P.: 2463
 D'AGATA, V.: T008
 D'AMICO, A.G.: T008
 D'ANTIN, J.C.: **F067**
 DACOSTA, J.: 3522
 DAIEN, V.: **3255**
 DAL MONTE, M.: **F042**
 DALKE, C.: 3462, **3264**
 DAMATO, B.: 4474
 DANA, R.: **3534**
 DANIEL, S.: 2522
 DANIELLE, S.: 2523
 DAULL, P.: **T034**
 DAURES, J.P.: 3255
 DAVARI ASHTEYANI, R.: T025
 DAVIDSON, A.: 1332, 3163, **1331**
 DAVIES, N.: F051
 DAVIS, B.: **3223**
 DE BAERE, E.: F061, T020
 DE BATS, F.: 2111, **2112**
 DE BLESER, E.: **T020**
 DE BRUYN, D.: **F106**
 DE CHAUMONT, C.: 2574
 DE COGAN, F.: 4272
 DE DOMPABLO, E.: 2575, T098
 DE FRANCESCO, S.: F082
 DE GROEF, L.: **3575, 4451**
 DE HERTOOGH, G.: 2218, 2252, S050
 DE JUAN, V.: 2575, F009, T098
 DE KLEIN, A.: 4144
 DE LA MATA, G.: F093

- DE LAEY, J.J.: **3273**
DE LAZZER, A.: **2522**
DE MORAES, G.: **S055**
DE NICOLA, C.: 1141
DE OLIVEIRA MAIA JR., O.: F107, S016, S049
DE POTTER, P.: **4461**
DE SCHRYVER, I.: F106, S013, S015
DE ZAEYTIJD, J.: F061, F102, F106, S013
DECKERS, K.: 4224
DEFOORT-DHELLEMMES, S.: 3472
DEGLI-ESPOSTI, S.: 4242
DEKEN-DELANNOY, V.: S059
DEL BUEY, M.: F074, S077, S078, T012, T045, T065, T072, T077
DEL BUEY, M.Á.: T052, **T044, T066, S043**
DELAZZER, A.: 2523
DELBARRE, M.: S020, **T079**
DELBEKE, H.: F035
DELBOSC, B.: 2413, F062
DELCOURT, C.: 2665
DELCROIX, M.: 3165
DELMAS, D.: F039
DEMIREL, S.: 4473, F030
DENIRO, M.: **S034, S052**
DENIS, P.: 4228, F004
DEORARI, A.K.: F045
DESCHASSE, C.: **2413**
DESJARDINS, L.: **1223, 2641, 4141**
DESLER, C.: 3576
DEVILLIERS, H.: 2523
DI SIMPLICIO CHERUBINI, S.: S086
DIAMOND, J.: **1124**
DIAS-SANTOS, A.: 2214, 3458, F112, S064
DIAZ VALLE, D.: **2333, T048**
DICK, A.: 2573, **1131, 1136, 4211**
DIEHM, T.: 3475
DIETZEL, A.: S080
DÍEZ, L.: F009
DIMIER-POISSON, I.: T096
DIRKS, M.: 4132
DITTMER, U.: 4132
DO, M.: T046
DOAN, S.: T048, T049, **2237, T040, T085**
DOBROWOLSKI, D.: **1242**
DOELLER, B.: F053, F073
DOMÍNGUEZ-VICENT, A.: F068
DONATI, G.: 2614
DOOLEY, I.: 4115
DORIN, J.: T030
DOSSARPS, D.: 2522
DOT, C.: S048, S072, S089, S090
DOUCHET, C.: 3441
DOYLE, S.: 2573
DRAGO, F.: T008
DRASCHL, P.: **F073**
DRASLAR, K.: 4177, T014
DREXLER, W.: 3476
DUA, H.: 1344, T058
DUA, H.S.: **1143, 1145, 1352, 3134**
DUARTE, L.: **S066**
DUCASSE, A.: S082, S083
DUMOLLARD, J.M.: 3441
DURBANT, E.: **4274**
EBNETER, A.: T092
EBRAHIMI, F.: F079
ECROYD, H.: 3251
EDWARD, D.: **3446**
EIBL-LINDNER, K.: 3153
EIDE, N.: F081
EIDET, J.R.: 2238, 4271, S094, T032, T053, T086, **2231, T051**
EIS-HÜBINGER, A.M.: 4132
EL ALFY, M.: T058
EL CHEHAB, H.: S072, S089, **S090**
EL MATRI HASSAIRI, A.: **S014, S067**
EL MATRI, L.: S014, S060, S067, T017, **S046, S079, T016**
EL-CHEHAB, H.: S048
ELDRED, J.: **3152**
ELENA, P.P.: T031, T034
ELHOUSSEINI, Z.: S006
ENRIQUEZ DE SALAMANCA, A.: 2272
EOM, T.J.: 2236, T028
EPPIG, T.: **4432, 4433**
ERB, C.: F012
ERICKSON, K.: 4154
ESEN, E.: S087
ESMAEELPOUR, M.: 3476
ESPENSEN, C.A.: **4441**
ESPINASSE, M.: **3442**
ESTEBAN, O.: **T009, T012, F025, S008, S043, S075, S078, S093, T044, T052, T072**
ETIENNE, I.: **S001**
EVANS, C.: **3163, 1332**
EVANS, J.: 2521
FACSKÓ, A.: 4174
FAGERHOLM, P.: 2173
FAJNKUCHEN, F.: S073
FALCAO-REIS, F.: 2411
FARAJ, L.: **1344, T058**
FEA, A.: 4223
FEARON, U.: 2572
FEKIH, O.: S005, T054
FEL, A.: 3455, F069, F110, T094
FELSZECHY, S.: T007
FELTGEN, N.: **2666**
FENOLLAND, J.R.: F010, F023
FERAILLE, L.: T031, T034
FERNÁNDEZ-CUENCA, S.: F070
FERNANDEZ-SANCHEZ, L.: S077
FERNANDEZ, I.: 2272
FERNÁNDEZ, S.: F093
FERRARA, V.: **1212**
FERRARI, G.: **4231**
FERREIRA, J.: **1113, 2213, 2215, 3256, 3451, 3458, F037, F071, F112, S062, S065, 2214, S064**
FERREIRA, Q.: F037
FERRER, C.: F093
FERTE, A.: 2414
FEYEN, J.: 2416, F033, S001, S003
FILIPE, H.P.: **2243, F076, T059**
FILLOY, A.: S078
FINDL, O.: 3476, F053, F073, T078
FINZI, A.: F003, 4227
FLANAGAN, D.: 3522
FLAUSSE, R.: 3543
FLECK, O.: **2524**
FLETCHER, J.: 2572
FLORES, M.: F062, **T093**
FOG, L.S.: 4441
FOREST, F.: 2431, 2432, 3441, 3442, F086, T061, T068, T070
FORTUNE, B.: 4473, F030
FOUSSAT, A.: 2571
FRÉNEAUX, P.: 3444
FRÈRE, A.: **4153**
FRÉROT, M.: 2413
FROUNTZOU, E.: 2614
FROUSSART-MAILLE, F.: S020, T079
FRUSCHELLI, M.: **2662, S038**
FUCHS, H.: 3462, 3561
FUCHSLUGER, T.: 2434, **3235, 4233**
FUENTES-BROTO, L.: S077
FUERTES, I.: F092
FUJII, Y.: S022
FUJINO, Y.: 2155
FURUKAWA, T.: S022
GABISON, E.: 2432, 2557, T040, T049, T070, T090, **2652, 3172**
GABRIELLE, P.H.: 2522, **2523**
GACA-WYSOCKA, M.: 2528, S030
GAILLARD, R.: **F023, F010**
GAILUS-DURNER, V.: 3561
GAIN, P.: 2431, 2432, 2435, 2552, 2556, 3441, 3442, F086, S026, T041, T061, T062, T068, T069, T070, T073, T074, T089
GALARRETA, D.: T038
GALGAUSKAS, S.: F036, S063
GALICHANIN, K.: **3551**
GALLAGHER, K.: F051
GALLAR, J.: T055, **T056**
GALLEGO, R.: S066
GALLENMÜLLER, C.: F108
GAMA, I.: **2543**
GANDOLFI, S.: **2623**
GANNE, P.: **3161**
GANTI, A.: 3453
GARCÍA-MARTIN, E.: F092, F043
GARCÍA-MONTESINOS, J.: 2575, T098
GARCIA, T.: 4274
GARDINER, S.: **4473, F030**
GARHÖFER, G.: **2143, F044, F038**
GARRED, Ø.: F081
GARRETT, L.: 3264
GARRIGUE, J.S.: T034, T057
GARRIOCH, R.: 3161
GARWAY-HEATH, D.: **1322**
GAUCHER, D.: 2413, S011
GAVET, Y.: T062
GAVRILENKO, A.: 2134
GEBOS, K.: 2218, S050
GEERAERTS, E.: 3575, **4258**
GEOFFREY, E.R.: 4464
GEORGE, J.L.: F087
GEORGEON, C.: 2551
GEORGIEV, G.: 2234
GERTNER-DARDENNE, J.: 2571
GHOSH, A.: 1347, 2555, 4241, T082, T083, T083, T088, 1348
GHOUBAY, D.: 2551
GHULAM, M.: **2453**
GIBBONS, B.: 2241, S021
GIEBEL, B.: 4132
GIL, M.H.: 2243
GIOCANTI-AUREGAN, A.: S073
GIORDANO, L.: 2463
GIRAUD, J.M.: F010, F023
GIRMENS, J.F.: S026
GIULVEZAN, S.: **F051**
GIZZI, C.: **F003, 4227**
GJEDDE, A.: T010
GLEIZE, S.: 2557, T090
GLITTENBERG, C.: 2417, S009
GOCHO, K.: **4273**
GOERGENS, A.: 4132
GOMOLKA, M.: 3264

- GONÇALVES, I.: 4476, F006, 2543
 GONZALEZ-GARCIA, M.J.: 2272
 GONZALEZ-MENENDEZ, I.: 2461
 GONZÁLEZ-VIEJO, I.: F093
 GONZALEZ, C.: **2526, S023, S024, S025**
 GOUVEIA, P.: 2411
 GOVONI, S.: T005, T008
 GRABER, M.: S020, T079
 GRAJEWSKI, L.: **F079**
 GRAMLICH, O.: F027
 GRÄSBECK, S.: S068, **S057**
 GRÄSBECK, T.: S057, **S068**
 GRAW, J.: 3264, 3561, **3462**
 GRAY, J.: F022
 GREITER, M.: 3264
 GRENET, T.: S073
 GRESTI, G.: 1133
 GRIESHABER, M.: 4421, **4221, 4424**
 GRIEVE, K.: 2551
 GRIFFITH, M.: **4133**
 GRIVET, D.: 2556, 3442, T089, **3441, F086**
 GRUENERT, A.: **2434**
 GRUS, F.: F027
 GRZYBOWSKI, A.: **1361, 2528, 3274, 4161, 4264, 4416, S030**
 GUALINO, V.: **2665, 3511**
 GUCCIARDO, E.: 2664
 GUERRIER, G.: **T060**
 GUHA, N.: 4241
 GUINDOLET, D.: **2432, T070**
 GUIOMAR, A.J.: 2243
 GUNDIMEDA, S.: 4241
 GUO, X.: 3572
 GURUBARAN, I.S.: T010
 GURUNBARAM, R.: 3576
 GUTHOFF, R.F.: **2133**
 GUTHRIE, G.: S004
 GUY, M.: 3453
 GUYTON, D.: 3454
 HAAGDORENS, M.: **4255**
 HABIBI, I.: **T017, T016**
 HADJISTILIANOU, T.: **F082**
 HALFELD FURTADO DE MENDONCA, R.: **F107, S016, S049**
 HALL, G.: 1252, 3464
 HALLAL, D.: T060
 HALLER, J.: F063
 HAMEL, C.: **1251**
 HAMILTON, R.: **3522**
 HAMMOUD, S.: 2546
 HAMRAH, P.: **3531**
 HAN, Y.G.: F031
 HÄNER, N.S.: T092
 HANSEN, M.S.: **T064**
 HAOUAS, M.: **S026**
 HAOUCHINE, B.: 2546
 HARADA, C.: 3572
 HARADA, T.: **3572**
 HARDCASTLE, A.: 1332, 3163
 HART, S.L.: 4225, F001
 HASAN-OLIVE, M.: T010
 HASHEMI, H.: T025, T071
 HASSAIRI, A.: S046, S060, S079, T016
 HATZ, K.: S027
 HAWLINA, M.: 4177, T014
 HE, Z.: 2432, 2435, 2552, T041, T068, T069, T073, T074, **2431, T070**
 HEEGAARD, S.: 1346, T067, T081, **3445**
 HEEMSKERK, M.H.M.: 4146
 HEILIGENHAUS, A.: 4132, 4152
 HEISSIGEROVA, J.: **4154**
 HEITMAR, R.: **S045**
 HENGSTLER, J.: S092
 HENRIKSEN, U.: T010
 HENRIQUES, J.M.: T059
 HERAVIAN, J.: T025, T071
 HERBEPIN, P.: 2435
 HERBORT, C.P.: 4151, **1135, 1234, 2154**
 HERNÁNDEZ, C.: 1112, 2253
 HERRMANN, R.: **F063**
 HIE, M.: 4156
 HIETALA, A.: F088
 HILL, L.: 4272
 HINDMAN, H.: 2552
 HIRNSCHALL, N.: F053, F073
 HIROYUKI, M.: F075
 HJORTDAL, J.: 1346, T081
 HOARAU, C.: T095
 HOESCHEN, C.: 3264
 HOLDER, G.: **1254, 3244**
 HOLM, E.: T010
 HOLMSKOV, U.: F040
 HÖLTER, S.: 3264
 HOMMER, A.: 4475, F005, **2122**
 HONG, S.: F016, F032
 HONRRUBIA, A.: S008
 HOR, G.: T041, **T062**
 HORNHARDT, S.: 3264
 HORWITZ, A.: 4471, **F021**
 HOUTMAN, A.C.: **2441**
 HOUZET, J.: T073, T074
 HOYT, W.: 3456, F109
 HRAB_DE ANGELIS, M.: 3462, 3561
 HRARAT, L.: **S073**
 HUBERT, M.F.: 2571
 HUDSON, C.: **2144**
 HUNTER, A.: S084
 HVALA, A.: 4177, T014
 HWANG, H.: **3252**
 HWANG, K.Y.: **F072**
 HYTTI, M.: 4173, 4176, T002, T003, T006, **4175, T001**
 HYTTINEN, J.: 4172, T006
 IBRAHIM, A.: 2452
 IDIOPE, M.: F043
 IDOATE, A.: F025, F074, S041, S075, T009, T045, T052, T066, **S008**
 IMADA, H.: S096
 IMBEAU, L.: **F058**
 IMTIAZ NAWAZ, M.: 2252
 IRSCH, K.: **3454**
 ISMAIL, D.: T057
 IVANOVA, K.: 4222
 IZDEBSKA, J.: 2436, T087
 JACKSON, I.: **3562**
 JACQUIN, M.: 2571
 JACQZ-AIGRAIN, E.: 3457, F100
 JAGER, M.J.: 4243, **4146**
 JÄGER, W.: F044
 JAKUBOWSKA, B.: 4446, F084
 JANS, E.: S092
 JANSSENS, X.: 4153
 JEAN-CHARLES, A.: 3452
 JEANCOLAS, A.L.: 2414, **F087**
 JEFFERIES, C.: 2232, 2574
 JENSEN, P.K.: F024
 JENSEN, P.S.: S037, **S056**
 JENTZEN, V.: 4234
 JEONG, H.: T033
 JEPPESEN, H.: **T067**
 JEPPESEN, J.: 4471, F021
 JOHNSTON, R.: **2225**
 JONAS, J.B.: F052
 JONCKX, B.: 2416, F033, S001, S003
 JOO, C.K.: 1342, 2236, 3162, 4171, F072, T027, T028
 JOOSSEN, C.: **4253**
 JOUROT, P.: 2546
 JU, H.J.: 3162
 JUDICE, L.: 4153
 JULIAN, H.: T064, T067
 JULLIEN, M.: **S059**
 JULLIENNE, R.: T069, **T061**
 JUMELLE, C.: **T073, T074**
 JUN, J.H.: **4171**
 JUNG, J.W.: **T050**
 JUST, J.: T040
 JUUTI-UUSITALO, K.: 4172
 KAARNIRANTA, K.: 3574, 4173, 4175, 4176, F019, T001, T002, T003, T004, T005, T006, T007, T013
 KABURAKI, T.: **2155**
 KADZIAUSKIENE, A.: **F036**
 KAESER, P.F.: **2562, 2564**
 KAHLERT, C.: F052
 KAHLOUN, R.: 1233
 KALIRAI, H.: 4145
 KAMEYA, S.: 4273
 KANG, E.M.: F016
 KANG, J.H.: F017
 KAPLAN, J.: 2653
 KARANJIA, R.: 2265, **3453**
 KARSKA-BASTA, I.: S019
 KARVONEN, E.: F048
 KASHYAP, S.: 1343
 KASPER, M.: 4132
 KATAMISH, T.: **1142, 3133**
 KAUFFMANN, Y.: 2413
 KAUPPINEN, A.: 4175, 4176, T001, T002, T003, T004, T006, **4173**
 KAWASAKI, A.: F090, **1151, 3243**
 KAWASHIMA, H.: 2155
 KAYA, M.: **S036**
 KEMPF, S.: 3264
 KENNARD, C.: 4464
 KEPPI, J.J.: S011
 KESTELYN, P.: **2533, 3272**
 KHABAZKHOOB, M.: T025, T071
 KHAIRALLAH, M.: 2237, T085, **1233**
 KHAN, A.: **1333**
 KHAW, P.T.: 3573, 4225, F001
 KHOUEIR, Z.: 2546
 KIILGAARD, J.F.: 4441, **2673, 4415**
 KILIC, E.: **4144**
 KIM, C.B.Y.: 2423
 KIM, C.Y.: F016, F029, F032
 KIM, E.: **S012**
 KIM, G.A.: **F032**
 KIM, H.: T033
 KIM, H.K.: S012
 KIM, J.: **T075**
 KIM, J.R.: **S035**
 KIM, J.W.: S017
 KIM, J.Y.: F097
 KIM, K.: S088
 KIM, M.: S039
 KIM, M.K.: 1342
 KIM, N.: **S047**
 KIM, S.: F017, F017, **T011**

- KIM, S.E.: **1341**
KIM, S.H.: **F031**
KIM, S.J.: **F103**
KIM, S.W.: S081, **S017**
KIM, T.K.: **S042**
KIM, Y.G.: **F017**
KIM, Y.H.: S081
KIMURA, A.: 3572
KINOSHITA, S.: 1342
KIRWAN, J.: F034
KIRWAN, J.F.: 4477, F007
KISELEVA, T.: 2132
KISSELEVA, T.: **2134**
KITAHASHI, M.: S085
KIVELÄ, T.: 4142, F078, **1222, 1353, 2644, 2645**
KIVINEN, N.: **T007**
KIZLAITIENE, R.: F091
KLAFTEN, M.: 3462
KLAUS, R.: F044
KLEMM, M.: **S080**
KLEMP, K.: 4441
KLOPSTOCK, T.: F108
KLÖPZIG, S.: 4234
KLOTSCH, J.: 4152
KLU, A.: 3154
KNAPP, S.: 2241, S021
KNEIFEL, C.: F079
KNOP, E.: **2471**
KNOP, N.: 2471
KO, J.: F032
KOCIECKI, J.: 4244, F080, S044
KODJIKIAN, L.: 2111, 2665, S089
KOEHRER, P.: 2523, 2524
KOEY, K.: **F059, F060**
KOKONA, D.: **T092**
KOLKO, M.: 3576, 4174, 4474, F021, F111, T010, **4471, F024**
KOMAE, K.: 2155
KOOPMANS, S.: **3155**
KOPPEN, C.: T043
KORHONEN, E.: **4176, T002, 4173, 4175, T001, T006**
KORBELNIK, J.F.: 2413, 2665
KOROBKO KULIKOVA, V.: T077
KORT, F.: S014, S046, S060, T017, T016
KOSATKA, M.: 3154
KOTECHA, A.: **2221, 3524**
KOULIKOVSKA, M.: 2173
KOURTIS, C.: **4114**
KOURTI, P.: **F090**
KOZMIK, Z.: 3563
KRATTEL, H.: **3475, F052**
KRATHOLM, N.: **S037**
KRAUSE, L.: F079
KRAWCZYK, A.: 4132
KREPS, E.O.: **F061**
KRIJGSMAN, D.: 4146
KRINGELHOLT, S.: S037
KRONSCHLAGER, M.: **3555, F077, T078**
KRUSE, F.E.: 2434, F026
KSIAA, I.: 1233
KUBARKO, A.: 3475
KUBICKA-TRZASKA, A.: 4443, S019
KUDRYAVTSEVA, O.: **2661**
KURER, A.: 3153
KUKLIN, A.: 2134
KULKA, U.: 3264
KUMAR, A.: F045
KUMAR, D.: 1348, T083
KUMAR, S.: 1348, T083
KUNZE, S.: 3462
KUOLIENE, K.: F036, **S040**
KURUN, S.: 2414, 2418, S010
KWAK, S.W.: F016
KYOUNG YUL, S.: T050
LA COUR, M.: 4474
LA MORGIA, C.: 2265, 2463
LABALETTE, P.: F014, S059, **2577, T100**
LABEILLE, B.: 2556, 3441, 3442, F086, T061, T089
LABETOULLE, M.: **T037, T038, T057**
LACHAPPELLE, P.: **3471**
LACHKAR, Y.: 2546
LACHOVA, J.: 3563
LACOMBE, S.: 3255
LAFUENTE OJEDA, N.: T077
LAGALI, N.: **2173**
LAI, J.: F066
LALA, E.: T095
LAM, C.S.: **4266**
LAMBRECHT, P.: S013, **2534**
LAMIREL, C.: T049
LANCHARES, E.: T044, T066
LANDAUER, M.: 3475
LANGENBUCHER, A.: **4433, 4432**
LANGMANN, T.: **4214**
LANIS, M.: 2552
LAO, M.: 2436, T087
LARGUECHE, L.: S079, T016
LARSEN, D.A.: **F096**
LARSEN, L.M.: **2212**
LASUDRY, J.: **3141**
LATEEF, S.: 4241
LAUDERDALE, J.: **2651**
LAURELL, C.G.: F068
LAUREYS, G.: F102
LAVILLA, L.: T066, T077
LAVIN, C.: 4223
LAWRENSON, J.: **2521**
LAY, B.: S024
LAYTON, C.: S055
LAZREG, S.: **1345, T029, T080**
LE HOANG, P.: 3455, F069, F110
LE MER, Y.: 2413, **3512, 4414**
LEABACK, R.: 2665
LEAL, I.: 2541, 4476, F006, F037, **2542**
LEBERRE, J.P.: S072
LEE, B.: F017, S081
LEE, C.J.: 4133
LEE, D.: T075
LEE, H.S.: T027
LEE, J.: F017, S088, T011
LEE, J.H.: F083, S042, T075, **S071**
LEE, K.: S017
LEE, M.Y.: S042
LEE, N.: 3252, F017
LEE, S.: F103, T011
LEE, S.C.: F083
LEE, S.H.: **F016**
LEE, S.J.: S069, **F097**
LEE, S.Y.: F099, F101
LEE, W.: **F029**
LEE, W.K.: S047, S071
LEE, Y.C.: F101
LEFEBVRE, P.: 4153
LEFEVERE, E.: **4452**
LEGEAIS, J.M.: T060
LEHMANN, M.: 2113
LEHOANG, P.: 4156, T094
LEHTI, K.: 2664
LEINONEN, M.: **3473**
LEITE-MOREIRA, A.: 2242, F046
LELEZ, M.L.: T095
LEMAITRE, S.: **3444**
LEMEE, G.: T096
LEMIJ, H.: F012, F018, **3523**
LENAERS, G.: 2264, **2462**
LEONARDI, A.: **3171, T057**
LEPINET, T.: 2552, T041
LEROY, B.P.: F061, F106, S013, S015, T020, **1255, 3242**
LESLIE PEDRIOLI, D.: 2172
LEVEZIEL, N.: **3111**
LEVIN, L.A.: **2622**
LEVONEN, A.L.: T003, T013
LEVY, C.: 4141
LEVY, J.: T060
LEWIN-KOWALIK, J.: 3574
LEYS, A.: **3165**
LEYSSEN, I.: **2475**
LI, C.: S091
LI, D.: **3164**
LIBERT, S.: **4458**
LIEGL, R.: 3153
LIINAMAA, J.: F048
LIM, S.H.: S039
LIM, S.L.: **2415, S002**
LIMA-RAMOS, P.: S058
LINDEGAARD, J.: T067
LIPSKI, D.: **4453**
LIRAVI, P.: **F026**
LISCH, W.: **3232**
LISKOVA, P.: **1334, 3463**
LIU, J.: 2573
LIU, Y.: 3446
LIVEIKIENE, A.: F091
LÍVIO, C.: 2213
LLOYD, I.C.: 3464
LOB, F.: F108
LOCKWOOD, A.: 2412, 2527, 4477, F007, F034, S031, S074, S086, T024
LOCKWOOD, A.J.: **F022**
LODGE, A.: **2675**
LOEFFLER, K.: **2642, 3142**
LÖFGREN, S.: T078, **S092**
LOGAN, A.: 4272
LOHI, J.: 2664
LOIS, N.: **3212**
LONGSTAFF, S.: **1123**
LÓPEZ DE LA FUENTE, C.: T065
LOPEZ TORRES, L.T.: **T019**
LOPEZ-MIGUEL, A.: 2272
LÓPEZ-PEDRAJAS, R.: F041
LORENTE-HEVIA, M.P.: F070
LOUKOVAARA, S.: **2664**
LU, Y.: 3164
LUGOVKINA, K.: 2132
LUHMANN, U.: **3422**
LUK, S.J.: 4146
LUMBROSO, B.: **2613**
LUMBROSOLEROUIC, L.: 4141
LUNA, C.: T056, **T055**
LUND-ANDERSEN, H.: S028
LUO, Y.: 3164
LUPIDI, M.: 2612, 3215
LUYTEN, G.P.M.: 4146
LYBERG, T.: 4271, S094
LYNCH, A.: **2433**

- LYONS, C.: 3166, T018
 LYTVYNCHUK, L.: **2417, 4178, S009, T015**
 LYU, B.: 3252
 MAALOUF, J.: F087
 MAAMOURI, R.: S046, S060, S067
 MACEDO, A.F.: S058
 MACHON, O.: 3563
 MACHOUART, M.: T030
 MADIGAN, M.C.: **4243**
 MAGILL, H.: **S004**
 MAHJOUR, A.: S005
 MAJOR, J.: 2436, T087
 MAJSTEREK, I.: F028
 MAJZOU, S.: F058
 MAKHOUL, D.: 4153
 MALCLÈS, A.: S089, S090, **S048, S072**
 MALIIEVA, O.: T076
 MALLIPATNA, A.: 4241
 MALMBERG, F.: 2544
 MALMQVIST, L.: 2544
 MALONE, C.: 2574
 MALYSKO, K.: S040
 MAMONTOVAITE, G.: F091
 MAMUNUR, R.: **4142**
 MANCZAK, H.: **2476**
 MÄNTYSAALO, T.: 3473
 MANU, M.D.: **F064, F065**
 MANUNTA, M.: 4225, F001
 MAPANI, A.: 3522
 MARAGKOS, I.: S006
 MARCHESI, N.: T005
 MARESCA, A.: 2463
 MARGRAIN, T.: 3474
 MARILL, A.F.: F010, F023
 MARKIEWICZ, A.: 4443, F084, **4446**
 MARKKINEN, S.: F078
 MAROT, Y.: T095
 MARQUES-NEVES, C.: **1111, 3122, 2541, 2542, 4224, 4476, F006, F037**
 MARQUES, N.: 2215, S062
 MARTIN-MONTANEZ, V.: 2272
 MARTÍN-RIDURA, M.D.C.: F055, F057
 MARTÍNEZ VELEZ, M.: F074
 MARTÍNEZ, M.: F025, S008, S043, S075, T012, T044, T052, **S078, T045, S093**
 MARTINI, F.: 1114
 MARTINUZZI, A.: **2261**
 MARUYHAMA, K.: **2156**
 MASCHI, C.: 4442, **2667**
 MASSAMBA, N.: T094
 MASSY, R.: **4151**
 MASTROPASQUA, L.: 1141
 MATA, J.L.G.: 2243, F076, T059
 MATEO OROBIA, A.J.: F074, T072, **T077**
 MATEO, A.: F092
 MATHIS, T.: **2111, 2112**
 MATSUSHIMA, H.: **1364**
 MATTHYSEN, S.: **4455**
 MAUCLAIR, C.: T073, T074
 MAUGET-FAÏSSE, M.: 2111, 2112, 2113, 2114, 3214
 MAURAGE, C.A.: 2577, T100
 MAURINO, V.: T038
 MAURIS, N.: T093
 MAURIZI, E.: 2172
 MAURO, V.: T031
 MAY, K.: F022
 MAY, S.: S051
 MAYER, W.: 3153
 MAYUMI, N.: **F075**
 MAZHARIAN, A.: F010
 MAZY, R.: **3521**
 MCKIE, L.: 3562
 MCLEAN, I.: 2172
 MCNAUGHT, A.: **2223, 4222**
 MEHANNA, C.: T060
 MEIER, T.: F108
 MEKKI, M.B.: **2474**
 MELLER, D.: **3234**
 MENSINK, H.: 4144
 MERLE, H.: 3452
 MESSMER, E.: T037
 MESSNER, A.: 4234
 METZ, G.: **F108**
 METZIG, C.: 2211, 2212
 MEUNIER, A.: **T021**
 MICHAEL, R.: F067
 MIDENA, E.: 1114, **2513, 4122**
 MIDENA, G.: 1114
 MIETTINEN, P.J.: S057, S068
 MILLERET, C.: **2442**
 MINDEN, K.: 4152
 MIRANDA, M.: **F041**
 MIRZA, N.: **F050**
 MITCHELL, A.: F022
 MIYACHI, E.: **S096**
 MIZOTA, A.: 4273
 MOCKEVICIUTE, E.: F091, S063
 MOE, M.: F081, **2174**
 MOHAMMAD, G.: 2252
 MOK, J.W.: 3162
 MOLASY, M.: F028
 MOLEIRO, A.: 2242, F046
 MOLENBERGHS, G.: 4226, F002
 MONTEIRO-GRILLO, M.: 2543
 MONTENEGRO, G.A.: F067
 MONTOYA, J.: T012
 MOONS, L.: 3575, F033
 MOORE, J.: 2172
 MOORE, T.: **2172**
 MORAES-FILHO, M.: 3453
 MORAWSKI, K.: 4443
 MORGADO, J.: F037
 MORGAN, I.: **4262**
 MORGAN, J.E.: **2421**
 MORISSE, S.: T096
 MORN, E.: **3474**
 MORREALE BUBELLA, R.: **T097**
 MORRIS, J.: 2241, S021
 MOTHES, N.: F052
 MOTTE, J.: S083
 MOUINGA, A.: F010
 MOULIN, A.: **3443**
 MOUNA, A.: 2414, **2418, S010**
 MOUNIER, C.: S072
 MOURIAUX, F.: T037, **3143**
 MOURTZOULO, S.: S074
 MRUKWA-KOMINEK, E.: T038
 MUKHINA, A.: F094
 MÜNCH, M.: F090
 MUNIER, F.: T017, T016
 MUNOZ - NEGRETE, F.J.: **2575, F009, F012, T098**
 MURA, M.: **1214**
 MURPHY, C.: **2574, 2232, 2572**
 MURPHY, C.C.: 2235, T084
 MURRAY, I.J.: F050
 MYAKOSHINA, E.: 4143
 NA, K.S.: 2236, 3162, T028
 NACEF, L.: S005, T054
 NADAL-NICOLÁS, F.M.: 2422
 NAGEL, E.: S080
 NAHOKO, O.: F089
 NAKAZAWA, T.: S022
 NAMEKATA, K.: 3572
 NANGOUM-FOSSO, T.: 2435
 NATH, M.: **F045**
 NAUS, N.: 4144
 NEFF, F.: 3264
 NEGISHI, K.: 4263
 NERI, P.: **1133**
 NERINCKX, F.: S015
 NEROEV, V.: 4143
 NESBIT, A.: 2172
 NESS, C.: **F081**
 NEUMANN, M.: F027
 NEWSOM, R.: S086
 NGUYEN, D.T.: **2557, T090**
 NGUYEN, P.M.: **F053, F073**
 NGUYEN, Q.D.: 4154
 NI DHUBHGAILL, S.: T043
 NI GABHANN, J.: 2235, 2574, T084, **2232**
 NICKELLS, R.W.: 2423
 NICOLAISSEN, B.: F081
 NICOLAS, M.: 3443
 NICOLAU, R.: T060
 NIELSEN, K.: 1346, T081
 NIEWERTH, M.: 4152
 NIJS, I.: 3165
 NILSSON, M.: F068, F088, S076
 NINCLAUS, V.: F106, **F102**
 NISHIGUCHI, K.: **S022**
 NIZAWA, T.: **S085**
 NOER, A.: F081
 NOLAN, P.: 3562
 NORDMANN, J.P.: **2711, 2712**
 NOREIKYTE, M.: S063
 NORK, T.M.: **2423**
 NORMANDO, E.M.: **1323**
 NOWINSKA, A.: **1244**
 NUBILE, M.: **1141**
 NÚÑEZ, E.: F025, T009, S043
 NYKTER, M.: **2274**
 O'NEILL, J.: 4272
 O'ROURKE, M.: **2572**
 OBLANCA-LLAMAZARES, N.: 2575, F009, T098
 ODDONE, F.: 4475, F005
 OGUNDELE, A.: T037, T038
 OH, J.R.: **S081**
 OH, S.: F031
 OHKUMA, M.: S096
 OHNO-MATSUI, K.: **2161, 4261**
 OHTOMO, K.: 2155
 OJALA, M.: 3473
 OKINAGA, K.: 2155
 OLDAK, M.: T022, T063
 OLMIERE, C.: T069, F039
 OLSEN, A.S.: F111, **4474**
 OLSTAD, O.K.: 4271, S094
 OMETTO, G.: **S084**
 ONO, F.: S022
 OPDENAKKER, G.: **2251, 2218, S050**
 ORDUNA, E.: T065
 ORGUEL, S.: F015
 ORTÍN-MARTÍNEZ, A.: 2422
 OSBORNE, N.: **2141, 4163**
 OSHITARI, T.: F104, **S095**
 OSTADIMOGHADDAM, H.: T025, T071

- OSZKINIS, G.: S044
OTIN, S.: F043, F092
OZ, Y.: T035
OZCAN, A.A.: **F020, S087**
OZOG-BARAN, J.: S019
PABLO, L.: F092
PADALKO, E.: S015
PADMANABHAN, A.: 4241
PAHUJA, N.: 1347, 1348, T082, T083, **2555, T088**
PALLOT, C.: 2522
PALOMO-ÁLVAREZ, C.: F057
PALUCH, M.: 2528, S030
PANKHURST, Q.: 4464
PAPARELLA, G.: 2261
PAPASTEFANOU, V.: **4113, 4115, 4242**
PAPAVASILEIOU, E.: **S018, S070**
PAPAYANNIS, A.: 2261
PAPINAUD, L.: 3255
PÂQUES, M.: S026, **3211, 3514, 2551**
PARADISO, P.: T059
PARIDAENS, D.: 4144
PARK, H.: **S098**
PARK, H.J.: **F083**
PARK, J.: F017
PARK, J.H.: 1341
PARK, J.M.: F097, **S069**
PARRY, N.R.A.: F050
PARSA, C.: **1153, 3456, 4462, F109**
PASCALE, A.: T005, T008
PASOVIC, L.: **4271, S094**
PATEL, P.: 4242
PATEL, S.: **2553**
PATERNO, J.J.: **T003, F019, T013**
PAVESIO, C.: 3522, 4155
PECOUT, A.: T046
PEIRO EMBID, C.: T077
PEIRO, C.: T072
PENWARDEN, A.: F034, **2527, S031**
PEOC'H, M.: 3441, T061, T068, T070
PEOCH, M.: 2432
PERERA, S.: 2415, S002
PERESTRELO, S.P.: S058
PEREZ CARRASCO, M.J.: **F070**
PEREZ GARCIA, D.: T077
PEREZ NAVARRO, I.: T072, **S043**
PÉREZ-CARRASCO, M.J.: F057
PÉREZ, I.: S008, S075, T009, T045, T052, **F025, S093, T066**
PERMATASARI, N.: 3571
PERONE, J.M.: T036
PERRACHE, C.: 2431, 2432, 2435, T068, T069, T070, T073, T074
PERROT, J.L.: 2556, 3441, 3442, F086, T061, T089
PETACCHI, E.: 2261
PETERSEN, A.: **3553**
PETERSEN, L.: S036, **2245, F047**
PETROVSKI, G.: 1344, 4174, 4178, T015, **2175**
PEYNSHAERT, K.: **4257**
PFEIFFER, N.: F027
PICA, A.: 4445
PIETRUCHA-DUTCZAK, M.: 3574
PIGNATELLO, R.: T008
PIHJALANIEMI, T.: T007
PIIPPO, N.: 4173, 4175, 4176, T001, T002, T004, **T006**
PILOTAZ, F.: **T046, T047**
PILSON, Q.: 2232, **2235, T084**
PIMENTA, A.: 2243, F076
PINBORG, L.H.: F111
PINCHINAT, S.: 2665
PINILLA CORTÉS, L.: F067
PINILLA, I.: F074, S077, T044, T065, T066
PINNA, A.: **F013, T026**
PINOLI, J.C.: T062
PINTO FERREIRA, N.: 2541
PINTO-FRAGA, J.: 2272
PINTO, F.: 2541, 2542
PINTO, J.: 2541
PINTO, L.A.: 2215, 4472, S062
PIRANI, V.: 1133
PISELLA, P.J.: F058, T095, T096, **2332**
PISELLI, S.: 2432, 2435, T068, T069, T070, T073, T074
PLANCHER, C.: 4141
PLESU, G.: F064
PLEYER, U.: **1134, 1232, 1351**
PLOSKE, R.: T022, T063
POCIEJ-MARCIK, W.: S019
POLO, V.: F043
POLOSA, A.: 3471
POPOVIC, Z.: S076
POSTELMANS, L.: 4153
POTTER, P.: 3562
POURJAVAN, S.: **3525, 4478, F008**
POURNARAS, C.J.: **2514, 2614**
POURNARAS, J.A.C.: **1215, 3113, 3513, 4112**
POYER, F.: 3444
PRAUSE, J.U.: T067
PRAYITNANINGSIH, S.: **3571**
PRIETO, E.: F043, F093
PRIOR FILIPE, H.: 4476, F006
PRIVATO, F.: 2261
PROCACCIO, V.: 2264
PROENÇA, R.: 1113, 2213, 2214, 3458, F112, S064
PROKOSCH-WILLING, V.: **3425**
PROSDOCIMO, G.: 2261
PRÜNTE, C.: S027
PRZYBYŁOWSKA-SYGUT, K.: F028
PUCCETTI, L.: 2662, S038
PUELL, M.: F055, F057, F070, **F054**
PUEYO, V.: F093
QUIJANO, C.: S070
QUIRCE, S.: T055, T056
RÆDER, S.: 2231, 2238, T032, T051, T053, T086
RAFAT, M.: 2173
RAGEADE, D.: T070, **2435**
RAGUNATHAN, S.: **S033**
RAJIV KUMAR, N.: 2555, T088, **1347, T082**
RAMAZANOVA, K.: **2132, 2134**
RAMBAUD, C.: S020, T079
RAMÍREZ, D.T.: F041
RAMSDEN, S.: 1252, 3464
RANCHO, L.: T057
RASMUSSEN, A.: S028
RASMUSSEN, L.: 3576
REBOLLEDA, G.: 2575, F009, T098
REGEADE, D.: 2432
REHAK, J.: 1373
REHFELDT, S.: 4234
REICHENBACH, A.: **4164**
REINA, M.: 4476, F006
REITSAMER, H.: 4223
REKAS, M.: **3154**
REMOND, A.L.: F069
RENARD, J.P.: 4228, F004, F010, F023
REPO, P.: 2664
REPPE, S.: 4271
REVERT, R.: T056
REYNAUD, J.: 4473, F030
REYNIER, P.: 2264
REYNS, G.: 2416, S003
REZVAN, F.: T025, T071
RIBEIRO, L.: 4475, F005
RICHTER-MÜKSCH, S.: F044
RICOUD, F.: **F062**
RIHOVA, E.: 4154
RIMSEVICIUS, L.: S063
RIZZO, R.: **F056**
ROBERT, P.Y.: **3543**
ROBITAILLE, J.M.: 3166, T018
ROCHA DE SOUSA, A.: **2242, 2411, 3121, F046, S058**
RODRIGO, M.J.: **F092, F043, F093**
RODRÍGUEZ-LLARENA, S.: 2422
ROELS, D.: **S015**
ROGGENDORF, M.: 4132
ROH, Y.J.: S035
ROLLAND, J.P.: 2552
ROMANENKO, D.: F049
ROMANOWSKA DIXON, B.: 4446, F084, **4443, S019**
RONDET, S.: T060
ROSE, K.: 4262
ROSEMANN, M.: 3264
ROSÉN, R.: S076
ROSENBERG, R.: F010, F023
ROSPOND-KUBIAK, I.: **4244, F080, S044**
ROSSETTI, L.: 4475, F005
ROSSI, G.C.M.: T038
RÖSSLER, U.: 3264
ROUGER, H.: T049
ROULAND, J.F.: 4228, F004, F014, **F011**
ROWLINSON, J.: 2241, **S021**
ROZET, J.M.: 2653
RUÃO, M.: S066
RUBERTE, J.: **3564**
RUGGERI, A.: **2554**
RUIZ HILDALGO, I.: **4254**
RUIZ-PESINO, E.: T012
RUPPS, R.: 3166, T018
RUSSELL, G.: **4174**
RUSSO, A.: S048, S072, S089, S090
RUSZKOWSKA, E.: T022
RYABTZOVA, A.: 3253
SA, D.: 4241
SAADOUN, D.: 4156
SAAKYAN, S.: **4143**
SAARELA, V.: F048
SABAN, D.R.: **3532**
SABRAUTZKI, S.: 3462
SADUN, A.: 3453, **2265**
SAGONG, M.: **S039**
SAGOO, M.S.: 4242
SAHEL, J.A.: 2465, S026
SAHIN, A.: T035
SAID, D.: T058, **1144, 3135**
SAKAI, K.: S096
SAKER, S.: 2217, S054
SALDO, J.: T047
SALEH, M.: F062, T093
SALES, A.: 2571
SALGARI, N.: 1141

- SALINAS-NAVARRO, M.: 2422
 SALOMAO, S.: 3453
 SALVEN, P.: 2664
 SAMAMA, C.M.S.: T060
 SAMPINEN, K.: 3473
 SANCHEZ MARIN, J.I.: F074, **T052**
 SÁNCHEZ-CANO, A.: S077, T065
 SANCHEZ, J.: T009
 SÁNCHEZ, J.I.: S008, S075, F025, S041, S043, T045
 SÁNCHEZ, N.: T044
 SANDBERG MELIN, C.: **2544**
 SANDER, B.: **S028**
 SANTANA, R.: S058
 SANTOS, A.: 2213, 3451, S065
 SANTOS, B.: 2214, S064
 SANTOS, C.: 2242, F046
 SARAMAGO, B.: F076, T059
 SARDA, V.: S073
 SARIYEVA, A.: F020
 SATO, G.: F056
 SATUE, M.: F092
 SAUNDERS, D.: **T024**, 2412
 SAVIGNONI, A.: 4141
 SAVYTSKA, I.: 4178, T015
 SAWAI, H.: 1342
 SCAGLIARINI, A.: F039
 SCANU, B.: F013
 SCAPELLATO, C.: 2662, S038
 SCARPA, F.: 2554
 SCEMAMA TIMSIT, C.: 2111, 2112, **2114**, **3214**
 SCEMAMA, C.: 2113
 SCHALENBOURG, A.: 3443, 4444, **4445**
 SCHENCK, S.: 4152
 SCHLEEF, M.: 2434
 SCHLICHTENBREDE, F.: 3475
 SCHLOSSER, A.: F040
 SCHLÖTZER-SCHREHARDT, U.: **3231**, F026
 SCHMEER, M.: 2434
 SCHMETTERER, L.: 2142, F038, F044, **2131**, **2334**, **2632**, **3124**, **3221**, **4162**
 SCHMIDL, D.: **1374**
 SCHMIDT, C.: 4234
 SCHNEWEIS, K.E.: 4132
 SCHNOEDT, M.: 2434
 SCHOELS, L.: 2461
 SCHOETZAU, A.: 4221
 SCHOINDRE, Y.: 4156
 SCHORDERET, D.: T017, T019
 SCHORNACK, M.: **2473**
 SCHULMEISTER, K.: F077
 SCHULTZE-LUTTER, S.: F052
 SCHULZ, C.: **2412**, T024
 SCHUSCHITZ, S.: F053
 SCHWEITZER, D.: S080
 SCIEZYNSKA, A.: T022, T063
 SCOTT, R.: **4272**
 SECHE, E.: T096
 SEGURA, F.: **S077**, **T065**
 SEITZ, B.: 4432, 4433
 SELLAM, A.: **T094**
 SEN, S.: 1343
 SENDON, D.: T079, **S020**
 SENGELOEV, H.: T067
 SENNLAUB, F.: **4213**
 SEO, K.Y.: 1342
 SEONG, G.J.: F016, F029
 SERGIENKO, A.: 4178, T015
 SERRO, A.P.: 2243, F076, T059
 SHADALOUÉE, Z.: T025
 SHAHNAZARYAN, D.: 2574
 SHALABY, A.: **S007**, **S086**
 SHAN, S.W.: 2525, S029
 SHARKAWI, E.: 4421, **4422**
 SHARMA, A.: 1343
 SHARMA, N.: 1343
 SHETTY, R.: 1347, 1348, 2555, 4241, T082, T083, T088
 SHIBESH, A.: 4226, F002
 SHIMOZAWA, N.: S022
 SHORTT, A.: **2714**
 SHROFF, R.: 2555, T088, **1348**, **T083**
 SIDNEY, L.: 2663, S032
 SILVA-GOMES, R.: 2242, F046
 SILVESTRE, D.: F041
 SIM, S.Y.: **S006**
 SIMCOCKX, P.: **1213**
 SIMÓ-SERVAT, O.: 2253
 SIMÓ, R.: **2253**, **1112**
 SIMON, M.: 3562
 SIMONSEN, U.: S037
 SIN, M.: **1373**
 SINGER, A.: 3441
 SINGH, B.: F045
 SINOVA, I.: 1373
 SITBON, C.: **3455**, **F110**
 SIWAKOTI, A.: 3575
 SJÖGREN, L.: T060
 SJÖSTRAND, J.: **S076**
 SKOTTMAN, H.: 4172, **2171**, **2671**
 SKVARCIANY, I.: S063
 SKYTT, D.: 3576, T010
 SMEDOWSKI, A.: F019, T003, **1243**, **3574**, **T013**, **T039**
 SMITH, S.: 2574
 SMOLIKOVA, J.: 3563
 SODEIK, B.: 4132
 SÖDERBERG, P.: 2544, 3555, F077
 SOLINAS, G.: T026
 SORENSEN, G.L.: F040
 SOTOZONO, C.: 1342
 SPALTON, D.: **1362**, **3151**
 SPARAGNA, C.: F082
 SPECHT, L.: 4441
 SPILEERS, W.: **3241**
 SPIRA, C.: 4432, 4433
 STACHS, O.: **2631**
 STALMANS, I.: 2244, 2545, 3575, 4224, 4226, 4472, F002, F018, F033, F035, **2124**, **4223**, **4475**, **F005**
 STALMANS, P.: 2416, 4224, 4245, 4472, F085, S003
 STANAKOVA, L.: 1373
 STANGOS, A.: **3515**
 STANZEL, B.V.: **2674**
 STAPPLER, T.: **1211**
 STARBUCK, B.: 3562
 STAURENGHI, G.: **2211**, **3213**
 STEEL, D.: S004
 STEENSBERG, A.T.: **F111**
 STEFANSSON, E.: **1354**, **1371**, **4235**
 STEGMANN, R.: 4221
 STENMAN, L.: 3445
 STEPHAN, S.: 2557, T090, **T049**
 STERN, M.E.: 2272, **3535**
 STEWART, E.: 1344, **2217**, **2663**, **S032**, **S051**, **S054**
 STOJANOVIC, A.: 2238, T032, T053, T086
 STOOOR, K.: **F048**
 STORM-MATHISEN, J.: T010
 STORSBERG, J.: **4234**
 STREICHER, R.: F063
 STRUELENS, L.: **3263**
 STRUPAITE, R.: **F091**, **S063**
 STRUYF, S.: 2218, S050, **2252**
 SUJUTI, H.: 3571
 SUMMANEN, P.A.: S057, S068
 SUNARIC MÉGEVAND, G.: **2123**, **4124**, 4475, F005
 SUNDARAM, P.A.: 4154
 SURESHBABU, V.: **4241**
 SUSTRONCK, P.: **3452**
 SUZUKI, M.: S022
 SUZUKI, N.: **2216**, **4275**, **S061**, **S097**
 SWEENEY, C.: 2572
 SYNOFZIK, M.: 2461
 SZABÓ, Á.: 4174
 SZAFLIK, J.: 2436, F028, T087
 SZAFLIK, J.P.: T022, T063, **2436**, **F028**, **T087**
 SZATMARY, G.: **1152**
 SZENTMÁRY, N.: **4431**, 4432, 4433
 SZIKLAI, P.: 4174
 SZYMANEK, K.: F028
 TABORSKY, J.: S033
 TACK, M.: T020
 TADASHI, S.: F075
 TADAYONI, R.: 2413
 TAGALAKIS, A.: 4225, F001
 TAHIR, H.J.: F050
 TAKAHASHI, H.: 4273
 TAKAMOTO, M.: 2155
 TAKASE, H.: **2153**
 TAKEUCHI, M.: **2151**, **2454**
 TALEBIZADEH, N.: 2544, 3555, F077, T078, **3552**
 TALL, M.: **2643**
 TAM, F.: T091
 TAMARIT, J.M.: S077
 TAN, L.: 2415, S002
 TANG, W.C.: 4266
 TANG, Y.: 3164
 TANKAM, P.: 2552
 TAO, X.: F027
 TAPIO, S.: 3264
 TAPPEINER, C.: **4152**
 TARAK, A.: F095
 TARFAOUI, N.: **T095**, **T096**
 TARNAWSKA, D.: T039
 TASSIGNON, M.J.: T043
 TAVARES-FERREIRA, J.: S058
 TAVI, P.: T003, T013
 TAWFIK, A.: 2452
 TAYLOR, S.: T091
 TEISTER, J.: **F027**
 TEMPEST-ROE, S.: **T091**
 TEN TUSSCHER, M.: **2444**
 TEO, L.: **2578**, **T101**
 TESON, M.: 2272
 THARIAT, J.: 2667
 THEILLAC, V.: F010
 THEODOROPOULOU, S.: **2573**
 THEURER, Y.: 2461
 THIBAUD, M.F.: T093
 THILLAY, A.: F058
 THOMAS, C.: 3444
 THOMAS, S.: F066
 THORNELL, E.: **3251**
 THOUVENIN, O.: 2551

- THURET, G.: 2431, 2432, 2435, 2556, 3441, 3442, F086, S026, T041, T061, T062, T068, T069, T070, T073, T074, T089, **2552, 2634**
THYGESEN, J.: 4471, **2713**
TITAH, O.: 2474
TO, C.H.: 2525, 4266, S029
TODOROVA, M.: F015, T019, **1372**
TOFT-KEHLER, A.K.: **3576**
TOGO, M.: S022
TOKUNAGA, K.: 1342
TOMO, N.: **F089**
TON, H.: 4243
TOOP, H.: 2241, S021
TOPHAM, D.: 2552
TORII, H.: **4263**
TOROPAINEN, E.: F019
TORP-PEDERSEN, C.: 4471, F021
TORRALBA, M.Á.: S075
TOSSOUNIS, C.: S007
TOUITOU, V.: 4156, F110, 3455
TOUTÉE, A.: **4156**
TRACHSEL-MONCHO, L.C.: F041
TRÄG, S.: 4234
TRAVERSO, C.: **2121**
TRECHOT, F.: T023, **T036**
TREISMAN, R.: 3573
TRIER, K.: **4265**
TRZECIECKA, A.: **F019**
TSUBOTA, K.: 4263
TUFT, S.J.: 3163, **1332**
TUGAL-TUTKUN, I.: **2152, 2531**
TUMAHAI, P.: F062
TURKSEVER, C.: **F015, S027**
TURNER, S.: 4222
TURUNEN, J.: **F078**
TUULONEN, A.: **2125, 2222**
TWARDOSZ-PAWLIK, H.: 4244, F080
TY, M.: S053
TZOURIO, C.: 2522, 2523, 2524
UDODOV, E.: F052
UDZIELA, M.: **T022, T063**
UETA, M.: **1342**
UETTWILLER, F.: T095
UNGER, K.: 3264
URIBE, M.: S051
UTHEIM, Ø.: **2238, T086, 2231, T032, T051, T053**
UTHEIM, T.P.: 2231, 2238, 4271, S094, T032, T051, T053, T086
UUSITALO, H.: **2273**
UZZAN, J.: 2111, 2112, **2115**
VAARWATER, J.: 4144
VADER, M.: 4243
VALENTE, A.R.B.: T059
VALENTINE, M.E.: 4155
VALENTINO, M.L.: 2463
VALGAEREN, H.: **4251**
VALIENTE-SORIANO, F.J.: 2422
VALMAGGIA, C.: T019
VAN BERGEN, T.: **F033**
VAN CALSTER, J.: 4224, **2576, T099**
VAN DAMME, J.: 2218, 2252, S050
VAN DEN BOGERD, B.: **4256**
VAN DEN EYNDE, K.: 2218, S050
VAN DER MEULEN, I.: T038
VAN DER VELDEN, P.: 4146, 4243
VAN GINDERDEUREN, R.: 2576, T099, **3544, 4245, F085**
VAN KEER, K.: 4224, 2545, 4226, F002, **2244, 4454, F035**
VAN RAEMDONCK, K.: 2218, 2252, S050
VANDEPUTTE, J.: **S013**
VANDEWALLE, E.: 2244, 4224, 4226, 4472, F002, F035, **2545, 3123**
VANHAECHT, K.: 4478, F008
VARDI, K.: 4274, S082, **S083**
VARONA, R.: 4154
VARISITS, R.: F053
VAVLA, M.: 2261
VÁZQUEZ-ALFAGEME, C.: 4242
VECINO, E.: **3423**
VED, N.: F040
VELARD, M.E.: 2665
VELI, N.: 3163
VELPANDIAN, T.: F045
VENUGOPAL, R.: **1343**
VER HOEVE, J.N.: 2423
VERITY, D.H.: **4464**
VERTOMMEN, J.: 4224
VEZINA, M.: **S091**
VICENTE, A.: 1113, 2214, 2215, 3256, 3451, 3458, F071, F112, S062, S064, **2213, S065**
VIDAL-SANZ, M.: **2422**
VIÉ, A.L.: **S089**
VIEIRA, A.P.: 2243
VIGNAL-CLERMONT, C.: **2465**
VILAIN, C.: T021
VILLAIN, M.: 3255
VILLANI, G.M.: F056
VILLARÉ, J.: 4141
VILLEGAS-PÉREZ, M.P.: 2422
VITTI, R.: 4154
VOHRA, R.: **T010**
VON LIVONIUS, B.: F108
VOSBORG, F.: T010
VOTRUBA, M.: 3161, 3474
VUJOSEVIC, S.: **1114**
WACKER, K.: 2553
WAGSCHAL, T.: 3453
WAHLBERG-RAMSAY, M.: F088
WALCZAK, A.: F028
WALREADT, S.: F102
WANG, F.: 2452, S053
WANG, Y.: F050
WEARMOUTH, S.: 2241, S021
WEBER, M.: **3476, 2413**
WEGENER, A.: **3262**
WEI, R.: 2663, S032, S051
WEINBERGER, D.: **4412**
WELINDER, L.: **3166, T018**
WERKMEISTER, R.: F038, **2142**
WERTHEIMER, C.: **3153**
WEST-MAYS, J.: 3575
WESTON, K.: 2527, S031, **F034**
WIEDEMANN, P.: **2512**
WILDSCHÜTZ, L.: 4132
WILLEKENS, K.: 2545, 4224, 4226, F002, F035, **2416, 4252, 4472, S003**
WILLEMS, A.: 3165
WILLERMAIN, F.: 4153, **1231**
WILLSHIRE, C.: **2233**
WILSKA, R.: F078
WILSON, C.: **3222**
WILSON, S.: 2433
WIRIX, M.: 3165
WISBY, L.: 3562
WISSINGER, B.: **2461**
WOLFF, B.: 2111, 2112, 2113, 2114, 3214
WON, J.Y.: T027, **T042**
WORMSTONE, M.: 3152
WOWRA, B.: **1245**
WROBLEWSKA-ZIERHOFFER, M.: 4244, F080
WU, J.: 2573
WU, Z.: **S053**
WURST, W.: 3264
WYLEGALA, E.: F019, T013, T039, **1241, 1246, 4434**
XEROUDAKI, M.: 2173
XIROU, T.: 4242, **4111**
XU, H.: **2254, 3424, 4212**
YAGMUR, M.: T048
YAHIAOUI, S.: 2474
YAMAKI, K.: 4273
YAMAMOTO, S.: F104, S085, S095
YAMANE, K.: 2216, 4275, S061, S097
YANG, J.: 3164
YANG, S.: **3162, T027**
YAVUZYIGITOGU, S.: 4144
YAZ, Y.: T035
YE, H.: 3164
YEKTA, A.A.: **T025, T071**
YEKTA, R.: T025, T071
YEOM, J.H.: T075
YEUNG, A.: T058
YEWEL, L.: 2416, S003
YICHENG, N.: 2416, S003
YILDIRIM, N.: T035
YIM, H.: 3252
YING, H.: 3454
YOKOI, N.: 2234
YOKOUCHI, H.: **F104**
YOKOYAMA, Y.: S022
YOO, T.Y.: S012
YOO, Y.S.: 2236, T028
YOON, G.Y.: F072
YOON, I.: S088
YOON, K.C.: 1342
YOON, S.: **T033**
YOSHIDA, A.: 2155
YOU, H.: F017
YOU, T.: T033
YOUNIS, S.: S018, S070
YU-WAI-MAN, C.: **3573, 4225, F001**
YU-WAI-MAN, P.: **2162, 2262, 2464**
YU, J.: S088
YU, W.Y.: **2525, S029**
YU, Z.: 2544, 3555, T078, **F077**
YUGAY, M.: **3253**
ZACCHEDDU, F.: T026
ZAHAF, A.: **S005, T054**
ZAIDI, M.: **T030**
ZAITSEVA, O.: 4143
ZAKARIA, N.: T043
ZAMBARAKJI, H.: **4115**
ZANLONGHI, X.: 3472
ZAYANI, M.: S005, T054
ZEITLINGER, M.: F044
ZENKEL, M.: F026
ZETTERBERG, M.: 3553, **3554**
ZGHAL, I.: S005, T054
ZHANG, J.: 2241, S021
ZILOVA, L.: 3563
ZINKERNAGEL, M.S.: T092
ZIPPEL, N.: F063
ZITZELSBERGER, H.: 3264
ZOGRAFOS, L.: 3443, 4445, **1225, 2615, 4444**

HERMES

RHODES 1

RHODES 2

RHODES 3

RHODES 4

GALLIENI 1&2

GALLIENI 5

Wednesday, October 7, 2015

12:00 - 13:30	RV: The diabetic retinopathy: A neurodegenerative disease <i>FERREIRA J - VILJOSEVIC S</i> RV: Macular hole surgery: New facts and tips for a successful result <i>PAPPAS G</i>	G: Virtual review: Setting new standards in glaucoma care <i>CRAWLEY L - AHMED F</i> PO: Mistakes in the diagnosis of fundus tumors <i>DESJARDINS L - ZOGRAFOS L</i>	IM: EBO course: Intraocular inflammation and infection (Part 1) <i>BODAGHI B - HERBORT CP</i> EBO course: Intraocular inflammation and infection (Part 2) <i>BODAGHI B - HERBORT CP</i>	COS: How to perform deep anterior lamellar keratoplasty <i>DUA HS</i> COS: In vivo confocal microscopy in corneal disorders <i>WYLEGALA E - SIMEDOWSKI A</i>	NSPH: Papilloedema and its Mimics: What's new in pseudotumor cerebri syndrome? <i>SZATMARY G - KAWASAKI A - PARSA C</i> MBGE: Grand rounds in ophthalmic genetics <i>LEROY B - HAMEL C</i>	
13:30 - 15:00						
15:00 - 15:30	Coffee break					
15:30 - 15:50	Opening Ceremony: Welcome by the President EVER 2015 - <i>LEROY B</i>					
15:50 - 16:00	EVERf Fellowship highlights - <i>SCHMETTERER L</i>					
16:00 - 16:40	EVER Past president lecture: Retinal Vein Occlusions : From pathophysiological mechanism to clinical therapeutic issues - <i>POURNARAS C</i>					
16:40 - 17:00	European Ophthalmology Heritage - a celebration: Homage at Professor Ignacio Barraquer - <i>BARRAQUER J</i>					
17:00 - 18:30	Women 4 EVER <i>DESJARDINS F - KAWASAKI A</i>	G: OCT in glaucoma: Clinical and experimental applications <i>NORMANDO EM - GARWAY-HEATH D - CORDEIRO MF</i>	MBGE: Monogenic corneal disorders <i>LISKOVA P - DAVIDSON AE</i>	COS: Free paper session - Cornea and ocular surface inflammation <i>GICQUEL JJ</i>	How to publish - hints and "tricks".... <i>PLEYER U</i>	LC: But doctor, will this IOL last my lifetime? <i>GRZYBOWSKI A - BEIKO G</i> <i>HARDARSON S - SIN M</i>
18:30 - 18:50	European Ophthalmology Heritage Lecture: Visual impairment in opera characters - <i>AYDIN P</i>					
18:50 - 19:30	Keynote Lecture: Rare retinoblastoma: a goldmine for discovery of fundamental principles of biology and healthcare - <i>GALLIE B</i>					
19:30 - 21:00	EVER Welcome Reception					

Thursday, October 8, 2015

07:30 - 08:00	Coffee and Croissants					
08:00 - 09:30	RV: Focus on fundus autofluorescence imaging: review and perspectives <i>MAUGET-FAYSSSE M - WOLFF B</i>	G: All you ever wanted to know about the EGS! <i>STALMANS J - HOMMERA</i>	PBP: Ultrasound course <i>SCHMETTERER L - KISSELEVAT</i>	PBP: Relationship between retinal neurons, glia and blood vessels <i>GARHÖFER G</i>	IMI: Uveitis in the East and West <i>NERI P - TAKEUCHI M</i>	NSPH: New perspectives on the funny looking disc <i>KAWASAKI A - OHNO-MATSUI K</i> <i>PETROVSKI G - MOE M</i>
09:45 - 10:25	EVER-Acta Lecture: Regulating the body clock – The unrecognised role of the eye - <i>FOSTER R</i>					
10:30 - 12:00	RV: Free paper session - Diabetes <i>CREUZOT C - STAURENGHI G</i>	G: Lifetime risk of blindness from glaucoma <i>KOTECHA A - MCNAUGHT A</i>	COS: Free paper session - Tear film exploration and dry eye <i>DOAN S - GICQUEL JJ</i>	PBP: Free paper session - Pharmacology / drug delivery / physiology <i>OSBORNE N - GARHÖFER G</i>	IMI: Inflammation in diabetic retinopathy-part 1 <i>ABU EL ASRAR A</i>	MBGE: Mitochondrial optic neuropathies - classical disease and novel manifestation <i>VOTRUBA M - YU-WA-MAN P</i> <i>UUSTALO H - BEUERMAN R</i>
12:00 - 13:00	Industry-sponsored lunchtime symposium: Ocular surface: What's new ? - <i>SCHMETTERER L - BAUDOUIN C</i>					
13:10 - 13:45	Ophthalmic Research Lecture: Degenerative myopia and its treatment - <i>WIEDEMANN P</i>					
13:45 - 15:15	RV: Free paper session - Surgery <i>BERROD J - POURNARAS C</i>	G: Does glaucoma affect only retinal ganglion cells in the retina? <i>VIDAL-SANZ M - NORK M</i>	COS: Free paper session - Corneal bioengineering <i>THURET G - LYNCH A</i>	NSPH: The role of the corpus callosum in binocularity and strabismus <i>TEN TUSSCHER M</i>	IMI: Inflammation in diabetic retinopathy-part 2 <i>ABU EL ASRAR A</i>	MBGE: Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies <i>VOTRUBA M - YU-WA-MAN P</i> <i>KNOP E - MEKKI MB</i>
15:15 - 16:00	Coffee with the Prof					
15:15 - 16:00	Poster session 1: • Anatomy / Cell Biology • Molecular Biology / Genetics / Epidemiology • Cornea / Ocular Surface • Immunology / Microbiology					
16:00 - 17:30	RV: Diabetic retinopathy and macular edema <i>CREUZOT C - MIDENA E</i>	RV: Free paper session - AMD <i>LEYS A - LAWRENSEN J</i>	G: New and/or under diagnosed entities in glaucoma <i>STEVENS AM - KESTELYN P</i>	G: Free paper session - Imaging and biomechanics <i>CORDEIRO MF - CORDEIRO SOUSA D</i>	COS: Free paper session - Ocular surface anatomy updates <i>BORDERIE V - RUGGERI A</i>	NSPH: Nystagmus and non-nystagmic abnormal spontaneous eye movements <i>BORRUAT FX - KAESER P</i>
17:30 - 19:00	RV: New developments in OCT-Angiography <i>POURNARAS C - ZOGRAFOS L</i>	G: Neuroprotection in glaucoma: Coming of age? <i>CORDEIRO MF - LEVIN L</i>	COS: Corneal imaging <i>SCHMETTERER L - GUTHOFF RF</i>	PO: It is a masquerade! Eye cancers lurking behind innocent appearances <i>KIVELÄ T - DESJARDINS L</i>	NSPH: An update on aniridia <i>BREMOND-GIGNAC D - LAUDERDALE JD</i>	RV: Free paper session - Retinal vasculopathy <i>LEYS A - BAILLIF S</i>
19:00 - 20:30	Industry-sponsored evening symposium: How to create a new generation of glaucoma patient ? - <i>NORDMANN J</i>					

SPONSORS AND EXHIBITORS

Main



CIS - Industry Sponsored Symposium



SIS - Special Interest Symposium



Exhibitors



Marketing



EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2015. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.